---
document_datetime: 2023-09-21 19:36:38
document_pages: 86
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/zirabev-epar-public-assessment-report_en.pdf
document_name: zirabev-epar-public-assessment-report_en.pdf
version: success
processing_time: 128.2273592
conversion_datetime: 2025-12-15 19:52:29.969785
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

13 December 2018 EMA/97237/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Zirabev

International non-proprietary name: bevacizumab

Procedure No. EMEA/H/C/004697/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 6                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier .....................................................................................6      |                                                                                                          |
| 1.1. Steps taken for the assessment of the product                                                                         | ........................................................7                                                |
| 2. Scientific discussion................................................................................                   | 8                                                                                                        |
| 2.1. Quality aspects                                                                                                       | ....................................................................................................9    |
| 2.1.1. Introduction......................................................................................................9 |                                                                                                          |
| 2.1.2. Active Substance...............................................................................................9    |                                                                                                          |
| 2.1.3. Finished Medicinal Product................................................................................          | 13                                                                                                       |
| 2.1.4. Discussion on chemical, pharmaceutical and biological aspects..............................                         | 18                                                                                                       |
| 2.1.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                  | ...................... 18                                                                                |
| 2.1.6. Recommendation(s) for future quality development.............................................                       | 18                                                                                                       |
| 2.2. Non-clinical aspects............................................................................................      | 19                                                                                                       |
| 2.2.1. Introduction....................................................................................................    | 19                                                                                                       |
| 2.2.2. Pharmacology                                                                                                        | ................................................................................................. 19     |
| 2.2.3. Pharmacokinetics ............................................................................................       | 20                                                                                                       |
| 2.2.4. Toxicology......................................................................................................    | 20                                                                                                       |
| 2.2.5. Ecotoxicity/environmental risk assessment.........................................................                  | 23                                                                                                       |
| 2.2.6. Discussion on non-clinical aspects .....................................................................            | 24                                                                                                       |
| 2.2.7. Conclusion on the non-clinical aspects ...............................................................              | 25                                                                                                       |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 25    |
| 2.3.1. Introduction....................................................................................................    | 25                                                                                                       |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 28          |
| 2.3.3. Pharmacodynamics..........................................................................................          | 35                                                                                                       |
| 2.3.4. Discussion on clinical pharmacology...................................................................              | 35                                                                                                       |
| 2.3.5. Conclusions on clinical pharmacology.................................................................               | 36                                                                                                       |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 36    |
| 2.4.1. Dose response study(ies)                                                                                            | ................................................................................. 36                     |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 36 |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 58                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy                                                                                | .................................................................... 60                                  |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 60  |
| 2.5.1. Discussion on clinical safety..............................................................................         | 77                                                                                                       |
| 2.5.2. Conclusions on the clinical safety                                                                                  | ...................................................................... 78                                |
| 2.6. Risk Management Plan........................................................................................          | 78                                                                                                       |
| 2.7. Pharmacovigilance                                                                                                     | ............................................................................................. 81         |
| 2.8. Product information............................................................................................       | 82                                                                                                       |
| 2.8.1. User consultation ............................................................................................      | 82                                                                                                       |
| 2.8.2. Additional monitoring.......................................................................................        | 82                                                                                                       |

<div style=\"page-break-after: always\"></div>

| 3. Biosimilarity assessment ...................................................................... 82   | 3. Biosimilarity assessment ...................................................................... 82          |
|---------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| 3.1. Comparability                                                                                      | exercise and indications claimed ...................................................... 82                     |
| 3.2. Results supporting                                                                                 | biosimilarity............................................................................ 83                   |
| 3.3. Uncertainties and                                                                                  | limitations about biosimilarity..................................................... 84                        |
| 3.4. Discussion on                                                                                      | biosimilarity .................................................................................. 84            |
| 3.5.                                                                                                    | Extrapolation of safety and efficacy ...................................................................... 85 |
| 3.6. Conclusions                                                                                        | on biosimilarity and benefit risk balance .............................................. 85                    |
| 4. Recommendations................................................................................. 85  | 4. Recommendations................................................................................. 85         |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

Ab

Antibody

ADA

Anti-drug antibodies

AE

Adverse event

AESI

Adverse events of special interest

ALK

Anaplastic lymphoma receptor tyrosine kinase

ALT

Alanine aminotransferase

ANC

Absolute neutrophil count

ANOVA

Analysis of variance

AST

Aspartate aminotransferase

ATE

Arterial thromboembolic events

AUC

Area under the curve

AUCT

Area under the serum concentration time profile from time 0 to the

time of the last quantifiable concentration

AUC0-∞

AUC measured from the time of dosing and extrapolated to infinity

BOR

Best overall response

CNS

Central nervous system

CI

Confidence interval

Cmax

Measured maximum serum concentration after administration

CR

Complete response

CSR

Clinical study report

CTCAE

Common Terminology Criteria for Adverse Events

Ctrough

Observed pre-dose trough serum drug concentration

CV%

Coefficient of variation as percentage

DOR

Duration of response

ECG

Electrocardiogram

ECL

Electrochemiluminescence

ECOG

Eastern Cooperative Oncology Group

EGFR

Epidermal growth factor receptor

ELISA

Enzyme-linked immunosorbent assay

EMA

European Medicines Agency

eNCA

Electronic noncompartmental analysis

EOS

End of Study

EOT

End of treatment

GLP

Good Laboratory Practice

GM

Geometric mean

ITT

Intent-to-Treat

IV

Intravenous/intravenously

MAA

Marketing Authorisation Application

MoA

Mechanism of action

NAb

Neutralizing antibody

NSCLC

Non-small cell lung cancer

ORR

Objective response rate

OS

Overall survival

PD

Pharmacodynamics

PK

Pharmacokinetics

PL

Package leaflet

PP

Per protocol

PR

Partial response

RD

Risk difference

RECIST

Response evaluation criteria in solid tumours

RR

Risk ratio

SAE

Serious adverse event

SD

Standard deviation

SMQ

Standardized MedDRA Queries

SOC

System organ class

<div style=\"page-break-after: always\"></div>

t½ Terminal half-life Tmax The time point when Cmax occurred TEAE Treatment-emergent adverse event TK Toxicokinetic VEGF Vascular endothelial growth factor

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Pfizer Europe MA EEIG submitted on 1 February 2018 an application for marketing authorisation to the European Medicines Agency (EMA) for Zirabev, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004.

The applicant applied for the following indication:

Zirabev in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.

Zirabev in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.

Zirabev, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.

Zirabev in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.

Zirabev in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see Section 5.1).

## The legal basis for this application refers to:

Article 10(4) of Directive 2001/83/EC - relating to applications for a biosimilar medicinal products

The application submitted is composed of administrative information, complete quality data, appropriate non-clinical and clinical data for a similar biological medicinal product.

## Information on Paediatric requirements

Not applicable.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## New active Substance status

The applicant indicated the active substance bevacizumab contained in the above medicinal product to be considered as a known active substance.

## Scientific advice

The applicant received Scientific advice from the CHMP:

| Scientific advice         | Date            | Area                                       |
|---------------------------|-----------------|--------------------------------------------|
| EMA/CHMP/SAWP/430458/2014 | 24 July 2014    | the SA pertained to non-clinical, clinical |
| EMA/CHMP/SAWP/238092/2015 | 24 April 2015   | the SA pertained to non-clinical, clinical |
| EMA/CHMP/SAWP/667247/2015 | 22 October 2015 | the SA pertained to non-clinical, clinical |

## 1.1. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Bjorg Bolstad

Co-Rapporteur:  Alexandre Moreau

| The application was received by the EMA on                                                                              | 1 February 2018   |
|-------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                | 1 March 2018      |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                          | 22 May 2018       |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                                       | 22 May 2018       |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                     | 5 June 2018       |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                | N/A               |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                 | 28 June 2018      |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                     | 12 September 2018 |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on | 22 October 2018   |

<div style=\"page-break-after: always\"></div>

| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | N/A              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The CHMP agreed on a list of outstanding issues to be sent to the applicant on                                                                                                          | 15 November 2018 |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                         | 20 November 2018 |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                        | 28 December 2018 |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on                                                                 | N/A              |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Zirabev on | 13 December 2018 |

## 2. Scientific discussion

## About the product

Zirabev (PF-06439535) is a recombinant humanised immunoglobulin G1 kappa (IgG1k) monoclonal antibody (mAb). PF-06439535 is composed of 2 heavy chains (gamma 1) and 2 light chains (kappa), linked by disulfide bonds and has the same primary amino acid sequence as bevacizumab-EU. PF-06439535 is produced by recombinant technology in a Chinese hamster ovary (CHO) cell line.

## Type of Application and aspects on development

This application concerns a centralised procedure for marketing authorisation of Zirabev (PF-06439535) bevacizumab concentrate for solution for infusion for intravenous administration of 25 mg/mL, as a biosimilar product to the European reference product Avastin (EU/1/04/300/001-002).

The development programme is in general compliance with CHMP guidance/scientific advice.

## Non-clinical

In a formal scientific advice from 2015, the CHMP agreed that the proposed preclinical and pharmacological similarity approach seemed to be sufficient to evaluate preclinical and pharmacological similarity of the biosimilar compared to the reference product, and adequate to permit submission and review of a Bevacizumab (PF-06439535) MAA for Zirabev as a proposed biosimilar to Avastin.

The two studies performed in animals were conducted in accordance with Good Laboratory Practice (GLP) Regulations.

<div style=\"page-break-after: always\"></div>

## Clinical

Formal scientific advice(s) given by EMA for this medicinal product:

-  EMA/CHMP/SAWP/430458/2014, 27.07.2014

Initial advice on the data generated to date and the proposed phase 3 development

-  EMA/CHMP/SAWP/238092/2015, 24.04.2015 EMA/CHMP/SAWP/667247/2015, 22.10.2015 (follow-up)

Feedback on statistical aspects of design and sample analysis for immunogenicity assessment

Scientific advice(s) given by Member State(s) for this medicinal product:

Presenting the overall development program and seek advice on the clinical data filing strategy and dossier development

-  Denmark, 16.09.2016
-  Finland, 19.09.2016
-  Austria, 21.09.2016

## 2.1. Quality aspects

## 2.1.1. Introduction

Zirabev is presented as a similar biological application to the reference medicinal product Avastin.

The finished product (FP) is presented as a concentrate for solution for infusion containing 25 mg/ml of bevacizumab as active substance (AS).

Other ingredients are sucrose, succinic acid, disodium edetate, polysorbate 80, sodium hydroxide (for pH adjustment) and water for injections.

The product is available as a 4 ml or 16 ml solution in a vial (Type I glass) with a stopper (butyl rubber) containing 100 mg of bevacizumab or 400 mg of bevacizumab, respectively. The finished product comes in a pack size of 1 vial.

Prior to administration the concentrate for solution for infusion should be diluted to the required administration volume with sodium chloride 9 mg/ml (0.9%) solution for injection to a concentration of the final bevacizumab solution between 1.4 mg/ml to 16.5 mg/ml.

## 2.1.2. Active Substance

## General information

Bevacizumab (also referred to as PF-06439535 by the Applicant) is a humanised IgG1κ mAb with two identical heavy chains (HC) and two identical light chains (LC), covalently linked with four inter-chain disulphide bonds. The monoclonal antibody (mAb) is produced in a Chinese Hamster Ovary (CHO) cell line, the same cell line used for manufacturing of the reference product Avastin. The confirmed amino acid sequence, the molecular mass (theoretical and experimental) for the deglycosylated molecule and experimental molecular mass including glycosylation, the molecular formula of the light and heavy chains of PF-06439535 number of cysteines, the number of intra and inter disulphide bonds and the general properties are provided.

<div style=\"page-break-after: always\"></div>

The N-linked glycosylation consensus sequence in the CH2 region is essentially fully occupied with asialo, core-fucosylated, complex-type biantennary oligosaccharides, predominately with structures containing zero and one terminal galactose residues. The molecular mass is approximately 149 kilodaltons (kDa).

## Manufacture, characterisation and process controls

Bevacizumab active substance (AS) is manufactured according to current Good Manufacturing Practices (GMP) at Wyeth BioPharma Division, One Burtt Road, Andover, MA 01810, USA. The site is covered by a valid GMP certificate.

## Description of the manufacturing process and process controls

The manufacturing process of the AS has been well described by the Applicant.

The manufacturing process for PF-06439535 active substance uses a recombinant CHO cell line. Cells are grown in suspension culture using chemically-defined (CD), animal-derived component-free (ACF) media. The main steps of the manufacturing process are cell culture, recovery and purification. The process begins with the thawing of cells from the working cell bank (WCB) followed by expansion. The purification of PF-06439535 comprises several chromatography steps and orthogonal dedicated virus clearance steps.

The cell culture process starts with the thawing of a working cell bank (WCB) vial which is progressively expanded. During culture expansion and maintenance critical process parameters and critical material attributes are identified and justified with acceptable ranges (alert and termination limits). Inoculum culture from a seed bioreactor is added to production medium in the production bioreactor to a pre-defined target seed density. The production bioreactor culture is harvested and clarified by centrifugation and depth filtration to remove cells and debris. After this harvest step, the product is purified by an affinity chromatography step, a virus inactivation step, and ion exchange chromatography steps.  The product is then processed through a virus retaining filter (VRF) followed by concentration and solution exchange in an ultrafiltration/diafiltration (UF/DF) step. Lastly, the excipients are added to the product to achieve the final formulation of active substance, followed by final filtration and freezing.

The process controls include a combination of critical process parameters (CPP), non-critical process parameters (non-CPP), critical material attributes (CMA), and in-process tests. The filtered PF-06439535 active substance is filled into a suitable container closure system, labelled, frozen, and shipped frozen to the finished product manufacturing site.

## Control of materials

Raw materials are sufficiently described and controlled.

With the exception of CloneDetect (Human IgG (H+L) Specific, Fluorescein-conjugated) derived from sheep and used in the development of the recombinant cell line, no materials of animal or human origin are used during the production of the active substance.

The fermentation growth medium is a proprietary dry powder medium.  It is a protein-free, chemically-defined medium and contains no proteins or peptide components of animal or plant origin and no undefined lysates or hydrolysates.

The details regarding the origin of materials, pharmacopoeial reference or internal specification, and the stage of the manufacturing process, where the material is used, are provided.

<div style=\"page-break-after: always\"></div>

Details on the coding sequence and generation of the expression vector to code for bevacizumab amino acid sequence have been provided and are consistent with Pfizer-generated mass spectrometry and biochemical data for the reference product bevacizumab-US and bevacizumab-EU.

A two-tiered cell banking system, consisting of a master cell bank (MCB) and a working cell bank (WCB), was established for commercial production. The MCB and WCB were characterised according to ICH requirements, e.g. Q5A (R1), Q5B and Q5D. The adventitious agents assays test results indicate that the cell bank is sterile and free of detectable mycoplasma and viruses. During routine production, cell culture age is controlled to less than the limit of in vitro cell age (LIVCA). The provided data support the proposed PF-06439535 LIVCA. The LIVCA is supported by several assays demonstrating phenotypic and genotypic stability. Data have been provided to indicate that the cell line is robust with respect to critical parameters. MCB and WCB stability under the defined storage conditions will be monitored.  All newly prepared WCBs will also be manufactured in accordance with a pre-specified protocol and cGMP guideline and qualified, complying with ICH Q5D and Q5A (R1). The protocol for establishment of a new WCB is provided. If the protocol to establish a new WCB differs from the current protocol, a variation procedure shall be submitted.

## Control of critical steps and intermediates

The Applicant has presented critical and non-critical quality attributes (QAs) of bevacizumab, their relevance to the similarity assessment, and the justification for the criticality and similarity assignment. For QAs that have been ranked as CQAs, most are controlled through release and stability testing. The in-process controls including process parameters and material attributes with ranges and in-process tests with control limits have also been provided.

The PF-06439535 manufacturing process is built upon the Applicant's CHO cell-derived mAb platform process. Principles outlined in ICH Q8-ICH Q11 are applied. The control strategy was defined using a holistic approach. The understanding of the PF-06439535 manufacturing process has been obtained by performing manufacturing-scale runs and process characterisation studies, including design of experiments (DOE) studies, and by using scale-down models of individual unit operations. In alignment with ICH Q10, quality systems are in place to support continuous quality/process verification and change management post approval.

## Process validation

The validation of the PF-06439535 active substance manufacturing process included three process performance qualification (PPQ) batches from three independent consecutive thaws of the WCB. Process parameters (inputs) were maintained within pre-defined limits. The process validation was demonstrated by meeting pre-determined acceptance criteria for product quality and performance parameters.

Process validation was conducted on a number of consecutive batches from consecutive thaws of the WCB. Manufacturing-scale runs and process characterisation studies were performed, which include DOE studies using scale-down models of individual unit operations representative of the commercial process and univariate and multivariate experiments.

All process validation batches met acceptance criteria and conform to the commercial specifications. In addition, process parameter and in-process test data from the process validation campaign are within committed control limits for the commercial process. Process validation results demonstrate control, effectiveness and consistency of the AS manufacturing process.

The final container closure system has been appropriately validated. The two sizes of container were considered during the process validation studies and process manufacture development studies. Container integrity is confirmed visually at the time of use.

<div style=\"page-break-after: always\"></div>

## Manufacturing process development

Only minor modifications were made during the process development history, and all batches used for nonclinical and clinical studies were manufactured at the intended commercial launch site using the intended commercial process. Some process parameters were tightened as the program progressed to process validation to optimize process performance and consistency, while remaining within prior established target ranges. Overall, the process changes have no significant impact on process performance or product.

In order to reduce the sparger clogging, which was observed during the development phase of the process a different sparger configuration and a new impeller configuration was used thereafter.

## Characterisation

All characterisation and elucidation studies were conducted on PF-06439535 manufactured by the commercial manufacturing process. The analytical techniques and methodologies applied to the characterisation of PF-06439535 are capable of evaluating primary structure, molecular mass, posttranslational modifications, charge and size heterogeneity, extinction coefficient, higher order structure, aggregation and fragmentation, biological activity and degradation pathways. The results demonstrated that PF-06439535 has the expected structure and functional properties.

## Specification

Adequate active substance specifications have been provided. The list of test parameters for the active substance specification includes tests of identity, purity and impurities, potency and other general tests. The acceptance criteria are applicable to batch release and end of shelf-life unless specified.

In-house method numbers for the analytical procedures used for active substance release are specified in the dossier. Stated impurities have been studied in non-clinical studies.

## Analytical methods

The analytical methods used for active substance testing have been described in detail. The majority of analytical procedures are common to both AS and FP. Compendial analytical procedures used for batch release and stability studies are clarity, coloration, pH, bioburden and endotoxin. Non-compendial analytical procedures used for batch release and stability studies were demonstrated to be suitable for the intended use.

The validation of the analytical methods was described in detail. The results are deemed sufficient and acceptable and the methods are considered appropriately validated.

## Batch analysis

Batch data from several PF-06439535 active substance batches which demonstrate that manufacturing generates a consistent active substance have been provided.  All batches comply with the commercial acceptance criteria with the exception of colouration since the colour standard was only specified for appearance testing for the process validation batches.

## Reference standard

The reference standard used for analysis of finished product is the same as that used for active substance. PF-06439535 reference standards were generated as follows: a clinical reference material, primary reference material (PRM) and a working reference material (WRM). A two tiered system for in-house PF-06439535 reference material has been implemented to support the commercial product. The existing primary reference

<div style=\"page-break-after: always\"></div>

material (PRM) and working reference material (WRM) have been suitably manufactured and characterised for their purpose.

A protocol for the qualification of future reference standard is provided, which is acceptable.

## Stability

A suitable shelf life is proposed for active substance stored at the intended storage conditions. This shelf life claim is based on an ICH compliant stability programme, including long term and accelerated conditions and under stressed conditions (thermal stress and photostability stress). Based on the data presented, the proposed active substance shelf life is supported. The proposed stability protocol containing adequate stability-indicating test parameters is considered appropriate.

## 2.1.3. Finished Medicinal Product

## Description of the product and pharmaceutical development

The finished product is presented as a liquid concentrate for solution for infusion as a 100 mg/4 mL presentation and a 400 mg/16 mL presentation.

Zirabev finished product, 100 mg/4 mL presentation, is supplied in a 5 mL Type I clear glass vial sealed with a stopper and an aluminum seal with flip-off plastic cap. To ensure that a 4 mL nominal volume can be withdrawn from the vial, there is an overfill of approximately 0.3 mL.

Zirabev finished product, 400 mg/16 mL presentation, is supplied in a 20 mL Type I clear glass vial sealed with a stopper and an aluminum seal with flip-off plastic cap. To ensure that a 16 mL nominal volume can be withdrawn from the vial, there is an overfill of approximately 0.5 mL.

For both presentations there is no manufacturing overage. The two presentations are comparable and representative of one another in that the AS and formulated bulk FP used to make the Zirabev are identical for the two presentations.

Zirabev finished product is formulated in succinate (buffer), sucrose (tonicifier), edetate disodium dihydrate (EDTA) (chelator), polysorbate 80 (surfactant), and water for injections (solvent) pH 5.5. The selected formulation for PF-06439535 is different from the licensed bevacizumab.

## Pharmaceutical development

The formulation development program for Zirabev evaluated the effects of buffer type, pH and excipient selection on the chemical and physical stability of the active molecule. The composition of the final formulation is different from the reference product.

There are two presentations for Zirabev intended to match the presentations in markets where the corresponding presentation of the Avastin licensed product is registered: 100 mg and 400 mg single-dose vials (100 mg/4 mL and 400 mg/16 mL). The formulation composition has remained the same throughout development. Only the 400 mg Zirabev presentation was used in clinical studies. Zirabev has been manufactured at the intended commercial manufacturing facility for the entirety of the clinical development program. No significant changes have been made to the overall process for Zirabev manufacturing throughout the product history.

<div style=\"page-break-after: always\"></div>

## Manufacture of the product and process controls

Zirabev 400 mg/16 mL and 100 mg/4 mL (both 25 mg/mL) presentations are manufactured using the same process steps and controls. The only differences between the presentations are the fill volume and the container closure system. All other manufacturing steps and process parameters are the same.

The batch formula for Zirabev presentations 400 mg/16 mL and 100 mg/4 mL consists of the same bulk Zirabev formulation including 25 mg/mL PF-06439535, 85 mg/mL sucrose, 0.05 mg/mL edetate disodium dihydrate (EDTA), 0.2 mg/mL polysorbate 80, in 20 mM succinate buffer at pH 5.5.

Frozen PF-06439535 active substance is shipped in appropriate containers. The active substance is thawed and transferred to a manufacturing vessel.  Dilution buffer is prepared and the active substance is diluted with the buffer to the target protein concentration.  The bulk finished product is then sterile filtered, aseptically filled into vials, stoppered and capped with a crimp seal.  Following the capping operation, the vials are visually inspected.

## Validation

The manufacturing process has been validated. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. Process controls with their control limits for the finished product manufacturing process have been provided and are acceptable.

Sufficient information is provided on filter validation and shipping validation.

There is no excipient of human or animal origin and no novel excipient. An adequate elemental impurities risk assessment is presented in accordance with ICH Q3D.

## Product specification

The list of test parameters for the finished product specification contains tests for control of identity, purity and impurities, potency and other general tests. The acceptance criteria are applicable from lot release to end of shelf-life.  The  specification  for  the  finished  product  release  has  been  set  in  accordance  with  Ph.  Eur. Requirements and ICH Q6B.

## Reference standard

The reference standard used for analysis of Zirabev FP is the same as that used for the AS.

## Batch analysis

Batch analysis data are presented for FP lots for both presentations 100 mg  and 400 mg  used for clinical trials, stability and process validation. The results demonstrate consistency of the manufacturing process capabilities. All lots comply with the commercial acceptance criteria.

## Stability of the product

The proposed shelf-life for the unopened vial is 3 years when stored at the recommended temperature of 2 - 8 °C. The FP should not be frozen and the vial should be kept in the outer carton in order to protect from light. The stability program followed the relevant ICH guidelines for stability of the finished product and data is provided for both 100mg/4mL and 400mg/16mL presentations.

Stability data were provided for primary and supportive FP batches for both 100mg/4mL and 400mg/16mL presentations stored under the recommended long term conditions of 5 ± 3 °C, the accelerated condition of 25

<div style=\"page-break-after: always\"></div>

± 2 °C/60 ± 5% relative humidity (RH). In addition data from thermal stress and photostability conditions were included. Additional long term stability data are provided for FP batches, which is considered representative and support the 3-year shelf-life at 2°C - 8°C.

Based on the stability results an appropriate recommendation is made in the SPC.

Zirabev FP is formulated as a concentrate for solution for infusion. Prior to administration Zirabev needs to be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared solution and diluted to the required administration volume with sodium chloride 9 mg/ml (0.9%) solution for injection. Studies were performed to evaluate the physicochemical stability and compatibility of PF-06439535 in 0.9% sodium chloride with commercially available administration components that are commonly used during preparation and storage of the dosing solution and/or during infusion. These studies were completed using several lots of FP including an aged FP lot near the end of its shelf life.

## Adventitious agents

The approach for adventitious agents testing is described. The MCB and WCB testing is reviewed as part of the active substance control as well as the control of raw materials.

The only material of animal origin identified is an antiserum used in clone selection, which is derived from sheep and stabilized in bovine serum albumin. A CEP is not available for this reagent and bovine serum albumin (BSA). However, the information on the origin of the serum indicates low risk of viral contamination and testing performed to qualify the cell line could be expected to have detected adventitious agents from these species.

Viral clearance studies were performed with a suitable panel of model viruses on qualified small scale models. The total process clearance determined by summation of orthogonal removal/inactivation methods.

## Comparability exercise for finished medicinal product

The Applicant has performed an extensive comparability analysis to demonstrate biosimilarity to the reference product Avastin (Avastin bevacizumab-EU and Avastin bevacizumab-US).

The comparability assessment consists of a comparison of PF-06439535 to bevacizumab-EU, PF-06439535 to bevacizumab-US, and bevacizumab-EU to bevacizumab-US. Formulation differences were not considered to influence the analytical studies. Details of methods used in the characterisation and forced degradation studies, including method qualification or validation, are presented.

A summary of the analytical similarity assessment is provided in Error! Reference source not found. . In general,  the  biosimilarity  assessment  performed  by  the  Applicant  is  considered  adequate  to  confirm  the analytical similarity between PF-06439535 and EU-approved Avastin.

## Table 1 Summary of the methods used to analyse PF-06439535, bevacizumab-US and bevacizumab-EU

| Quality attribute                                     | Criteria for similarity       | Analytical procedure                                       | Similarity conclusion       |
|-------------------------------------------------------|-------------------------------|------------------------------------------------------------|-----------------------------|
| Primary Structure and Posttranslational Modifications | Identical amino acid sequence | LC/MS/MS - Peptide Mapping with specialized bioinformatics | Identical primary sequence. |

<div style=\"page-break-after: always\"></div>

|                                     |                                                                                                                   | Peptide Mapping/ Edman Degradation                                         |                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                     | Similar molecular mass and size                                                                                   | nanoElectrospray Ionization Mass Spectrometry                              | Comparable results.                                                                                                                                                                                                                                                                                                                                 |
|                                     | Similar posttranslational modifications                                                                           | nanoElectrospray Ionization Mass Spectrometry                              | Comparable profiles.                                                                                                                                                                                                                                                                                                                                |
|                                     | Similar posttranslational modifications                                                                           | LC/MS - Subunit Analysis LC/MS and LC/UV - Peptide Mapping (Trypsin)       | Comparable profiles.                                                                                                                                                                                                                                                                                                                                |
| VEGF binding to Fab Domain          | Similar range of inhibition of VEGF response and binding to VEGF                                                  | Inhibition of Cell Growth Assay                                            | Slightly lower inhibition of cell growth activity observed for PF-06439535 batches as compared to bevacizumab-EU. However, the statistical quality range for relative potency of bevacizumab-EU covers the range for PF-06439535.                                                                                                                   |
| VEGF binding to Fab Domain          | Similar range of inhibition of VEGF response and binding to VEGF                                                  | Binding to VEGF165 Target Antigen by ELISA                                 | Comparable binding.                                                                                                                                                                                                                                                                                                                                 |
| VEGF binding to Fab Domain          | Similar binding to other VEGF isoforms                                                                            | Binding to other VEGF isoforms (VEGF121, VEGF189, VEGF206) by ELISA        | Comparable binding.                                                                                                                                                                                                                                                                                                                                 |
| ADCC Activity                       | Similar lack of ADCC activity                                                                                     | PBMC ADCC assay                                                            | Similar lack of ability to induce ADCC.                                                                                                                                                                                                                                                                                                             |
| Fc Ɣ Receptor Binding               | Similar binding kinetics                                                                                          | Binding to Fc Ɣ RI, Fc Ɣ RIIa, Fc Ɣ RIIb, Fc Ɣ RIIIa and Fc Ɣ RIIIb by SPR | Comparable binding. Minor differences in relative KD (% KD) values for FcγRIIIa 158F are considered not significant. SPR response results demonstrate similar binding to FcγRIIIa 158F.                                                                                                                                                             |
| FcRn Binding                        | Similar range of binding to FcRn                                                                                  | Binding to FcRn by SPR                                                     | Comparable binding. Minor differences in relative KD (% KD) values for FcRn are considered not significant. SPR response results demonstrate similar binding to FcRn. Not considered to have an impact on PK.                                                                                                                                       |
| CDC Activity                        | Similar lack of CDC activity                                                                                      | CDC assay                                                                  | Similar lack of CDC activity.                                                                                                                                                                                                                                                                                                                       |
| CDC Activity                        | Similar dose-dependent response curves                                                                            | C1q binding assay                                                          | Comparable binding to C1q.                                                                                                                                                                                                                                                                                                                          |
| N-Linked Glycan Profile             | Similar N-linked glycan distribution profile, structure, composition, glycosidic linkages, and sialic acid levels | HILIC/MS                                                                   | Predominant N-linked glycans contents (G0F and G1F) similar. Slightly higher Man5 levels are not considered to have impact on PK.                                                                                                                                                                                                                   |
| N-Linked Glycan Profile             | Similar N-linked glycan distribution profile, structure, composition, glycosidic linkages, and sialic acid levels | Exoglycosidase Digestion/HILIC                                             | Predominant N-linked glycans contents (G0F and G1F) similar. Slightly higher Man5 levels are not considered to have impact on PK.                                                                                                                                                                                                                   |
| Charge Heterogeneity: Species       | Similar range for levels of acidic species                                                                        | iCE                                                                        | Slightly lower acidic and main species and largely higher basic species observed for PF-06439535 as compared to bevacizumab EU batches. Difference for basic species attributed to PF-06439535 (all batches) having a higher proportion of species containing one or two C-terminal lysine residues in the heavy chain are not clinically relevant. |
| Charge Heterogeneity: Basic Species | Similar range for levels of basic species                                                                         | iCE                                                                        | Slightly lower acidic and main species and largely higher basic species observed for PF-06439535 as compared to bevacizumab EU batches. Difference for basic species attributed to PF-06439535 (all batches) having a higher proportion of species containing one or two C-terminal lysine residues in the heavy chain are not clinically relevant. |
| Charge Heterogeneity: Main Species  | Similar range for levels of main species                                                                          | iCE                                                                        | Slightly lower acidic and main species and largely higher basic species observed for PF-06439535 as compared to bevacizumab EU batches. Difference for basic species attributed to PF-06439535 (all batches) having a higher proportion of species containing one or two C-terminal lysine residues in the heavy chain are not clinically relevant. |

<div style=\"page-break-after: always\"></div>

| Charge Heterogeneity   | Similar identity of major and minor charge isoforms                                                                                                                                   | Cation Exchange-HPLC profile characterized by MS                                                                                                               | Similar identity of charge isoforms present for PF-06439535, bevacizumab-EU batches.                               |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Charge Heterogeneity   | Similar identity of major and minor charge isoforms                                                                                                                                   | Carboxypeptidase B/iCE                                                                                                                                         | Comparable levels of charge species.                                                                               |
| Product Purity         | Similar range for levels of monomer                                                                                                                                                   | SE-HPLC                                                                                                                                                        | Increase in purity profile: higher monomer content and lower levels of HMMS leading to a better safety profile.    |
| Product Purity         | Similar range for levels of HMMS                                                                                                                                                      | SE-HPLC                                                                                                                                                        | Increase in purity profile: higher monomer content and lower levels of HMMS leading to a better safety profile.    |
| Product Purity         | Similar range for levels of HC + LC and fragment content                                                                                                                              | CGE (reducing)                                                                                                                                                 | Increase in purity profile: higher HC+LC content and lower levels of fragments leading to a better safety profile. |
| Product Purity         | Similar range for levels of Intact IgG                                                                                                                                                | CGE (Non-reducing)                                                                                                                                             | Higher level of intact IgG leading to a better safety profile.                                                     |
| Product Purity         | Similar banding pattern                                                                                                                                                               | SDS-PAGE (Total protein staining and Western blotting)                                                                                                         | Similar banding pattern.                                                                                           |
| Disulfide Bonds        | Similar state of cysteines and disulfide bonds                                                                                                                                        | Sulfhydryl Analysis                                                                                                                                            | Comparable results.                                                                                                |
| Disulfide Bonds        | Similar state of cysteines and disulfide bonds                                                                                                                                        | LC/MS - Non-reduced Peptide Mapping (Lys-C)                                                                                                                    | Comparable results.                                                                                                |
| Higher Order Structure | Similar secondary structure                                                                                                                                                           | Far-UV Circular Dichroism (CD) Spectroscopy                                                                                                                    | Similar graphical profiles.                                                                                        |
| Higher Order Structure | Similar secondary structure                                                                                                                                                           | Fourier Transform Infrared (FTIR) Spectroscopy                                                                                                                 | Similar graphical profiles.                                                                                        |
| Higher Order Structure | Similar tertiary structure                                                                                                                                                            | Near-UV CD Spectroscopy Fluorescence Spectroscopy                                                                                                              | Similar graphical profiles.                                                                                        |
| Higher Order Structure | Similar thermal stability                                                                                                                                                             | Differential Scanning Calorimetry (DSC)                                                                                                                        | Similar graphical profiles.                                                                                        |
| Forced degradation     | Similar degradation profiles under forced degradation conditions (elevated temperature, light exposure, and forced deamidation) and demonstrate there are no new degradation products | SE-HPLC, iCE, CGE (reducing and nonreducing), cell based bioassay, UV spectroscopy, LC/MS -Peptide mapping (Trypsin), HIAC (elevated temperature studies only) | Similar degradation pathways. No new degraded species.                                                             |

<div style=\"page-break-after: always\"></div>

## GMO

Not applicable.

## 2.1.4. Discussion on chemical, pharmaceutical and biological aspects

Module 3 of the dossier for PF-06439535 is of good quality and the information provided is sufficiently detailed.

No major objection was raised by CHMP. Other concerns were raised in relation to several issues. The Applicant was requested to justify and explain the rationale behind their proposed control strategy and provide particular examples of expected critical process parameters (CPP) (e.g. pH, oxygen, density, temperature etc.).

The Applicant provided additional data and explanations and was able to resolve all concerns. Two recommendations for post-authorisation follow-up related to the compound-specific toxicological risk assessment in case of any unexpected leachable and the ultrafiltration monitoring protocol for all parameters and scale down model viral clearance studies have been listed. One recommendation for pre-authorisation follow-up, relates to the provision of final protocols for the monitoring of chromatography resins and ultrafiltration membrane process steps.

During the procedure a concern was raised in relation to differences observed in biological activity by the cell growth assay between PF-06439535 and the EU reference product. The Applicant justified the differences on the basis of assay variability. In conclusion based on the totality of evidence it was considered that sufficient reassurance on the conclusion of biosimilarity of bevacizumab versus the EU reference product was obtained. The Applicant has committed to re-evaluate the acceptance criterion for potency/biological activity after manufacture of recommended number of commercial batches as a post-authorisation recommendation.

The analytical similarity between PF-06439535 and the reference products, Avastin bevacizumab-EU and Avastin bevacizumab-US, has been addressed in an extensive comparability exercise. The similarity between PF-06439535 and EU-approved Avastin can be confirmed.

In conclusion, from a quality point of view, the MAA of PF-06439535 is approvable as a biosimilar to Avastin bevacizumab-EU.

## 2.1.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

The analytical similarity between PF-06439535 and the reference products, Avastin bevacizumab-EU and Avastin bevacizumab-US, has been confirmed in an extensive comparability exercise.

In conclusion, from a quality point of view, the MAA of PF-06439535 is approvable as a biosimilar to Avastin bevacizumab-EU.

## 2.1.6. Recommendation(s) for future quality development

In the context of the obligation of the Marketing Authorisation Holder (MAH) to take due account of technical and scientific progress, the CHMP recommended additional following points for further investigation, where the Applicant commits to:

<div style=\"page-break-after: always\"></div>

-  notify authorities if an increase of a particular impurity of any unexpected leachable compound is observed at future time points of the on-going leachables study and provide the associated compound specific toxicological risk assessment.
-  provide final protocols for the monitoring of chromatography resins and ultrafiltration membranes process steps.
-  perform additional scale down model viral clearance studies in alignment with the manufacturing process.
-  re-evaluate the acceptance criterion for potency/biological activity for active substance and finished product for this assay after manufacture of the recommended number of commercial batches.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

The known mechanism of action (MoA) of bevacizumab is to bind VEGF, thereby inhibiting the interaction of VEGF and its receptors (VEGFR-1 and VEGFR-2 (Ellis, 2006)).

VEGF is a major mediator of tumour angiogenesis and signals through VEGFR-2, the major VEGF signalling receptor (Kerbel, 2008). VEGF binds to VEGFR-2 on the surface of endothelial cells, leading to receptor dimerization and autophosphorylation, and activation of intracellular signalling pathways, including PI3K, Src, Akt, and ERK (Matsumoto &amp; Claesson-Welsh, 2001). Activation of multiple signalling pathways eventually leads to biological responses which include cell activation, proliferation, differentiation, migration, survival, and vascular permeability. All of these activities mediate the formation of new blood vessels. The applicant did not perform any own pharmacodynamics studies with PF-06439535.

Physicochemical and functional characterization of PF-06439535, bevacizumab-US, and bevacizumab-EU was undertaken.

## 2.2.2. Pharmacology

## Primary pharmacodynamic studies

To assess the similarity of pharmacologic response for PF-06439535 compared with bevacizumab, PF-06439535 was tested in a panel of in vitro functional and binding assays that are reflective of the Mechanism of Action (MoA) of bevacizumab. In all of these assays, PF-06439535 was compared to bevacizumab-US and bevacizumab-EU, and bevacizumab-US was compared to bevacizumab-EU.

The known MoA for bevacizumab involves the binding of the Fab domain of the monoclonal antibody to the VEGF target antigen in the extracellular matrix and preventing it from binding to its receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting VEGF activities. A functional assay was developed to measure inhibition of VEGF-induced cell proliferation in human endothelial umbilical vein cells (HUVEC). In addition, the binding of bevacizumab to the target antigen human VEGF was assessed with a binding enzyme-linked immunosorbent assay (ELISA).

In compliance with Guideline on similar biological medicinal products containing monoclonal antibodies, following in vitro non-clinical studies have been performed:

<div style=\"page-break-after: always\"></div>

- Binding to targets antigen: binding of bevacizumab to the target antigen human VEGF (VEGF165, VEGF121, VEGF189, and VEGF206)
- Binding of PF-06439535, bevacizumab-US, bevacizumab-EU to representative isoforms of the relevant three Fc gamma receptors (FcγRI, FcγRII and FcγRIII), FcRn and complement (C1q)
- Fab-associated functions (Inhibition of VEGF binding to its receptors and cell proliferation)
- Fc-associated functions of PF-06439535, bevacizumab-US, bevacizumab- EU: Lack of ADCC and CDC activity in VEGF expressing cells

Together these assays broadly cover the functional aspects of PF-06439535.

## Secondary pharmacodynamic studies

No secondary pharmacodynamics study with PF-06439535 was conducted.

## Safety pharmacology programme

No stand-alone safety pharmacology study has been conducted. Information on cardiovascular and respiratory endpoints was collected in the repeat dose toxicity study in young male Cynomolgus monkeys (see section 2.2.4 Toxicology).

## Pharmacodynamic drug interactions

No pharmacodynamic drug interactions study has been conducted.

## 2.2.3. Pharmacokinetics

Toxicokinetic (TK) and anti-drug antibody (ADA) evaluations were conducted in support of a 1-month repeat-dose toxicity study in young male Cynomolgus monkeys with PF-06439535 and bevacizumab-EU (Study 13GR179) and a 2-week repeat-dose toxicity study of PF-06439535 in Sprague-Dawley rats (Study 8305590 [14MA078]). Validated assays were used for the TK and ADA evaluations.

Exposure to PF-06439535 was confirmed in both rat and monkey, and mean systemic exposure (as assessed by Cmax and AUC72) for PF-06439535 and bevacizumab-EU was similar in monkeys. The mean Cmax and AUC72 exposure ratios of PF-06439535 relative to bevacizumab (EU) on Day 1 and 25 ranged from 0.8 to 1.0. Antibodies to PF-06439535 or bevacizumab were not detected in any animals treated with PF-06439535 or bevacizumab (EU).

No studies on distribution, metabolism, excretion, or pharmacokinetic drug interaction have been conducted with PF-06439535.

## 2.2.4. Toxicology

## Single dose toxicity

No single-dose toxicity studies were conducted with PF-06439535.

<div style=\"page-break-after: always\"></div>

## Repeat dose toxicity

## Comparative study in monkey, PF-06439535 vs bevacizumab-EU (Study 13GR179, GLP)

PF-06439535  and bevacizumab-EU were each administered by IV bolus injection to young male Cynomolgus monkeys (4/group) at 10 mg/kg/dose twice weekly for 1 month (Days 1, 4, 8, 11, 15, 18, 22, 25, and 29). A separate group of monkeys (4 males) received the vehicle control article/diluent 1 used with PF-06439535 (20 mM succinate, 85 mg/mL sucrose, 0.05 mg/mL EDTA, 0.2 mg/mL polysorbate-80, pH 5.5). Another group of 4 males received the vehicle control article/diluent 2 used with bevacizumab-EU (60 mg/mL trehalose, 5.8 mg/mL sodium phosphate [monobasic], 1.2 mg/mL sodium phosphate [dibasic], 0.4 mg/mL polysorbate-20, pH 6.2). A 10 mg/kg twice weekly dose was justified on the basis of the Originator's toxicity studies in which physeal dysplasia was observed.

Assessments included mortality, clinical signs, body weights, food intake, ophthalmic examinations, heart rate, electrocardiograms, respiration rate, haematology, coagulation, clinical chemistry, and urinalysis parameters. Blood samples were collected from all animals for measurement of PF-06439535 or bevacizumab-EU serum concentrations and determination of TK parameters. Blood samples were also collected from all animals for evaluation of ADA induction. At the end of the dosing phase, a complete necropsy was conducted, organs were weighed, and tissues were collected for microscopic evaluation.

Administration of PF-06439535 or bevacizumab-EU was well tolerated. There were no PF-06439535 or bevacizumab-EU-related findings in clinical signs, body weight, food intake, ophthalmology examinations, respiration rate, electrocardiograms, haematology, coagulation, clinical chemistry, or urinalysis parameters. All animals survived to their scheduled euthanasia and there were no PF-06439535 or bevacizumab-EU-related changes in organ weights or macroscopic findings.

All animals were sexually immature based on the microscopic appearance of the male reproductive tract tissues. All animals were skeletally immature based on the presence of active (open) growth plates observed microscopically in the distal femur. PF-06439535 or bevacizumab-EU-related microscopic findings were limited to the expected pharmacologically-mediated response of physeal dysplasia of the growth plate of the distal femur, with apparent similarity in incidence and severity (minimal to moderate) in all animals dosed with PF-06439535- or bevacizumab-EU. This finding was considered to be adverse for growing animals. There were no findings of physeal dysplasia in the two concurrent vehicle control groups.

## Non-comparative study in rat, PF-06439535 (study 8305590, GLP)

A 2-week IV bolus repeat-dose study was conducted in SD rats (13-14/sex/group) administered PF-06439535 at 0, 15, or 150 mg/kg IV twice weekly for 2 weeks (5 doses, Days 1, 4, 8, 11, and 15). Assessment of toxicity was based on mortality, clinical observations, body weight, food consumption, ophthalmic examinations, and clinical and anatomic pathology. Blood samples were collected from toxicokinetic animals for toxicokinetic evaluations and ADA analysis.

PF-06439535 had no effect on survival, clinical observations, food consumption, or ophthalmic examinations or clinical pathology parameters. PF-06439535 was associated with a non-adverse, statistically significantly minimally higher mean body weight gain in males administered 150 mg/kg/dose. This finding was not considered adverse because it was small in magnitude, did not correlate with other findings, and was within the range observed for this strain at this age.

<div style=\"page-break-after: always\"></div>

No direct PF-06439535-related changes were present in the haematology, coagulation, clinical chemistry, or urinalysis test results. On Day 16 of the dosing phase, the male group administered 150 mg/kg/dose had minimally higher mean serum total protein concentration, and male and female groups administered 150 mg/kg/dose had minimally to mildly higher serum globulin concentrations with concurrent minimally lower albumin:globulin ratios. Comparison of serum globulin concentrations to the plasma concentration of the test article (an immunoglobulin) indicated that higher serum globulin concentrations and changes in other serum protein parameters were due to the physical presence of the test article and not to a biological effect of test article administration.

PF-06439535 was associated with minimal sinusoidal cell hyperplasia in the liver of males and females administered 150 mg/kg/dose. In males, this finding correlated with higher absolute and relative group mean liver weights (1.14 to 1.31x control) and was not adverse because of the minimal severity, lack of correlating clinical pathology findings, and absence of clinically observed detrimental effects on the health of the animals.

## Genotoxicity

No genotoxicity study with PF-06439535 was conducted.

## Carcinogenicity

No carcinogenicity study with PF-06439535 was conducted.

## Reproduction Toxicity

No reproduction and development study with PF-06439535 was conducted.

## Toxicokinetic data

## Repeat-dose toxicokinetics of PF-06439535 in SD rats (Study 8305590, GLP)

After twice-weekly IV dosing of PF-06439535 at 15 or 150 mg/kg/dose in SD rats for 2 weeks, systemic exposure (as assessed by Cmax and AUC72) was similar in males and females across dose groups ( Error! Reference source not found. ). Mean systemic exposure increased with increasing dose in a slightly less than dose-proportional manner on Days 1 and 11. Based on mean AUC72 values, mean accumulation ratios (AUC72, Day 11/Day 1) ranged from 2.3 to 2.6 in males and from 2.7 to 3.0 in females across all dose groups. ADAs were not detected in animals dosed with vehicle or PF-06439535.

Table 2: Mean ± SD toxicokinetic parameters for PF-06439535 in SD rats (n = 4/sex/group) after twice-weekly administration of PF-06439535

|   Dose (mg/kg/dose) |   Study Day | Sex    | Cmax (µg/mL)   | AUC 72 (µg•h/mL)   |
|---------------------|-------------|--------|----------------|--------------------|
|                  15 |           1 | Male   | 308 ± 34.2     | 12200 ± 904        |
|                  15 |           1 | Female | 308 ± 8.54     | 12000 ± 624        |
|                  15 |          11 | Male   | 659 ± 53.9     | 31600 ± 2360       |
|                  15 |          11 | Female | 720 ± 56.3     | 35800 ± 2720       |
|                 150 |           1 | Male   | 2740 ± 341     | 110000 ± 7760      |
|                 150 |           1 | Female | 2780 ± 1170    | 96800 ± 20000      |
|                 150 |          11 | Male   | 6260 ± 394     | 250000 ± 34100     |

<div style=\"page-break-after: always\"></div>

| Female   | 6660 ± 400   | 258000 ± 12400   |
|----------|--------------|------------------|

AUC72 = Area under the serum drug concentration-time curve for 0-72 hours; Cmax = Highest drug concentration observed in serum.

## Repeat-dose toxicokinetics of PF-06439535 and bevacizumab-EU in Cynomolgus monkeys (Study 13GR179, GLP)

After twice-weekly IV dosing of PF-06439535 or bevacizumab-EU at 10 mg/kg/dose in young male Cynomolgus monkeys for 1 month there were no quantifiable concentrations of PF-06439535 or bevacizumab-EU in samples collected and analysed prior to dosing on Day 1, or in samples analysed from vehicle control groups. Quantifiable concentrations of PF-06439535 or bevacizumab-EU at all time points collected and analysed from day 1 through day 30 (day 29, 24 hours post-dose) confirmed exposure to PF-06439535 or bevacizumab-EU over the duration of the study. Mean systemic exposure (as assessed by Cmax and AUC72) for PF-06439535 and bevacizumab-EU was similar. The mean Cmax and AUC72 exposure ratios of PF-06439535 relative to bevacizumab-EU on Day 1 and 25 ranged from 0.8 to 1.0. ADAs were not detected in animals dosed with PF-06439535 or bevacizumab-EU.

Table 3: Mean ± SD toxicokinetic parameters for PF-06439535 and bevacizumab-EU in male Cynomolgus monkeys (n = 4/group) after twice-weekly administration of PF-06439535 or bevacizumab-EU at 10 mg/kg/dose

|                |    | Cmax (µg/mL)   |       | AUC 72 (µg•h/mL)   |       |
|----------------|----|----------------|-------|--------------------|-------|
| PF-06439535    |  1 | 241 ± 37.2     | 0.809 | 12100 ± 876        | 0.823 |
| Bevacizumab-EU |  1 | 298 ± 29.6     | 0.809 | 14700 ± 2260       | 0.823 |
| PF-06439535    | 25 | 789 ± 54.7     | 0.925 | 45500 ± 5420       | 1.01  |
| Bevacizumab-EU | 25 | 853 ± 91.5     | 0.925 | 45100 ± 3670       | 1.01  |

AUC72 = Area under the serum drug concentration-time curve for 0-72 hours; Cmax = Highest drug concentration observed in serum.  a . PF-06439535: bevacizumab-EU ratio.

## Local Tolerance

No separate local tolerance studies have been conducted with PF-06439535. Compared with their respective vehicle controls, there were no adverse findings suggestive of injection site toxicity observed with PF-06439535 or bevacizumab-EU in monkey (Study 13GR179). In the 2 week study in rat (Study 8305590), minimal to mild perivascular haemorrhage and/or mixed cell inflammation was observed at the intravenous injection site. The findings were considered unrelated to the test article because they were distributed randomly among groups, including the control group, and were considered secondary to the mechanical trauma associated with the injection procedure.

## Other toxicity studies

Immunogenicity of PF-06439535 in comparison with bevacizumab (EU) was assessed as part of the 1-month toxicology study in monkeys (Study 13GR179), and for PF-06439535 in the 2 week study in rat (Study 8305590). No antidrug antibodies (ADA) were detected in the PF-06439535 or bevacizumab (EU) treated groups.

## 2.2.5. Ecotoxicity/environmental risk assessment

Bevacizumab is a protein, which is expected to biodegrade in the environment and not be a significant risk to the environment. Thus, according to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for

<div style=\"page-break-after: always\"></div>

Human Use' (EMEA/CHMP/SWP/4447/00), bevacizumab is exempt from preparation of an Environmental Risk Assessment as the product and excipients do not pose a significant risk to the environment.

## 2.2.6. Discussion on non-clinical aspects

## Pharmacology

The comparability exercise indicates that PF-06439535, bevacizumab-US, bevacizumab- EU can be considered biosimilar except for the binding affinity to the Fc Ɣ RIIIa 158 F isoform and the FcRn SPR Binding Activity for which some differences were observed. During the assessment procedure, the applicant discussed specific concerns related to this in accordance with the current knowledge on different FcgRIII variants (e.g. ADCC mediation, proinflammatory cytokines production, potential link of some phenotypes of FcgRIII to neutropenia, Ab-Ag complex mediated damage or Lupus-like reactions). Bevacizumab does not have ADCC function and there is no pro-inflammatory cytokine production expected. Binding of bevacizumab to FcgRIII variants were concluded to be of no concern at the clinical level with respect to neutropenia, lupus-like reactions or antigen-antibody complex mediated damage.

In conclusion, the small differences in bevacizumab FcgRIIIa 158F binding parameters or differences in patient FcgRIIIa genotype are considered unlikely to have clinical consequences.

Based on the results from the similarity assessment, the lack of in vivo pharmacology studies with PF-06439535 is acceptable and in line with guidance documents.

Dedicated studies on secondary pharmacodynamics, safety pharmacology, and pharmacodynamics drug interactions were not conducted. This is considered acceptable for a biosimilar product, and is also in accordance with Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues (EMA/CHMP/BMWP/403543/2010).

## Pharmacokinetic

Sensitive analytical procedures for quantification of PF-06439535 and bevacizumab (ELISA and ligand binding assay), and ADAs against bevacizumab (ECL), have been developed and validated for rat and monkey serum. The analytical methods are of adequate quality and are considered acceptable.

Systemic exposure (as assessed by Cmax and AUC72) for PF-06439535 and bevacizumab (EU) was comparable in monkey. ADAs were not detected neither in rats, nor monkeys dosed with PF-06439535 or bevacizumab-EU. However, quantifiable concentrations of PF-06439535 or bevacizumab (EU) present in samples may have interfered with the detection of ADA.

The lack of studies on distribution, metabolism, excretion, or pharmacokinetic drug interaction for PF-06439535 is acceptable and in line with EMA/CHMP/BMWP/403543/2010.

## Toxicology

Repeated dose toxicity studies in non-human primates are usually not recommended for similar biological products (EMA/CHMP/BMWP/403543/2010). Nevertheless, a 4-week repeat-dose toxicity study was conducted with PF-06439535 and bevacizumab (EU) in young Cynomolgus monkeys. In addition, and on the request of a regulatory authority outside Europe, the applicant performed a 2-week toxicology study in rat to detect potential adverse effects related to the formulation. From a 3R perspective and with reference to the European guidance document EMA/CHMP/BMWP/403543/2010, neither the study in monkey, nor the study in rat were warranted.

<div style=\"page-break-after: always\"></div>

At 10 mg/kg twice per week, both PF-06439535 and bevacizumab (EU) were well tolerated in the 4-week repeat dose toxicity study in sexually and skeletally immature Cynomolgus monkeys, with similar incidence and severity of findings related to the pharmacological effect (physeal dysplasia) in both treatment groups. The study design included only one dose level (10 mg/kg twice per week). This was selected based on original study results with bevacizumab, allowing for comparison of effects on physeal dysplasia, the most sensitive finding in the original 4-week toxicity study in monkeys with bevacizumab. Overall, results indicate comparable toxicity, immunogenicity and exposure levels, between PF-06439535 and bevacizumab (EU) at a dose level of 10 mg/kg twice per week.

In the rat study the NOAEL was established at the highest dose level (150 mg/kg/dose twice weekly for 2 weeks). Given the lack of reactivity between PF-06439535 and VEGF in rat, the high NOAEL is as expected.

The formulation for PF-06439535 is different from Avastin with respect to excipients used. The excipients are however well known and not expected to trigger adverse effects at the site of administration. No separate local tolerance studies have been conducted with PF-06439535. Compared with their respective vehicle controls, there were no adverse findings suggestive of injection site toxicity observed with PF-06439535 or bevacizumab-EU in monkey, or with PF-06439535 in rat.

No ADAs to PF-06439535 of bevacizumab (EU) were detected in either study. However, high levels of circulating drug could possibly have interfered with the ability to detect antibodies in the drug safety studies. In monkeys, a pharmacological response was observed in all animals dosed with PF-06439535 or bevacizumab-EU. This finding supports that any theoretical formation of ADAs did not neutralise the effect of the mAb. In line with this, the animals' plasma concentration of PF-06439535 and bevacizumab (EU) increased from day 1 towards the end of study.

Overall, the results add to the totality of evidence to support the demonstration of PF-06439535 as a biosimilar product to bevacizumab (EU).

Studies on genotoxicity, carcinogenicity, and reproduction and developmental toxicity were not conducted. This is considered acceptable, and in accordance with EMA/CHMP/BMWP/403543/2010. Sections 4.6 and 5.3 of the proposed SmPC are in line with the approved product information for Avastin.

PF-06439535 is not expected to pose a risk to the environment.

## 2.2.7. Conclusion on the non-clinical aspects

PF-06439535  can be considered similar to the reference product Avastin in terms of in vitro functionality (except for the binding affinity to the Fc Ɣ RIIIa 158 F isoform and the FcRn SPR binding activity for which some not clinically relevant differences were observed ), in vivo toxicological, toxicokinetic and immunogenicity profiles. The Summary table in Module SII of the RMP adequately reflects the important non-clinical findings with bevacizumab. The non-clinical findings with PF-06439535 were similar to findings reported for the reference product Avastin. Consequently, no additional measures are required.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

<div style=\"page-break-after: always\"></div>

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

##  Tabular overview of clinical studies

## Table 4.  Summary of Clinical Studies Included in This Submission

| Study Identifier (Country/Region)/ Status   | Study Design                                                                                                   | Treatment                                                                                                                         | Study Population                                    | Number of Subjects/Pati ents Randomized                     | Objectives                                                                                                                                                                                                                                                               |
|---------------------------------------------|----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B7391002 a (EU, single center)/Completed    | Single-arm, single-dose, open-label, pilot PK variability study                                                | A single dose of bevacizumab-EU was administered at a dose of 5 mg/kg as a 90 minute IV infusion.                                 | Healthy male subjects between 18 to 55 years of age | N=21 Bevacizumab-E U=21                                     | Primary  To assess the inter-subject variability in single dose PKs of bevacizumab in healthy subjects Secondary  To assess single dose safety (including immunogenicity) and tolerability of bevacizumab in healthy subjects  To assess the PK                       |
| B7391001 a (US, single center)/Completed    | Double-blind (sponsor unblinded), randomized (1:1:1), parallel-group, single-dose, 3-arm, comparative PK study | A single dose of PF-06439535, bevacizumab-EU, or bevacizumab-US was administered at a dose of 5 mg/kg as a 90 minute IV infusion. | Healthy male subjects between 21 to 55 years of age | N=102 PF-06439535=3 3 Bevacizumab-U S=33 Bevacizumab-E U=36 | after single dose PK Similarity  To compare the PK of PF-06439535 to bevacizumab-EU and PF-06439535 to bevacizumab-US PK Bridging  To compare the PK of bevacizumab-EU to bevacizumab-US Safety  To evaluate the single-dose safety, tolerability, and immunogenicity |

<div style=\"page-break-after: always\"></div>

Table 4.  Summary of Clinical Studies Included in This Submission

| Study Identifier (Country/Region)/ Status   | Study Design                         | Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Study Population                                                                                                                                                                          | Number of Subjects/Pati ents Randomized                                                                   | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B7391003 (WW)/Completed                     | Randomized (1:1), Double-blind Study | Patients receive at least 4 cycles and no more than 6 cycles of either PF-06439535 plus paclitaxel and carboplatin or bevacizumab-EU plus paclitaxel and carboplatin, followed by the previously assigned blinded bevacizumab monotherapy. Bevacizumab: 15 mg/kg by IV infusion on Day 1 of each of the 3-week (21-day) cycles. The initial dose was 15 mg/kg over 90 minutes as an IV infusion. If the first infusion was well tolerated, the second infusion may have been administered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions may have been administered over 30 minutes. Paclitaxel: administered as the first drug when chemotherapy was administered. 200 mg/m 2 by IV infusion over 3 hours on Day 1 in 21-day cycles. Carboplatin: | Patients  18 years of age with newly diagnosed Stage IIIB or IV non-squamo us NSCLC or recurrent non-squamo us NSCLC who have not received previous chemotherap y for metastatic disease | N=719 PF-06439535 plus paclitaxel and carboplatin=358 Bevacizumab-E U plus paclitaxel and carboplatin=361 | Primary To compare the confirmed ORR by Week 19 following treatment with PF-06439535 in combination with paclitaxel and carboplatin to bevacizumab-EU plus paclitaxel and carboplatin in patients who had not received previous treatment for advanced non-squamous NSCLC Secondary  To evaluate the safety of PF-06439535 plus paclitaxel and carboplatin and bevacizumab-EU plus paclitaxel and carboplatin;  To evaluate secondary measures of tumour control;  To evaluate the population PK of PF-06439535 and bevacizumab-EU;  To evaluate the immunogenicity of PF-06439535 and bevacizumab-EU |
|                                             |                                      | administered as the second drug when chemotherapy was administered. IV infusion dosing was based on the use of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                           |                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

Table 4.  Summary of Clinical Studies Included in This Submission

| Study Identifier (Country/Region)/ Status Study Design Treatment                                                           | Study Population   | Number of Subjects/Pati ents Randomized   | Objectives   |
|----------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------------------------------|--------------|
| mathematical formula, based upon a patient's GFR in mL/min and carboplatin AUC in mg/mL•min) over a minimum of 15 minutes. |                    |                                           |              |

Abbreviations: AUC=area under the concentration versus time curve; EU=European Union; GFR=glomerular filtration rate; IV=intravenous; N=total number of subjects/patients randomized; NSCLC=non-squamous non-small cell lung cancer; ORR=objective response rate; PK=pharmacokinetics; US=United States; WW=worldwide.

a. Efficacy was not assessed in this study.

## 2.3.2. Pharmacokinetics

The  pharmacokinetic  properties  of  PF-06439535  were  studied  and  compared  to  those  of  both  EU-  and US-sourced bevacizumab (Avastin) in the clinical program:

-  The first study (Study B7391002) was a single-dose, single-arm pilot pharmacokinetic (PK) variability study conducted with the reference EU product bevacizumab (not the test product PF-06439535) in healthy male subjects (n= 21). The Study was conducted to characterize inter-subject PK variability and safety profiles including immunogenicity of bevacizumab-EU following IV administration to healthy male subjects. The inter-subject variability, as indicated by the %CV, were 16%, 12%, and 15% for Cmax, AUCt, and AUCinf, respectively.
-  The phase I clinical study B7391001 in healthy male subjects: the primary objective was to demonstrate the PK similarity of PF-06439535 relative to the EU and US reference bevacizumab, and of bevacizumab-EU to bevacizumab-US, following a single 5 mg/kg dose intravenously (IV) infusion. A complete blood sampling for PK assessment were collected from pre-dose and at specified times up to day 100 of study visits.
-  The phase III  clinical  study  B7391003  in  patients:  the  secondary  objectives  of  the  study  included evaluation of serum trough bevacizumab concentrations at selected cycles. Blood sampling for predose (Cmax) PK assessment were collected prior to bevacizumab infusion at every cycle through cycle 17, and at end of treatment/Withdrawals. In addition, post-dose samples (apparent Cmax) were collected at 1 hour after the end of the IV infusion for Cycle 1 and 5 (if the patient received Cycle 5).

The same enzyme linked immunosorbent assay (ELISA) bioanalytical method was used for the phase I study (B7391001) and the phase III study (B7391003).  PF-06439535 and bevacizumab-EU were determined by electrochemiluminescence (ECL) following an antibody capture procedure. Description and validation reports were provided with satisfactory results regarding precision, accuracy, selectivity and sensitivity,  short  and long-term stability and incurred sample reanalysis.

In the Phase I PK study B7391001, the PK data were analysed using standard NCA approach with an internally validated  electronic  noncompartmental  analysis  (eNCA,  version  2.2.4)  software  system.  Pharmacokinetic parameters, e.g. AUCt, AUCinf, Cmax, CL, Vss, and t1/2 were calculated according to standard procedures.

<div style=\"page-break-after: always\"></div>

Standard  summary  statistics  ( means,  median,  SD,  CV  etc… )  have  been  used.  Point  estimates  and  90% confidence  interval  (CIs)  for  the  ratios  of  the  geometric  means  (GMs)  for  AUClast,  AUCinf,  and  Cmax  were estimated using an ANOVA model for comparisons between PF-06439535 and bevacizumab-EU.

To establish bioequivalence, the 90% CI for the test-to-reference ratio of GM for AUCt, AUCinf, and Cmax was to fall within the protocol-specified bioequivalence criteria of 0.80 and 1.25.

## Absorption

## · Bioavailability

The drug product is for intravenous use.

## · Bioequivalence

## Phase I study (b7391001)

This study was a double blind, single centre, randomised, parallel-group, single-dose, 3-arm, phase I study.

The Primary objective was to demonstrate the PK similarity of PF-06439535 to bevacizumab-US and bevacizumab-EU following 5 mg/kg single IV dose administration of the three products. The primary PK endpoints were: Cmax, AUCinf and AUClast based on PK samples collected through Day 71. Ad hoc PK analysis was also conducted based on PK samples collected through Day 100.

Test product was PF-06439535 (batch number 13-110832). Reference products were EU-sourced bevacizumab (batch 13-111567 and 13-111286) and US-sourced bevacizumab (batch 13-110446).

The PK bridging objective was to compare the PK of bevacizumab-EU to bevacizumab-US. The safety objective was to evaluate the single-dose safety, tolerability, and immunogenicity.

A total of 97 subjects of 101 (who received the assigned drug) in 3 parallel groups (32, 33, and 32 subjects, respectively) were included in the PK data analysis. Exclusions from the per-protocol population for the primary PK analysis (4 subjects) are properly discussed and justified.

To note, a sample size of 29 subjects per arm was calculated (based on the pilot PK study using the bevacizumab-EU) to provide at least 85% power for comparison in AUC and Cmax for the similarity objective between PF-06439535 and bevacizumab-EU. Thus, the available PK data are considered sufficiently sensitive to draw valid conclusions from the study.

Demographic data (age, race, ethnicity, weight, height and BMI) were comparable among the 3 treatment groups.

Blood samples (5 mL) for PK assessment were collected at pre-dose, 1.5 (end of infusion), 4 and 24 hours after the start of dosing, at days 3, 5, 8, 15, 22, 29, 43, 57, 64, 71 and 100 of study visits.

Serum concentration-time data for bevacizumab (Pfizer), bevacizumab (US), and bevacizumab (EU) are summarised by treatment and time point in Table 5 . Median serum concentration-time profiles for PF-06439535, bevacizumab-EU, and bevacizumab-US are presented in Figure 2. The mean standard deviation (±SD) PK parameters for bevacizumab-Pfizer, bevacizumab-EU, and bevacizumab-US are summarized in Table 6.

<div style=\"page-break-after: always\"></div>

Table 5 : Serum Bevacizumab-Pfzier, Bevacizumab-EU concentration (ng/mL) versus time Summary (Per-Protocol Population)

Treatment Group=Bevacizumab-Pfizer

| Planned Time Post Dose   |   N |   NALQ | Mean   | SD     | CV (%)   | Median   | Min   | Max    |
|--------------------------|-----|--------|--------|--------|----------|----------|-------|--------|
| OH                       |  33 |      0 |        |        |          |          |       |        |
| 1 H 30 MIN               |  33 |     33 | 140700 | 21154  | 15       | 142000   | 95400 | 193000 |
| 4H                       |  33 |     33 | 137700 | 20935  | 15       | 140000   | 89000 | 180000 |
| 24H                      |  33 |     33 | 113000 | 16066  | 14       | 115000   | 79800 | 143000 |
| 48H                      |  33 |     33 | 93670  | 16023  | 17       | 95300    | 64800 | 121000 |
| 96 H                     |  33 |     33 | 71700  | 11842  | 17       | 71700    | 49500 | 103000 |
| 168 H                    |  33 |     33 | 54710  | 11477  | 21       | 54300    | 36100 | 96700  |
| 336 H                    |  32 |     32 | 37380  | 7644.9 | 20       | 36850    | 22500 | 63700  |
| 504H                     |  32 |     32 | 27130  | 5361.3 | 20       | 26850    | 15600 | 37700  |
| 672 H                    |  32 |     32 | 20960  | 5302.4 | 25       | 20650    | 4220  | 28000  |
| 1008H                    |  30 |     30 | 12220  | 2800.6 | 23       | 12100    | 5990  | 17000  |
| 1344 H                   |  31 |     31 | 6846   | 1974.1 | 29       | 6780     | 2870  | 10500  |
| 1512 H                   |  32 |     32 | 4964   | 1574.6 | 32       | 4720     | 2110  | 8490   |
| 1680H                    |  30 |     30 | 3719   | 1314.9 | 35       | 3470     | 1410  | 6440   |
| 2376H                    |  30 |     29 | 833.9  | 419.78 | 50       | 827.5    | 0.000 | 1790   |

| Treatment Group=Bevacizumab-EU    |    |      |        |        |        |        |       |        |
|-----------------------------------|----|------|--------|--------|--------|--------|-------|--------|
| Dosing Day Planned Time Post Dose | N  | NALO | Mean   | SD     | CV (%) | Median | Min   | Max    |
| 1 OH                              | 35 | 0    |        |        |        |        |       |        |
| 1 H 30 MIN                        | 35 | 35   | 138500 | 22962  | 17     | 140000 | 96200 | 205000 |
| 4H                                | 35 | 35   | 134000 | 20272  | 15     | 135000 | 92300 | 180000 |
| 24H                               | 35 | 35   | 107600 | 16750  | 16     | 107000 | 75600 | 146000 |
| 48H                               | 35 | 35   | 88090  | 14862  | 17     | 87900  | 58800 | 131000 |
| 96 H                              | 35 | 35   | 67630  | 9697.3 | 14     | 66900  | 47000 | 94500  |
| 168H                              | 35 | 35   | 53190  | 7403.7 | 14     | 53600  | 35900 | 73000  |
| 336 H                             | 34 | 34   | 37590  | 6930.4 | 18     | 36850  | 25400 | 54100  |
| 504 H                             | 34 | 34   | 27740  | 5488.3 | 20     | 27400  | 17800 |        |
| 672H                              | 34 | 34   | 22630  | 5496.7 | 24     | 21050  | 14100 | 43000  |
| 1008H                             | 33 | 33   | 13120  | 4020.4 | 31     | 13000  | 5460  | 22900  |
| 1344 H                            | 32 | 32   | 7557   | 2702.8 | 36     | 7455   | 2060  | 13900  |
| 1512 H                            | 31 | 31   | 5742   | 2588.8 | 45     | 5480   | 609   | 13700  |
| 1680H                             | 33 | 33   | 4330   | 2372.5 | 55     | 4010   | 290   | 11700  |
| 2376H                             | 32 | 31   | 1216   | 937.63 | 77     | 976.5  | 0.000 | 4790   |

| Planned Time Post Dose   |   N |   NALQ | Mean   | SD     | CV (%)   | Median   | Min    | Max    |
|--------------------------|-----|--------|--------|--------|----------|----------|--------|--------|
| OH                       |  33 |      0 |        |        |          |          |        |        |
| 1 H 30 MIN               |  33 |     33 | 127400 | 17961  | 14       | 128000   | 93200  | 187000 |
| 4H                       |  33 |     33 | 126500 | 17957  | 14       | 123000   | 101000 | 191000 |
| 24H                      |  33 |     33 | 103400 | 11445  | 11       | 103000   | 80300  | 130000 |
| 48H                      |  33 |     33 | 82970  | 11225  | 14       | 82100    | 62900  | 114000 |
| 96H                      |  33 |     33 | 64650  | 8229.4 | 13       | 63600    | 45600  | 87200  |
| 168H                     |  33 |     33 | 50170  | 4997.8 | 10       | 51400    | 37900  | 57400  |
| 336 H                    |  32 |     32 | 35450  | 4683.3 | 13       | 35350    | 28000  | 49500  |
| 504 H                    |  32 |     32 | 26200  | 3332.1 | 13       | 25400    | 20700  | 33300  |
| 672H                     |  32 |     32 | 21070  | 2799.6 | 13       | 20150    | 16000  | 26000  |
| 1008 H                   |  31 |     31 | 12250  | 2522.3 | 21       | 11700    | 8450   | 18900  |
| 1344 H                   |  32 |     32 | 7027   | 1738.6 | 25       | 6655     | 3740   | 11400  |
| 1512H                    |  32 |     32 | 5582   | 2374.2 | 43       | 5320     | 2350   | 15300  |
| 1680H                    |  31 |     31 | 4014   | 1352.6 | 34       | 3850     | 2040   | 7420   |
| 2376 H                   |  27 |     27 | 970.9  | 612.58 | 63       | 811.0    | 266    | 2780   |

<!-- image -->

'N' = Number of observations (non-missing concentrations)

<div style=\"page-break-after: always\"></div>

Figure 1 : Median Serum concentration time profiles of PF-06439535 ('Bevacizumab-Pfizer'), Bevacizumab-US, and Bevacizumab-EU following a single intravenous dose to healthy subjects at 5 mg/kg

<!-- image -->

Table 6: Mean (±SD) Pharmacokinetic Parameter Estimates of Bevacizumab-Pfizer, Bevacizumab-EU, and Bevacizumab-US (Ad-hoc analysis - up to day 100)

<div style=\"page-break-after: always\"></div>

| Parameters (units)   | PF-06439535    | Bevacizumab-EU   | Bevacizumab-US   |
|----------------------|----------------|------------------|------------------|
| N,n                  | 32,32          | 33.33            | 32,32            |
| Cmax (μg/mL)         | 142.9 ±20.278  | 137.0±20.473     | 130.0±18.189     |
| AUC (μghr/mL)        | 41990 ± 6827.9 | 42550 ± 7524.1   | 40070 ± 4881.7   |
| AUCinf (μghr/mL)     | 42580 ± 6764.8 | 43320±8085.9     | 41050±5252.3     |
| CL (mL/hr/kg)        | 0.1196± 0.021  | 0.1185±0.021791  | 0.1228±0.015463  |
| Vss (mL/kg)          | 60.53 ± 10.716 | 62.93 ±8.9201    | 66.83 ± 7.2737   |
| ty (hr)              | 334.9±55.310   | 359.0± 75.979    | 363.4±55.977     |

Source:  Table 14.4.3.1.1

Table 7. Summary of Statistical Comparisons of Pharmacokinetic Exposure Parameters (Cmax, AUCT, and AUC0-∞) between Test and Reference Products (Ad-hoc analysis -up to day 100)

|                     |                                    | Adjusted GeometricMeans   | Adjusted GeometricMeans   |                                        |                      |
|---------------------|------------------------------------|---------------------------|---------------------------|----------------------------------------|----------------------|
| Parameter (Units)   | Comparison (Testvs.Reference)      | Test                      | Reference                 | Ratio(Test/Reference)of AdjustedMeans\" | (%) 10 %06 ForRatioa |
| AUC,-D100 (μghr/mL) | PF-06439535versusBevacizumab-EU    | 41430                     | 41930                     | 98.79                                  | (92.61, 105.38)      |
| AUC,-D100 (μghr/mL) | PF-06439535versusBevacizumab-US    | 41430                     | 39790                     | 104.11                                 | (97.55, 111.11)      |
| AUC,-D100 (μghr/mL) | Bevacizumab-EUversusBevacizumab-US | 41930                     | 39790                     | 105.39                                 | (98.80, 112.42)      |
| AUC-D100 (μghr/mL)  | PF-06439535versus.Bevacizumab-EU   | 42030                     | 42620                     | 98.62                                  | (92.33 105.33)       |
| AUC-D100 (μghr/mL)  | PF-06439535versusBevacizumab-US    | 42030                     | 40730                     | 103.21                                 | (96.58, 110.29)      |
| AUC-D100 (μghr/mL)  | Bevacizumab-EUversusBevacizumab-US | 42620                     | 40730                     | 104.65                                 | (97.98, 111.78)      |
| Cx-D100 (Tu/Bn)     | PF-06439535versusBevacizumab-EU    | 141.5                     | 135.5                     | 104.42                                 | (98.36, 110.84)      |
| Cx-D100 (Tu/Bn)     | PF-06439535versusBevacizumab-US    | 141.5                     | 128.9                     | 109.79                                 | (103.38, 116.60)     |
| Cx-D100 (Tu/Bn)     | Bevacizumab-EUversusBevacizumab-US | 135.5                     | 128.9                     | 105.15                                 | (99.05,111.62)       |

Source:  Table 14.4.3.3.1

Median serum concentration-time profiles for PF-06439535 and bevacizumab-EU appear to be very similar. Consistently, the mean standard deviation (±SD) PK parameters (Cmax, AUCs, CL, Vss, t1/2) for PF-06439535 and bevacizumab-EU were very similar, with similar inter-subject variability (CV% around 15 to 20%) for each of the PK parameters.

For the purpose of PK similarity, the geometric LS means ratios from the primary PK analysis (based on up to Day 71 data) for the comparison of PF-06439535 and the reference beavcizumab-EU for Cmax, AUClast, AUCinf were 1.04, 1.00 and 0.99 and the corresponding 90%CIs  were [98.36-110.84], [93.69-105.93], [92.16-105.44], respectively.  Similarly, the geometric LS means ratios from the ad hoc PK analysis (based on up to 100 data) for the comparison of PF-06439535 and the reference beavcizumab-EU for Cmax, AUClast, AUCinf were 1.04, 0.99 and 0.99 and the corresponding 90%CIs  were [98.36-110.84], [92.61-105.38], [92.33-105.33], respectively. Thus, the primary endpoints (i.e. Cmax, AUClast, AUCinf) with their 90% confidence intervals are well within the predefined acceptance range of 80-125%.

Additionally to investigation following single-dose administration in healthy volunteers (n=32), PK of PF-06439535 has been characterised under repeated doses in patients with non-squamous NSCLC.

## Phase III study (B7391003)

This is a completed multinational, randomised, double-blind, active-controlled, multiple dose study in adult subjects with non-squamous NSCLC receiving first-line chemotherapy with carboplatin and paclitaxel. Paclitaxel and carboplatin were administered per dosing algorithm in the protocol. Bevacizumab (in combination or as monotherapy) was administered at the start of every 21-Day cycle (Q3W) at a dose of 15 mg/kg by IV infusion over 90 minutes.

<div style=\"page-break-after: always\"></div>

A total of 719 patients at 216 centers were enrolled and randomized with 358 patients to the PF-06439535 group and 361 patients to the bevacizumab-EU group. Of these, 714 patients received at least 1 dose of study therapy, 356 patients were assigned to the PF-06439535 group, and 358 patients were assigned to the bevacizumab-EU group.

Blood samples for PK measurement were collected prior to bevacizumab infusion at every cycle through Cycle 17, and at End of Treatment (EOT)/Withdrawals, and post-dose samples were collected at 1 hour (± 0.5 hour) after the end of the infusion of bevacizumab for Cycle 1 and 5 (if the patient received Cycle 5).

The current PK data include all serum PF-06439535 and bevacizumab-EU concentration, available up to and inclusive of the data cutoff date of 08 May 2017. At this date, all the randomized patients had either completed the Week 25 visit or discontinued. Approximately 20% of patients had not reached the Week 55 visit.

Serum concentrations of PF-06439535 and bevacizumab-EU versus time are summarized descriptively in Table 8.

Mean standard deviation (SD), and median serum concentration-time profiles for PF-06439535 and bevacizumab-EU are presented in Error! Reference source not found. .

Figure 2: Mean and Median Plot of Serum Bevacizumab Concentration with standard deviation - PK Population Study B7391003

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 8: Summary of serum concentration of PF-06439535 and bevacizumab-EU versus time - PK Population Study B7391003.

Treatment Group = PF-06439535

| Visit    | Planned Time Post Dose   | N   |   NALQ |      Mean | SD     | CV (%)   |   Median |    Min |    Max |
|----------|--------------------------|-----|--------|-----------|--------|----------|----------|--------|--------|
| CYCLE 1  | OH                       |     |      6 |     68.08 | 705.53 | 1036     |        0 |      0 |  11300 |
| CYCLE 1  | 2 H 30 MIN               | 319 |    309 | 280000    | 103260 | 37       |   282000 |      0 | 546000 |
| CYCLE 2  | OH                       | 310 |    308 |  54350    | 44479  | 82       |    49050 |      0 | 460000 |
| CYCLE3   | OH                       | 206 |    206 |  81090    | 48671  | 60       |    77450 |   4040 | 495000 |
| CYCLE 4  | OH                       | 277 |    277 | 100900    | 54979  | 54       |    94700 |   1000 | 475000 |
| CYCLE 5  | OH                       | 257 |    256 | 105300    | 48469  | 46       |   101000 |      0 | 494000 |
| CYCLE 5  | 1 H 30 MIN               | 192 |    192 | 360700    | 131170 | 36       |   372500 |  19700 | 636000 |
| CYCLE 6  | OH                       | 244 |    244 | 112000    | 40825  | 36       |   109000 |  10300 | 247000 |
| CYCLE 7  | H0                       | 192 |    192 | 117300    | 53844  | 46       |   109000 |  10600 | 566000 |
| CYCLE8   | OH                       | 195 |    195 | 123600    | 48893  | 40       |   122000 |  28100 | 376000 |
| CYCLE 9  | OH                       | 184 |    184 | 127200    | 46200  | 36       |   124000 |  14600 | 259000 |
| CYCLE 10 | OH                       | 170 |    169 | 125700    | 50769  | 40       |   124000 |      0 | 269000 |
| CYCLE 11 | OH                       | 170 |    169 | 129500    | 61329  | 47       |   121500 |      0 | 568000 |
| CYCLE 12 | OH                       | 141 |    141 | 135200    | 64560  | 48       |   125000 |  22300 | 500000 |
| CYCLE 13 | OH                       | 136 |    136 | 130900    | 58093  | 44       |   120000 |  10700 | 389000 |
| CYCLE 14 | OH                       | 131 |    131 | 128000    | 50840  | 40       |   119000 |  41700 | 294000 |
| CYCLE 15 | OH                       | 103 |    103 | 134000    | 55933  | 42       |   122000 |  39100 | 315000 |
| CYCLE 16 | OH                       | 92  |     92 | 137000    | 54813  | 40       |   131000 |  38900 | 278000 |
| CYCLE 17 | OH                       | 90  |     06 | 134800    | 86847  | 64       |   112000 |  26800 | 648000 |
| CYCLE 18 | OH                       | 15  |     15 | 142700    | 50144  | 35       |   149000 |  50500 | 243000 |
| CYCLE 19 | OH                       | 13  |     13 | 135800    | 49717  | 37       |   136000 |  52000 | 237000 |
| CYCLE 20 | OH                       | 10  |     10 | 135800    | 45205  | 33       |   138500 |  49900 | 221000 |
| CYCLE 21 | OH                       | 5   |      5 | 189000    | 51098  | 27       |   186000 | 146000 | 272000 |
| CYCLE 22 | OH                       | 2   |      2 | 190500    | 26163  | 14       |   190500 | 172000 | 209000 |
| CYCLE 23 | OH                       | 2   |      2 | 193500    | 40305  | 21       |   193500 | 165000 | 222000 |
| CYCLE 24 | OH                       | 1   |      1 | 242000    |        |          |   242000 | 242000 | 242000 |

| Visit    | Planned Time Post Dose   |   N | NALQ   | Mean     | SD     | CV (%)   |   Median |    Min |     Max |
|----------|--------------------------|-----|--------|----------|--------|----------|----------|--------|---------|
| CYCLE 1  | OH                       | 338 | 7      | 116.4    | 1032.1 | 886      |        0 |      0 |   12300 |
| CYCLE 1  | 2H30MIN                  | 326 | 321    | 302200   | 100360 | 33       |   300000 |      0 |  525000 |
| CYCLE 2  | OH                       | 326 | 324    | 58930    | 49452  | 84       |    52650 |      0 |  522000 |
| CYCLE 3  | OH                       | 211 | 211    | 83350    | 32384  | 39       |    79700 |   5270 |  259000 |
| CYCLE 4  | OH                       | 299 | 298    | 99750    | 50531  | 51       |    96500 |      0 |  697000 |
| CYCLE 5  | OH                       | 271 | 271    | 110000   | 65416  | 59       |   106000 |   5610 |  723000 |
| CYCLE 5  | 1 H 30 MIN               | 201 | 201    | 377200   | 142250 | 38       |   387000 |  28700 | 1010000 |
| CYCLE 6  | OH                       | 268 | 267    | 116700   | 53844  | 46       |   111500 |      0 |  469000 |
| CYCLE 7  | OH                       | 214 | 214    | 122100   | 47793  | 39       |   118000 |   8440 |  273000 |
| CYCLE 8  | OH                       | 208 | 207    | 126400   | 52985  | 42       |   125000 |      0 |  426000 |
| CYCLE 6  | OH                       | 193 | 192    | 140900   | 62548  | 44       |   131000 |      0 |  558000 |
| CYCLE 10 | OH                       | 179 | 178    | 135900   | 53975  | 40       |   138000 |      0 |  287000 |
| CYCLE 11 | OH                       | 169 | 169    | 135600   | 54531  | 40       |   130000 |   6980 |  289000 |
| CYCLE 12 | OH                       | 138 | 138    | 136300   | 51312  | 38       |   136000 |  29000 |  263000 |
| CYCLE 13 | OH                       | 121 | 121    | 139700   | 53750  | 38       |   138000 |  31400 |  257000 |
| CYCLE 14 | OH                       | 117 | 117    | 136200   | 53439  | 39       |   136000 |  28000 |  292000 |
| CYCLE 15 | 0H                       | 104 | 104    | 134000   | 49663  | 37       |   134000 |  36300 |  249000 |
| CYCLE 16 | OH                       |  95 | 95     | 128600   | 49742  | 39       |   127000 |  13100 |  258000 |
| CYCLE 17 | 0H                       |  92 | 92     | 127500   | 52784  | 41       |   125000 |   3000 |  280000 |
| CYCLE 18 | OH                       |  23 | 23     | 130400   | 46741  | 36       |   122000 |  48700 |  233000 |
| CYCLE 19 | OH                       |  18 | 18     | 135400   | 52368  | 39       |   126000 |  53300 |  227000 |
| CYCLE 20 | OH                       |  15 | 15     | 118000   | 49551  | 42       |   118000 |  46300 |  234000 |
| CYCLE 21 | OH                       |   8 | 8      | 96450    | 47311  | 49       |    98500 |  17800 |  155000 |
| CYCLE 22 | OH                       |   5 | 5      | 95180    | 57797  | 61       |    74200 |  46000 |  195000 |
| CYCLE 23 | OH                       |   2 | 2      | 94300    | 10889  | 12       |    94300 |  86600 |  102000 |
| CYCLE 24 | OH                       |   1 |        | 1 119000 |        |          |   119000 | 119000 |  119000 |
| CYCLE 25 | OH                       |   1 | 1      | 123000   |        |          |   123000 | 123000 |  123000 |
| CYCLE 26 | OH                       |   1 | 1      | 118000   |        |          |   118000 | 118000 |  118000 |
| CYCLE 27 | 0H                       |   1 | 1      | 104000   |        |          |   104000 | 104000 |  104000 |

N = Number of observations (non-missing concentrations)

Mean and median trough (pre-dose) and apparent peak (1 hour post end of infusion at Cycle 1 and cycle 5) concentrations appear to be comparable across the 2 treatment groups for all time points measured from baseline (time 0) through Cycle 18. Moreover, large but similar variance in each group (CV of 40 to 60%) was observed.

<div style=\"page-break-after: always\"></div>

The mean and median bevacizumab Ctrough values increase steadily up to Cycle 9. This finding was observed for the two treatment groups (test and reference) but not consistent with the half-live (between 18 and 20 days) of bevacizumab and the Q3W dosing regimen.

## · Influence of food

Not applicable for I.V. administration.

## Distribution

Not applicable.

## Elimination

Clearance and terminal half-life of PF-06439535, Bevacizumab-US, and Bevacizumab-EU were estimated in the phase I study b7391001. CL was 0.119 ml/hr/kg for PF-06439535, 0.122 ml/hr/kg for Bevacizumab-US, and 0.117 ml/hr/kg for Bevacizumab-EU. t½ was 397 hr for PF-06439535, 413 hr for Bevacizumab-US, and 417 h for Bevacizumab-EU. No statistically significant difference was found between the treatments for any of the parameters.

## Special populations

No studies were performed in patients with hepatic or renal impairment.

## 2.3.3. Pharmacodynamics

No new pharmacodynamic data has been submitted as part of this application.

No validated PD markers considered relevant to predicting efficacy of bevacizumab in patients do so far exist. Therefore, no PD markers were included in the PK study, and clinical endpoints were utilised in the phase 3 study in NSCLC patients.

As the mechanism of action of bevacizumab, inhibition of tumour vessel growth, is expected to be similar across all approved cancer indications, extrapolation to other cancer indications of the reference product than advanced NSCLC is considered acceptable provided that similarity of PF-06439535  to the bevacizumab reference product has been convincingly demonstrated through comparability studies both at the quality, non-clinical and clinical level.

## 2.3.4. Discussion on clinical pharmacology

Pharmacokinetics of PF-06439535 following a 5 mg/kg bodyweight single i.v. injection in healthy male volunteers has been determined in a pivotal PK similarity study (b7391001).

The study design (number of subjects and sampling scheme) was chosen based on the assessment of inter-subject variability in a single dose pharmacokinetics study of bevacizumab in healthy male subjects (b7391002), and appears to be adequate. To support the PK findings of the pivotal phase I study, trough and apparent peak serum levels were determined during the repeat dose phase III clinical study. The primary endpoints of the phase I clinical study (i.e. AUCinf, AUClast and Cmax) with their 90% confidence intervals are well within the predefined acceptance range of 80-125%.

<div style=\"page-break-after: always\"></div>

In the phase III study (B7391003), the observation that steady-state is achieved only around cycle 9 was explained by a decrease in number of patients evaluated for PK post cycle 6, and in addition a potential reduction in clearance of bevacizumab/ PF-06439535 in patients with therapeutic response. The basis for the latter explanation is not substantial, and is considered a postulation. However, the finding of slight increase of bevacizumab concentrations between Cycle 5 and Cycle 9 was reported for both test and reference treatments. Thus, PK similarity (the pivotal issue for this dossier) is not questioned. No formal investigations in subjects with impaired hepatic or renal function were performed. According to the originator´s product SmPC, PK of bevacizumab has not been investigated in patients with impaired renal or hepatic function. Thus, no study is required in the context of this biosimilar application.

The results indicate that PF-06439535 is comparable to Avastin at the PK level.

No new pharmacodynamic data has been submitted as part of this application. No validated PD markers considered relevant to predicting efficacy of bevacizumab in patients do so far exist. Therefore, no PD markers were included in the PK study, and clinical endpoints were utilised in the phase 3 study in NSCLC patients.

As the mechanism of action of bevacizumab, inhibition of tumour vessel growth, is expected to be similar across all approved cancer indications, extrapolation to other cancer indications of the reference product than advanced NSCLC is considered acceptable provided that similarity of PF-06439535  to the bevacizumab reference product has been convincingly demonstrated through comparability studies both at the quality, non-clinical and clinical level.

## 2.3.5. Conclusions on clinical pharmacology

The available PK/PD data support biosimilarity of PF-06439535 versus the EU reference product Avastin.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No dose response study was conducted.

## 2.4.2. Main study

## A Phase 3 randomized, double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer

## Methods

The main study B7391003 is a multinational, double-blind, randomised, parallel-group Phase 3 clinical trial comparing the efficacy and safety of PF-06439535 plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin as first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC.  A summary of study B7291003 is provided in Figure 3. The ITT population was comprised of 719 patients who were randomised to double-blind treatment, 358 patients to the PF-06439535 group and 361 patients to the bevacizumab-EU group. Randomisation was stratified by region (according to the location of the drug depot supplying the site), sex (male/female) and smoking history (never/ever). Two populations were defined for the efficacy analyses: ITT population and PP population. The ITT population was the primary efficacy analysis population. The PP population was used for sensitivity analyses of

<div style=\"page-break-after: always\"></div>

the primary and secondary efficacy endpoints. The estimated duration of study participation was approximately one year. Last subject last visit (LSLV) is defined as up to one year from randomisation of the last patient (End of Treatment) plus 28-day follow-up. The study was considered completed (End of Study) when the last patient completed the LSLV. See study scheme (Figure 3) for details.

Figure 3: Study scheme

<!-- image -->

## Study Participants

## Main inclusion criteria:

1. Male and female patients ≥18 years of age, or ≥age of consent in the region.
2. Newly diagnosed Stage IIIB or IV NSCLC (according to Revised International System for Staging Lung Cancer Criteria of 2010) or recurrent NSCLC.
3. Histologically or cytologically confirmed diagnosis of predominately non-squamous NSCLC.
4. At least one measurable lesion as defined by RECIST version 1.1
5. For patients with recurrent disease, at least 6 months must have had elapsed since completing adjuvant or neoadjuvant treatment.
6. Screening scan (computed tomography [CT] or magnetic resonance imaging [MRI]) of the head, chest, abdomen (with adrenal glands), and other disease sites as clinically indicated, to assess disease burden.
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

## Main exclusion criteria:

1. Small cell lung cancer (SCLC) or combination of SCLC and NSCLC. Squamous-cell tumours and mixed adenosquamous carcinomas of predominantly squamous nature.

<div style=\"page-break-after: always\"></div>

2. Evidence of a tumour that compressed or invaded major blood vessels or tumour cavitation that was likely to bleed.

3. Known sensitising epidermal growth factor receptor (EGFR) mutations (for example, exon 19 deletion or exon 21 L858R) or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) translocation positive mutations. If mutation testing was performed, the results must have been reviewed and confirmed as negative for mutations prior to randomisation.

4. History of other cancer within 5 years prior to screening for this study, with the exception of adequately treated ductal carcinoma in situ of the breast, cervical carcinoma in situ, or basal or squamous cell skin cancer.

5. Prior systemic therapy for NSCLC; prior neoadjuvant or adjuvant therapy was allowed if surgical resection for primary disease was performed.

6. History of local radiation for painful bone metastases in the last 2 weeks. Patients with bone metastases were eligible, however those with symptomatic or painful bone metastases should not have received palliative local radiation for at least 2 weeks prior to randomisation.

## Treatments

## Premedication for administration

On treatment days when both bevacizumab and paclitaxel-carboplatin were administered, the order of administration was: 1) paclitaxel, 2) carboplatin, 3) bevacizumab. Bevacizumab monotherapy was administered following completion of at least four cycles and no more than six cycles of chemotherapy.

Premedication to ameliorate the toxicities associated with the chemotherapy were to be administered according to the local label or institutional guidelines.

## Study drug administration

## Paclitaxel

Following premedication, paclitaxel was administered as the first drug when chemotherapy was administered. Paclitaxel at a dose of 200 mg/m 2  was administered by IV infusion over 3 hours on Day 1 in each cycle (21-day cycle). In the absence of progressive disease (PD), patients received paclitaxel treatment for at least 4 cycles but no more than 6 cycles. Dose reduction for toxicity was allowed.

## Carboplatin

Carboplatin was administered by IV infusion over a minimum of 15 minutes, and could be administered immediately after the paclitaxel infusion had completed. Patients were administered carboplatin for at least 4 cycles and no more than 6 cycles. Dose reduction for toxicity was allowed.

## Bevacizumab

Blinded bevacizumab was administered once at the start of every 21-day cycle. The initial dose was 15 mg/kg delivered over 90 minutes as an IV infusion. The concentration of bevacizumab solution was required to be kept within the range of 1.4 mg/mL to 16.50 mg/mL. Infusions were not allowed to be administered as an IV push or bolus injection. Infusions were not allowed to be administered or mixed with dextrose solutions.

<div style=\"page-break-after: always\"></div>

Patients received therapy until RECIST version 1.1 defined disease progression, unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred, or End of Treatment whichever came first.

## Objectives

Primary objective: To compare the efficacy of PF-06439535 versus Avastin (EU)

Secondary objective: To assess and compare the immunogenicity and safety profile of PF06439535 versus Avastin (EU)

## Outcomes/endpoints

Primary Endpoint

-  ORR - the percent of patients within each treatment group that achieved complete response (CR) or partial response (PR) by Week 19 of the study and subsequently confirmed on a follow-up tumour assessment by Week 25, based on the pre-specified equivalence margins required by EMA (-13% to 13%).

## Secondary Endpoints

-  Progression-free survival (PFS) at 1 year: Time from the date of randomization to first documentation of PD, or death due to any cause in the absence of documented PD
-  Survival at 1 year: Time from date of randomisation to death due to any cause while the patient is in the study
-  Duration of response (DOR): Time from date of the first documentation of objective tumour response (CR or PR) to the first documentation of PD, or to death due to any cause in the absence of documented PD

## Sample size

Based on the results of a meta-analysis combining Sandler (2006), Johnson (2004), and Niho (2012), the objective response rate (ORR) to bevacizumab + chemotherapy combination therapy was estimated to be approximately 40%, and the response rate to chemotherapy alone was estimated to be 21%. The relative risk (RR) of response for bevacizumab + chemotherapy versus chemotherapy alone was estimated to be 2.17 with 95% CI (1.74, 2.70).

Equivalence will be considered established if the 95% confidence interval of the risk difference falls into the margins (-0.13, 0.13).

A sample size of 656 patients (328 per treatment arm) provides approximately 86% power for achieving equivalence in risk difference (RD) under specified margin of (-13%, 13%) with 2.5% type I error rate assuming an ORR of 38% in both treatment arms. This target sample size of 656 patients will provide approximately a power of 84% given above assumptions and assuming ORR=41%.

Considering a possible ~7.5% attrition rate for patients reaching evaluation for ORR, a total sample size of approximately 710 patients (355 per treatment arm) were randomized to achieve the target sample size of 656.

<div style=\"page-break-after: always\"></div>

## Randomisation

After screening and sponsor approval patients were randomised through an online Interactive Web Response System (IWRS), and received a unique patient identification number (ID) retained throughout the study. Patients were randomised (1:1) to receive at least 4 cycles and no more than 6 cycles of either PF-06439535 plus paclitaxel and carboplatin or bevacizumab-EU plus paclitaxel and carboplatin, followed by the assigned blinded bevacizumab monotherapy. Randomisation was stratified by region (according to the location of the drug depot supplying the site), sex (male/female) and smoking history (never/ever). Randomisation was according to a randomisation schedule generated by the Sponsor, and to which the Sponsor's personnel directly involved in the study conduct were blinded. The only exception was in the event of an emerging safety issue which may have required breaking the blind.

## Blinding (masking)

Treatment assignments for this study were blinded to the patients, investigator/study staff and Sponsor's study team conducting the trial. The study pharmacists (or qualified designee) preparing treatment infusions were unblinded, and pharmacy records were monitored by a Sponsor appointed unblinded monitor.

## Statistical methods

This was a comparative study aiming at demonstrating clinical equivalence of PF-06439535 and bevacizumab reference product by comparing the confirmed ORR by Week 19 following treatment.

## Hypothesis

Two one-sided hypothesis tests was carried out in the study for ORR in order to show that bevacizumab-Pfizer is equivalent to bevacizumab-EU.

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

Where Rub is the largest acceptable difference for equivalence, and Rlb is the smallest acceptable difference for equivalence. Note: Rlb = -Rub=-0.13.

## Populations

The Intent-to-Treat (ITT) population was defined as all patients who were randomized to study treatment, and was used for patient accountability and all efficacy analyses. The Safety population was defined as all subjects who received at least one dose of study treatment inclusive of chemotherapy. Patients were assigned to treatment groups 'as randomized' for efficacy analyses, but 'as treated' for all other analyses (if receiving both treatments, assigned to treatment initially given). The Per-Protocol (PP) population was defined as all patients who were randomized and received the study treatment (PF-06439535 or bevacizumab-EU) as planned and had no major protocol deviations. The PP population was used for sensitivity analyses of the primary and secondary endpoints.

## Statistical method of analysis

The primary efficacy endpoint of the study was ORR defined as the percent of patients within each treatment group who achieved a BOR of CR or PR by Week 19 in accordance with RECIST version 1.1, and subsequently confirmed on a follow-up tumour assessment by Week 25, based on the Sponsor's derived best overall

<div style=\"page-break-after: always\"></div>

assessment using tumour measurements reported by the investigator in the CRF. The two 1-sided hypotheses were tested in this study for ORR in order to show that PF-06439535 was equivalent to bevacizumab-EU. For the EU, equivalence was considered established if the 95% CI of the risk difference falls into the margins (-13%, 13%).

The primary efficacy analysis for the primary endpoint in the ITT population was based on the Miettinen and Nurminen (1985) method without strata. Estimated risk ratio and risk difference and the asymptotic 95% and 90% CI in ORR between PF-06439535 and bevacizumab-EU were computed. These values were used to determine equivalence based on the criteria defined above.

The same analysis based on PP population was also performed as a sensitivity analysis. The Miettinen and Nurminen method was also carried out with additional stratification variables (region, gender and smoking history), to assess whether these variables would affect the risk ratio/risk difference of ORR between the 2 treatment groups. This analysis was performed based on both ITT and PP population as secondary analyses.

## Results

## Participant flow

## Table 9: Summary of the screened patients

| umber (%) of Patients             | n (%)        |
|-----------------------------------|--------------|
| Total number of patients screened | 1095 (100.0) |
| fumber of patients randomized     | 719 (65.7)   |
| Number of screen failure patients | 376 (34.3)   |

Table 10: Summary of the reasons for screen failure patients

| Number(%o) of Patients                    | Total N=376   |
|-------------------------------------------|---------------|
| Subject died                              | 2 (0.5)       |
| Lost to follow-up                         | 1 (0.3)       |
| Oiher                                     | 11 (2.9)      |
| Does not meet entrance criteria           | 343 (91.2)    |
| No longer willing to participate in study | 18 (4.8)      |
| Study termminated bySponsor               | 1 (0.3)       |

<div style=\"page-break-after: always\"></div>

Table 11: Patient Disposition

| Number (%) of Patients   | PF-06439535   | Bevacizumab-EU   | Total       |
|--------------------------|---------------|------------------|-------------|
| Randomized?              | 358           | 361              | 719         |
| Treated                  | 356 (99.4)    | 358 (99.2)       | 714 (99.3)  |
| Study                    |               |                  |             |
| Discontinued             | 356 (99.4)    | 358 (99.2)       | 714 (99.3)  |
| Randomized not treated   | 2 (0.6)       | 3 (0.8)          | 5 (0.7)     |
| Treatment                |               |                  |             |
| Discontinuedb            | 356 (99.4)    | 358 (99.2)       | 714 (99.3)  |
| Analyzed for efficacy    |               |                  |             |
| ITT population           | 358 (100.0)   | 361 (100.0)      | 719 (100.0) |
| PP population            | 351 (98.0)    | 355 (98.3)       | 706 (98.2)  |
| PK population            | 351 (98.0)    | 354 (98.1)       | 705 (98.1)  |
| Analyzed for safety      |               |                  |             |
| Safety populationd       | 356 (99.4)    | 358 (99.2)       | 714 (99.3)  |
| AEs                      | 356 (100.0)   | 358 (100.0)      | 714 (100.0) |
| Laboratory data          | 342 (96.1)    | 348 (97.2)       | 690 (96.6)  |

Source: Table 14.1.1.1

Patient 10941004 received paclitaxel and carboplatin but withdrew prior to receiving PF-06439535 so had no End of Treatmentpageforbevacizumab.

Patient 10621017 had no CRF AE page but had been confirmed to have had experienced no AEs.

Abbreviations:AE=adverse event, CRF=case report form,EU=European Union,ITT=Intent-to-Treat,

PK=pharmacokinetic,PP=Per-Protocol.

b. Treatment was defined as all 3 agents (blinded bevacizumab, paclitaxel and carboplatin).

a. The number of randomized patients was used as the denominator for percentages except for safety data.

C. PPpopulationwasnotreevaluatedinWeek55analyses andremained thesame.

d. The number of safety population was used as the denominator for percentages of AEs and laboratory data.

Of the 719 randomised, 714 patients were included in the safety population and received at least one dose of study therapy inclusive of chemotherapy. Five patients did not receive any blinded bevacizumab or paclitaxel/carboplatin, including two patients randomised to the PF-06439535 group, and three patients randomised to the bevacizumab-EU group. Of these five randomised patients who did not receive any randomised treatment, two patients were mistakenly unblinded by Principal Investigators on Cycle 1 Day 1 and discontinued from the study, one patient discontinued as per the decision of the Sponsor and the Principal Investigator due to exacerbation of chronic obstructive pulmonary disease (COPD) condition, one patient withdrew consent after randomisation but before receiving any study drug, and one patient met exclusion criterion 15 (CNS metastases). One additional patient in the PF-06439535 group did not receive blinded bevacizumab due to hypertension after the administration of paclitaxel and carboplatin. This patient was included in the safety population.

There were 714 (100.0%) patients who completed or discontinued from paclitaxel and carboplatin treatments (356 [100.0%] patients in the PF-06439535 group and 358 [100.0%] patients in the bevacizumab EU group). The majority of patients completed the protocol defined number of cycles (4-6 cycles) of chemotherapy. The most frequent reason for discontinuation from the study, including the survival follow up period, was death (136[38.2%] patients and 138 [38.5%] patients in the PF-06439535 and bevacizumab-EU groups, respectively).

<div style=\"page-break-after: always\"></div>

## Recruitment

The study was conducted at 216 centers in Australia, Brazil, Bulgaria, Chile, Croatia, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, India, Italy, Japan, Korea, Malaysia, Netherlands, Philippines, Poland, Romania, Russian Federation, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, and United States (US).

First Subject First Visit (FSFV): 20 April 2015

Primary completion date: 08 May 2017

Study Completion Date: 22 December 2017

## Conduct of the study

## Protocol amendments

The original protocol (version date: 04 November 2014) was amended 3 times. The main changes are summarised below:

Amendment 1 (version date: 05 May 2015):

-  Addition of inclusion criteria to require that patients be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin for the treatment of advanced or metastatic non-squamous NSCLC.
-  Clarification of mutation testing language.
-  Clarification of bevacizumab dose reductions.
-  Clarification of CHF and IRR guidelines.

Amendment 2 (version date: 06 July 2015); Changes incorporated feedback from investigators, regulatory agencies, and protocol template updates:

-  Clarification of study design language.
-  Updated to global sample size, statistical considerations, and addition of Japan specific statistical analysis.
-  Addition of maximum allowed doses for carboplatin.
-  Addition of exclusion criteria regarding local radiation for painful bone metastases within the past 4 weeks.
-  Addition of inclusion criteria to require that patients be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin for the treatment of advanced or metastatic non-squamous NSCLC.
-  Addition of toxicity information.
-  Addition of required discontinuation of bevacizumab due to severe or life threatening infusion reaction that is considered to be secondary to bevacizumab and not paclitaxel and/or carboplatin.
-  Addition of blood sample collection time points for ADA/NAb and corresponding drug concentrations, as well as the plan to analyze the samples, according to the Scientific Advice from the European Medicines Authority (EMA).

Amendment 3 (version date: 10 June 2016):

-  For EU, changed primary analysis from risk ratio to risk difference
-  Inclusion Criterion 6: window around baseline scan removed; specified in SOA.

<div style=\"page-break-after: always\"></div>

-  Inclusion Criterion 8: addition of plasma creatinine and UPC ratio.
-  Exclusion Criterion 3: added language that was previously in body of protocol, to require review of mutation testing results prior to randomization, if testing is performed.
-  Exclusion Criterion 6: reduced window for prior radiotherapy from four weeks to two weeks.
-  Exclusion Criterion 12: language revised to exclude active infections and remove window for prior anti-infective agents.
-  Exclusion Criterion 15: language added to define and allow treated and stable brain metastases.
-  Exclusion Criterion 21: clarification to exclude active hepatitis B and C infection instead of past infection.
-  Exclusion Criterion 25: added prior immunotherapy and bevacizumab.

Removed language regarding investigator's judgment in the following criterion: Exclusion Criterion 2 (tumour involving major blood vessels): 'in the opinion of the investigator'; 13 (comorbidities) 'as per the investigator's discretion'; 21 (hepatitis infection) 'based on investigator clinical judgment'.

## Protocol Deviations

Table 12 : Summary of Important Protocol Deviations - ITT Population

| Number (%o) of Patients                                                                                                                                            | PF-06439535 (N=358)   | Bevacizumab-EU (N=361)   | Total (N=719)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|--------------------------|-----------------|
| Number of patients with important protocol deviations                                                                                                              | 3 (0.8)               | 7 (1.9)                  | 10 (1.4)        |
| Inclusion/exclusion                                                                                                                                                | 3 (0.8)               | 5 (1.4)                  | 8 (1.1)         |
| Did not meet inclusion criterion 2: newly diagnosed Stage IIIB or IV NSCLC or recurrent NSCLC for which they had not received chemotherapy for metastatic disease. | 2 (0.6)               | 2 (0.6)                  | 4 (0.6)         |
| Did not meet inclusion criterion 4: at least                                                                                                                       | 1 (0.3)               | 2 (0.6)                  | 3 (0.4)         |
| 1 measurable lesion as defined by RECIST version 1.1 Met exclusion criterion 5: prior systemic therapy for metastatic disease                                      | 0                     | 1 (0.3)                  | 1 (0.1)         |
| Investigational product                                                                                                                                            | 0                     | 1 (0.3)                  | 1 (0.1)         |
| Blind broken - inadvertent unblinded before the patient reached Week 19 or End of Treatment milestone visit                                                        | 0                     | 1 (0.3)                  | 1 (0.1)         |
| Randomization                                                                                                                                                      | 0                     | 1 (0.3)                  | 1 (0.1)         |
| Randomized but not dosed                                                                                                                                           | 0                     | 1 (0.3)                  | 1 (0.1)         |

Source:Table 14.1.1.6.2

Abbreviations: EU=European Union, ITT=Intent-to-Treat, N=number of patients randomized to the study. NSCLC=non-small cell lung cancer, RECIST=Response Evaluation Criteria in Solid Tumors.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 13 : Demographic Characteristics - ITT Population

|                          | PF-06439535   | Bevacizumab-EU   | Total       |
|--------------------------|---------------|------------------|-------------|
| Number (%) of Patients   | 358           | 361              | 719         |
| Gender                   |               |                  |             |
| Male                     | 237           | 230              | 467         |
| Female                   | 121           | 131              | 252         |
| Age (years)              |               |                  |             |
| <18                      | 0             | 0                | 0           |
| 18-44                    | 19 (5.3)      | 17 (4.7)         | 36 (5.0)    |
| 45-64                    | 198 (55.3)    | 222 (61.5)       | 420 (58.4)  |
| 265                      | 141 (39.4)    | 122 (33.8)       | 263 (36.6)  |
| Mean                     | 61.7          | 60.9             | 61.3        |
| SD                       | 9.5           | 8.9              | 9.2         |
| Range                    | 25-87         | 31-83            | 25-87       |
| Race                     |               |                  |             |
| White                    | 319 (89.1)    | 319 (88.4)       | 638 (88.7)  |
| Black                    | 3 (0.8)       | 1 (0.3)          | 4 (0.6)     |
| Asian                    | 36 (10.1)     | 40 (11.1)        | 76 (10.6)   |
| Other                    | 0             | 1 (0.3)          | 1 (0.1)     |
| Ethnicity                |               |                  |             |
| Hispanic/Latino          | 13 (3.6)      | 16 (4.4)         | 29 (4.0)    |
| Not Hispanic/Latino      | 345 (96.4)    | 345 (95.6)       | 690 (96.0)  |
| Weight (kg)              |               |                  |             |
| Mean                     | 71.8          | 72.2             | 72.0        |
| SD                       | 15.1          | 15.6             | 15.4        |
| Range                    | 40.0-127.0    | 28.3-135.0       | 28.3-135.0  |
| Body Mass Indexa (kg/m²) |               |                  |             |
| Mean                     | 25.3          | 25.6             | 25.5        |
| SD                       | 4.7           | 5.1              | 4.9         |
| Range                    | 15.6-51.5     | 12.5-41.9        | 12.5-51.5   |
| Height (cm)              |               |                  |             |
| Mean                     | 168.4         | 167.6            | 168.0       |
| SD                       | 9.0           | 9.3              | 9.2         |
| Range                    | 146.0-196.0   | 144.0-195.0      | 144.0-196.0 |

Source Data: Module 5.3.5.1 Study B7391003 Table 14.1.2.1

Baseline was defined as the value recorded at Cycle 1, Day 1. If this value was missing. the value recorded at Screening was used.

Abbreviations: EU= European Union; ITT=Intent-to-Treat; SD=standard deviation.

a. Body mass index was defined as weight/(heightx0.01)

<div style=\"page-break-after: always\"></div>

Table 14: Primary Diagnoses - ITT Population

| Number (%) of Patients                          | PF-06439535 (N=358)   | Bevacizumab-EU (N=361)   | Total (N=719)   |
|-------------------------------------------------|-----------------------|--------------------------|-----------------|
| Histopathological classification                |                       |                          |                 |
| Mixed adenocarcinoma                            | 3 (0.8)               | 4 (1.1)                  | 7 (1.0)         |
| Adenocarcinoma                                  | 348 (97.2)            | 351 (97.2)               | 699 (97.2)      |
| Large cell carcinoma                            | 6 (1.7)               | 5 (1.4)                  | 11 (1.5)        |
| Other                                           | 1 (0.3)               | 1 (0.3)                  | 2 (0.3)         |
| Recurrence type                                 |                       |                          |                 |
| Newly diagnosed Stage IIIB                      | 48 (13.4)             | 29 (8.0)                 | 77 (10.7)       |
| Newly diagnosed Stage IV                        | 265 (74.0)            | 282 (78.1)               | 547 (76.1)      |
| Recurrent                                       | 45 (12.6)             | 50 (13.9)                | 95 (13.2)       |
| Prior surgeries for primary diagnoses           |                       |                          |                 |
| No                                              | 298 (83.2)            | 293 (81.2)               | 591 (82.2)      |
| Yes                                             | 60 (16.8)             | 68 (18.8)                | 128 (17.8)      |
| Prior systemic therapies for primary diagnoses  |                       |                          |                 |
| No                                              | 343 (95.8)            | 341 (94.5)               | 684 (95.1)      |
| Yes                                             | 15 (4.2)              | 20 (5.5)                 | 35 (4.9)        |
| Prior radiation therapies for primary diagnoses |                       |                          |                 |
| No                                              | 333 (93.0)            | 338 (93.6)               | 671 (93.3)      |
| Yes                                             | 24 (6.7)              | 23 (6.4)                 | 47 (6.5)        |
| Not reported                                    | 1 (0.3)               | 0                        | 1 (0.1)         |

Source Data: Module 5.3.5.1 Study B7391003 Table 14.1.2.2.1; 14.1.2.2.3

Recurrence: Patients whose cancer had retumed following an initial treatment with surgery, radiation therapy, and/or chemotherapy administered for curative intent.

Prior surgeries: Only included primary tumor resection.

Abbreviations: EU=European Union; ITT= Intent-to-Treat; N=number of patients randomized to the study.

## Numbers analysed

A total of 719 patients were randomized in this study and were included in the efficacy analyses (ITT population), 358 patients to the PF-06439535 group and 361 patients to the bevacizumab-EU group. Sensitivity analyses of the efficacy endpoints were performed in the per-protocol population.

<div style=\"page-break-after: always\"></div>

Table 15: Per-protocol (PP) Population - Summary of Exclusions from ITT Population

| Number (%) of Patients                                                                        | PF-06439535 (N=358)   | Bevacizumab-EU (N=361)   | Total (N=719)   |
|-----------------------------------------------------------------------------------------------|-----------------------|--------------------------|-----------------|
| Total patients excluded                                                                       | 7 (2.0)               | 6 (1.7)                  | 13 (1.8)        |
| Incorrect histopathological NSCLCa                                                            | 1 (0.3)               | 0                        | 1 (0.1)         |
| Randomized but never bevacizumab dosed                                                        | 3 (0.8)               | 3 (0.8)                  | 6 (0.8)         |
| Prior systemic anti-cancer therapy for Stage IllB or                                          | 1 (0.3)               | 2 (0.6)                  | 3 (0.4)         |
| IV disease                                                                                    |                       |                          |                 |
| Inadveitent unblinding of study therapy for reasons other than safety reasons before Week 19b | 1 (0.3)               | 1 (0.3)                  | 2 (0.3)         |
| Screening tumor assessment greater than 42 days prior to randomization                        | 1 (0.3)               | 1 (0.3)                  | 2 (0.3)         |

Source Data:Module 5.3.5.1 Study B7391003 Table 14.1.1.5

Abbreviations: EU=European Union; ITT=Intent-to-Treat; IV=intravenous; N=number of patients randomized to the study; NSCLC=non-small cell lung cancer; PP=per protocol a. Intended histopathological subtype: predominately non-squamous NSCLC

b. One (1) patient (Patient 10251001) also received the incorrect blinded bevacizumab study treatment (wrong kit used) for Cycle 1. An additional two patients not included in this category (10251002 and 11911003) were inadvertently unblinded on D1 prior to administration of study medication and were never dosed.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary endpoint: ORR

Table 16: Summary of Best Overall Response and ORR (Week 19) - ITT

|                                                               | PF-06439535 (N=358)      | Bevacizumab-EU (N=361)   | Total (N=719)   |
|---------------------------------------------------------------|--------------------------|--------------------------|-----------------|
| Best overall response, n (%)                                  |                          |                          |                 |
| Complete response (CR)                                        | 9 (2.5)                  | 4 (1.1)                  | 13 (1.8)        |
| Partial response (PR)                                         | 153 (42.7)               | 157 (43.5)               | 310 (43.1)      |
| Stable disease                                                | 154 (43.0)               | 166 (46.0)               | 320 (44.5)      |
| Objective progression                                         | 15 (4.2)                 | 14 (3.9)                 | 29 (4.0)        |
| Indeterminatea                                                | 27 (7.5)                 | 20 (5.5)                 | 47 (6.5)        |
| Objective response rate (CR + PR), n (%)                      | 162 (45.3)               | 161 (44.6)               | 323 (44.9)      |
| 95% exact CIb                                                 | [40.01, 50.57]           | [39.40, 49.89]           | [41.25, 48.64]  |
| Treatment comparison (versus bevacizumab-EU)                  |                          |                          |                 |
| Un-stratified risk difference in ORR (%) 95% CI of difference | 0.6531 [-6.6080, 7.9082] |                          |                 |
| Treatment comparison (versus bevacizumab-EU)                  |                          |                          |                 |
| Un-stratified risk ratiod                                     | 1.0146                   |                          |                 |
| 95% CI of risk ratiod                                         | [0.8628, 1.1933]         |                          |                 |
| 90% CI of risk ratiod                                         | [0.8856, 1.1625]         |                          |                 |

ORR was defined as the percentage of patients within each treatment group who achieved complete response or partial response by Week 19 of the study in accordance with RECIST version 1.1 which was subsequently confirmed by Week 25. Abbreviations: CI=confidence interval, CR=complete response, EU=European Union, ITT=Intent-to-Treat, n/N=number of patients with observation/total number of patients, ORR=objective response rate, PR=partial response, RECIST=Response Evaluation Criteria in Solid Tumors, US=United States.

a  Indeterminate: Early death, unevaluable tumour assessment, and early study discontinuations.

b  Exact method based on F-distribution was used.

c  Calculated based on 2-sided Miettinen and Nurminen method without strata for risk difference for confirmed response. EU equivalence margins (95% CI in -13% to 13%).

d  Calculated based on 2-sided Miettinen and Nurminen method without strata for risk ratio for confirmed response. US equivalence margins (90% CI in 0.73 to 1.37) and Japan equivalence margins (95% CI in 0.729 to 1.371).

<div style=\"page-break-after: always\"></div>

Table 17: Forest plot of risk differences in ORR (PF-06439535 versus Bevacizumab-EU) with 95% CIs (Week 19) by strata-ITT population

<!-- image -->

| Subgroup                                | PF-06439535 n/N (%)   | Bevacizumab-EU n/N (%)   | RD [95% C]            |
|-----------------------------------------|-----------------------|--------------------------|-----------------------|
| Smoking History: Ever                   | 115/255 (45.1)        | 104/251 (41.43)          | 3.66 [-4.97, 12.24]   |
| Smoking History: Never                  | 47/103 (45.63)        | 57/110 (51.82)           | -6.19 [-19.39, 7.24]  |
| Gender: MALE                            | 110/237 (46.41)       | 97/230 (42.17)           | 4.24 [-4.77, 13.18]   |
| Gender:FEMALE                           | 52/121 (42.98)        | 64/131 (48.85)           | -5.88 [-18.01, 6.44]  |
| Region: AMERICA and WEST EUROPE         | 45/140 (32.14)        | 47/135 (34.81)           | -2.67 [-13.79, 8.47]  |
| Region:EAST EUROPE                      | 85/164 (51.83)        | 83/164 (50.61)           | 1.22[-9.57, 11.98]    |
| Region: OTHER REGION                    | 32/54 (59.26)         | 31/62 (50)               | 9.26[-8.94,26.79]     |
| Age: <65                                | 102/217 (47)          | 110/239 (46.03)          | 0.98 [-8.16, 10.12]   |
| Age: >=65                               | 60/141 (42.55)        | 51/122 (41.8)            | 0.75 [-11.20, 12.62]  |
| Race: WHITE                             | 138/319 (43.26)       | 139/319 (43.57)          | -0.31 [-7.99, 7.36]   |
| Race: ASIAN                             | 22/36 (61.11)         | 20/40 (50)               | 11.11 [-11.32, 32.38] |
| DiseaseStage:NewlyDiagnosed STAGEIIIB   | 32/48 (66.67)         | 16/29 (55.17)            | 11.49 [-10.60, 33.40] |
| Disease Stage: Newly Diagnosed STAGE IV | 105/265 (39.62)       | 122/292 (43.26)          | -3.64 [-11.84, 4.63]  |
| DiseaseStage:Recurrent                  | 25/45 (55.56)         | 23/50 (46)               | 9.56 [-10.57, 28.92]  |
| Prior Radiation Therapy: Yes            | 8/24 (33.33)          | 5/23 (21.74)             | 11.59 [-14.53, 36.28] |
| Prior Radiation Therapy: No             | 154/333 (46.25)       | 156/338 (46.15)          | 0.09 [-7.44, 7.62]    |
| Prior Systemic Therapy: Yes             | 7/15 (46.67)          | 5/20 (25)                | 21.67 [-10.31, 50.82] |
| Prior Systemic Therapy: No              | 155/343 (45.19)       | 156/341 (45.75)          | -0.56[-8.00, 6.89]    |
| ECOG PS: 0                              | 47/105 (44.76)        | 54/122 (44.26)           | 0.50 [-12.37, 13.41]  |
| ECOG PS: 1                              | 115/252 (45.63)       | 107/239 (44.77)          | 0.87 [-7.93, 9.64]    |
|                                         |                       |                          | Risk Difference (%)   |

Abbreviations: BOR=best overall response, CI=confidence interval, CR=complete response, ECOG PS=Eastern Cooperative Oncology Group performance status, EU=European Union, ITT=Intent-to-Treat, N=total number of patients in the specified subgroup, n=number of patients who achieved a BOR of CR or PR by Week 19 in the specified subgroup, ORR=objective response rate, PR=partial response, RD=risk difference.

<div style=\"page-break-after: always\"></div>

Table 18: Summary of Best Overall Response and ORR (Week 19) - PP Population

<!-- image -->

|                                                                       | PF-06439535              | Bevacizumab-EU   | Total          |
|-----------------------------------------------------------------------|--------------------------|------------------|----------------|
|                                                                       | (N351)                   | (N355)           | (N=706)        |
|                                                                       | n (+)                    | n (±)            | n (+)          |
| Best Overall Response                                                 |                          |                  |                |
| Complete Response                                                     | 8 (2.3)                  | 3 (0.8)          | 11  (1.6)      |
| Partial Response                                                      | 153 (43.6)               | 157 (44.2)       | 310 (43.9)     |
| Stable Disease                                                        | 153 (43.6)               | 165 (46.5)       | 318 (45.0)     |
| Objective Progression                                                 | 14 (4.0)                 | 13(3.7)          | 27 (3.8)       |
| Indeterminate                                                         | 23 (6.6)                 | 17 (4.8)         | 40 (5.7)       |
| Objective Response Rate (CR+PR)                                       | 161 (45.9)               | 160 (45.1)       | 321 (45.5)     |
| 95+ Exact CI [1]                                                      | [40.57, 51.24]           | [39.81, 50.41]   | [41.75, 49.22] |
| SD Duration (weeks) [2]                                               |                          |                  |                |
| 0-<6 weeks                                                            | 7 (4.6)                  | 15 (9.1)         | 22 (6.9)       |
| 6-c12 weeks                                                           | 37 (24.2)                | 23 (13.9)        | 60 (18.9)      |
| 12 - c18 weeks                                                        | 28  (18.3)               | 28 (17.0)        | 56 (17.6)      |
| 18-c24 weeks                                                          | 30 (19.6)                | 45 (27.3)        | 75(23.6)       |
| =24 weeks                                                             | 51(33.3)                 | 54 (32.7)        | 105 (33.0)     |
| Treatment Comparison (vs Bevacizumab-Eu)                              |                          |                  |                |
| Un-Stratified Risk Difference in ORR (t) [3] 95+CI ofDifference（t)[3] | 0.7985 [-6.5371, 8.1267] |                  |                |
| Stratified Risk Difference in ORR (t) [4]                             | 1.1922                   |                  |                |
| 95+CI of Difference (t）[4]                                            | [-6.1023, 8.4738]        |                  |                |
| Treatment Comparison (vs Bevacizumab-BU)                              |                          |                  |                |
| Un-Stratified Risk Ratio [5]                                          | 1.0177                   |                  |                |
| 95+ CI of Risk Ratio [5]                                              | [0.8656, 1.1966]         |                  |                |
| 90t CI of Risk Ratio [5]                                              | [0.8885, 1.1658]         |                  |                |
| Stratified Risk Ratio [6]                                             | 1.0266                   |                  |                |
| 95+ CI of Risk Ratio [6]                                              | [0.8740, 1.2057]         |                  |                |
| 90+ CI of Risk Ratio [9]                                              | [0.8970, 1.1748]         |                  |                |

Analysis of the primary efficacy endpoint of ORR was repeated on the final data as a sensitivity analysis. The analysis of ORR showed an un-stratified risk ratio of 1.0146 (PF-06439535 versus bevacizumab-EU), with a 95% CI of (0.8628, 1.1933) and a 90% CI of (0.8856, 1.1625), and an un-stratified risk difference of 0.6531% (PF-06439535 versus bevacizumab-EU), with a 95% CI of (-6.6080%, 7.9082%). The results were consistent with those from the analysis performed previously at Week 25.

## Secondary endpoints

## One year progression-free survival rate

There were 228 (63.7%) and 255 (70.6%) patients who had objective progression or had died without objective progression in the PF-06439535 group and the bevacizumab-EU group, respectively. The probability of being progression free at Week 55 was 32.3% (95% CI: 26.9%, 37.8%) in the PF-06439535 group and 30.5% (95% CI: 25.3%, 35.8%) in the bevacizumab-EU group ( Table 19 ). A total of 236 patients (130 [36.3%] patients in the PF-06439535 and 106 [29.4%] patients in the bevacizumab-EU treatment groups) were censored ( Table 20 ).

<div style=\"page-break-after: always\"></div>

Table 19: Summary of progression-free survival (Week 55) - ITT Population

| Number (%) of Patients                                            | PF-06439535 (N=358)   | Bevacizumab-EU (N=361)   | Total (N=719)     |
|-------------------------------------------------------------------|-----------------------|--------------------------|-------------------|
| Number with event                                                 | 228 (63.7)            | 255 (70.6)               | 483 (67.2)        |
| Type of event                                                     |                       |                          |                   |
| Objective progression                                             | 192 (53.6)            | 219 (60.7)               | 411 (57.2)        |
| Death without objective progression                               | 36 (10.1)             | 36 (10.0)                | 72 (10.0)         |
| Number censored                                                   | 130 (36.3)            | 106 (29.4)               | 236 (32.8)        |
| Probability of being event free at Week 55a [95% C1']             | 32.3 [26.9, 37.8]     | 30.5 [25.3, 35.8]        | 31.4 [27.6, 35.2] |
| Kaplan-Meier estimates of time to event (week) quartiles [95% CI] |                       |                          |                   |
| 25%                                                               | 23.4 [18.9, 24.3]     | 24.0 [19.3, 24.3]        | 24.0 [20.3, 24.3] |
| 50%                                                               | 41.3 [33.1, 42.3]     | 33.6 [33.0, 37.0]        | 34.4 [33.1, 41.1] |
| 75%                                                               | 71.9 [59.7, 88.3]     | 68.9 [56.9, 75.0]        | 69.0 [60.9, 75.0] |
| Versus bevacizumab-EU                                             |                       |                          |                   |
| Hazard ratiod                                                     | 0.930                 |                          |                   |
| 95% CI of hazard ratio                                            | 0.776-1.114           |                          |                   |
| P-valuee                                                          | 0.4388                |                          |                   |

A hazard ratio=1 indicated no difference in PD/death between PF-06439535 and bevacizumab-EU;

&gt;1 indicated an increase in PD/death in PF-06439535;

&lt;1 indicated an increase in PD/death in bevacizumab-EU.

Abbreviations: CI=confidence interval, EU=European Union, ITT=Intent-to-Treat, N=total number of patients, PD=progressive disease.

a. Estimated from the Kaplan-Meier curve.

b. Calculated based on the product-limit method.

c. Based on the Brookmeyer and Crowley method.

d. Based on the Cox proportional hazards model stratified by smoking, gender, and region.

e. 2-sided p-value from the log-rank test stratified by smoking, gender, and region.

Table 20: Censorship reasons for analysis of progression-free survival (Week 55) - ITT population

| Number (%) of Patients                                                                        | PF-06439535 (N=358)   | Bevacizumab-EU (N=361)   | Total (N=719)   |
|-----------------------------------------------------------------------------------------------|-----------------------|--------------------------|-----------------|
| Number censored                                                                               | 130 (36.3)            | 106 (29.4)               | 236 (32.8)      |
| Reasons for censorship                                                                        |                       |                          |                 |
| No adequate baseline assessments                                                              | 2 (<1.0)              | 3 (<1.0)                 | 5 (<1.0)        |
| No on-study disease assessments                                                               | 18 (5.0)              | 10 (2.8)                 | 28 (3.9)        |
| Given new anti-cancer treatment prior to tumour progression                                   | 12 (3.4)              | 17 (4.7)                 | 29 (4.0)        |
| Withdrew consent for follow-up                                                                | 5 (1.4)               | 6 (1.7)                  | 11 (1.5)        |
| Lost to follow-up                                                                             | 4 (1.1)               | 7 (1.9)                  | 11 (1.5)        |
| Unacceptable gap (>14 weeks) between PD or death to the most recent prior adequate assessment | 19 (5.3)              | 16 (4.4)                 | 35 (4.9)        |
| In follow-up for progression                                                                  | 70 (19.6)             | 47 (13.0)                | 117 (16.3)      |

Abbreviations:  EU=European Union, ITT=Intent-to-Treat, N=total number of patients, PD=progressive disease.

<div style=\"page-break-after: always\"></div>

Figure 4: Kaplan-Meier plot of progression-free survival - ITT population

<!-- image -->

The analysis of PFS for patients in the PP population showed results consistent with the primary ITT population. The hazard ratio when comparing PFS between PF-06439535 and bevacizumab-EU was 0.931, with a 95% CI of (0.777, 1.117). The stratified log-rank test resulted in a 2-sided p-value of 0.4511. The Kaplan-Meier curves of PFS for the PP population in the two treatment groups were comparable.

<div style=\"page-break-after: always\"></div>

## Duration of response

Table 21: Duration of objective response (Week 55) - Patients in ITT population who had an objective response achieved by Week 19

| Number(%)ofPatients                                               | PF-06439535 (N=162)   | Bevacizumab-EU (N=161)   | Total (N=323)     |
|-------------------------------------------------------------------|-----------------------|--------------------------|-------------------|
| Number with event                                                 | 107 (66.0)            | 119 (73.9)               | 226 (70.0)        |
| Type of event                                                     |                       |                          |                   |
| Objective progression                                             | 101 (62.3)            | 110 (68.3)               | 211 (65.3)        |
| Death without objective progression                               | 6 (3.7)               | 9 (5.6)                  | 15 (4.6)          |
| Number censored                                                   | 55 (34.0)             | 42 (26.1)                | 97 (30.0)         |
| Probability of being event free at Week 55a [95% CI']             | 32.0 [24.2, 40.1]     | 30.8 [23.3, 38.6]        | 31.5 [26.1, 37.2] |
| Kaplan-Meier estimates of time to event (week) quartiles [95% CI] |                       |                          |                   |
| 25%                                                               | 25.3 [20.7, 27.1]     | 18.9 [17.9, 21.3]        | 21.3 [18.9, 24.4] |
| 50%                                                               | 36.3 [31.6, 43.6]     | 28.7 [27.0, 36.3]        | 35.9 [28.9, 36.6] |
| 75%                                                               | 69.1 [55.0, 86.1]     | 62.1 [51.3, 76.6]        | 63.6 [58.1, 75.6] |
| Versus bevacizumab-EU                                             |                       |                          |                   |
| Hazard ratiod                                                     | 0.790                 |                          |                   |
| 95% CI of hazard ratio                                            | 0.600-1.039           |                          |                   |
| P-valuee                                                          | 0.0906                |                          |                   |

A hazard ratio=1 indicated no difference in PD/death between PF-06439535 and bevacizumab-EU;

&gt;1 indicated an increase in PD/death in PF-06439535;

&lt;1 indicated an increase in PD/death in bevacizumab-EU.

Abbreviations: CI=confidence interval, CR=complete response, EU=European Union, ITT=intent-to-treat, N=number of patients who achieved confirmed objective response (CR or PR) by Week 19, PD=progressive disease, PR=partial response.

a. Estimated from the Kaplan-Meier curve.

b. Calculated based on the product-limit method.

c. Based on the Brookmeyer and Crowley method.

d. Based on the Cox proportional hazards model stratified by smoking, gender, and region.

e. 2-sided p-value from the log-rank test stratified by smoking, gender, and region.

Table 22: Censorship Reasons for Analysis of Duration of Objective Response (Week 55) - Patients in ITT Population Who Had an Objective Response Achieved by Week 19

| Number (%) of Patients                                                                        | PF-06439535 (N=162)   | Bevacizumab-EU (N=161)   | Total (N=323)   |
|-----------------------------------------------------------------------------------------------|-----------------------|--------------------------|-----------------|
| Number censored                                                                               | 55 (34.0)             | 42 (26.1)                | 97 (30.0)       |
| Reasons for censorship                                                                        |                       |                          |                 |
| Given new anti-cancer treatment prior to tumor progression                                    | 4 (2.5)               | 7 (4.3)                  | 11 (3.4)        |
| Withdrew consent for follow-up                                                                | 1 (<1.0)              | 4 (2.5)                  | 5 (1.5)         |
| Lost to follow-up                                                                             | 4 (2.5)               | 3 (1.9)                  | 7 (2.2)         |
| Unacceptable gap (>14 weeks) between PD or death to the most recent prior adequate assessment | 6 (3.7)               | 5 (3.1)                  | 11 (3.4)        |
| In follow-up for progression                                                                  | 40 (24.7)             | 23 (14.3)                | 63 (19.5)       |

Abbreviations: CR=complete response, EU=European Union, ITT=intent-to-treat, N=number of patients who achieved confirmed objective response (CR or PR) by Week 19, PD=progressive disease, PR=partial response.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviations: EU=European Union, ITT=intent-to-treat.

Figure 5 Kaplan-Meier Plot of Duration of Objective Response (Week 55) - Patients in ITT Population Who Had a Confirmed Objective Response Achieved by Week 19

## One year survival rate

Table 23: Summary of overall survival (Week 55) - ITT Population

| Number (%) of Patients                                            | PF-06439535 (N=358)   | Bevacizumab-EU (N=361)   | Total (N=719)     |
|-------------------------------------------------------------------|-----------------------|--------------------------|-------------------|
| Number of deaths                                                  | 144 (40.2)            | 149 (41.3)               | 293 (40.8)        |
| Number censored                                                   | 214 (59.8)            | 212 (58.7)               | 426 (59.2)        |
| Survival probability at Week 55? [95% CIb]                        | 65.8 [60.5, 70.6]     | 64.1 [58.6, 69.0]        | 65.0 [61.2, 68.4] |
| Kaplan-Meier estimates of time to event (week) quartiles [95% CI] |                       |                          |                   |
| 25%                                                               | 40.3 [34.0, 49.0]     | 42.9 [36.3, 47.9]        | 41.1 [37.4, 46.0] |
| 50%                                                               | 84.4 [71.7, -]        | 77.4 [69.3, 102.1]       | 83.0 [73.4, 98.7] |
| 75%                                                               |                       |                          |                   |
| Versus bevacizumab-EU                                             |                       |                          |                   |
| Hazard ratiod                                                     | 0.918                 |                          |                   |
| 95% CI of hazard ratio                                            | 0.729-1.157           |                          |                   |
| P-valuee                                                          | 0.4726                |                          |                   |

A hazard ratio=1 indicated no difference in death between PF-06439535 and bevacizumab-EU;

&gt;1 indicated an increase in death in PF-06439535;

&lt;1 indicated an increase in death in bevacizumab-EU.

Abbreviations: CI=confidence interval, EU=European Union, ITT=intent-to-treat, N=total number of patients.

<div style=\"page-break-after: always\"></div>

- a. Estimated from the Kaplan-Meier curve.
- b. Calculated from the product-limit method.
- c. Based on the Brookmeyer and Crowley method.
- d. Based on the Cox proportional hazards model stratified by smoking, gender, and region.
- e. 2-sided p-value from the log-rank test stratified by smoking, gender, and region.

Table 24: Censorship Reasons for Analysis of Overall Survival (Week 55) - ITT Population

| Number (%) of Patients                   | PF-06439535 (N=358)   | Bevacizumab-EU (N=361)   | Total (N=719)   |
|------------------------------------------|-----------------------|--------------------------|-----------------|
| Number censored                          | 214 (59.8)            | 212 (58.7)               | 426 (59.2)      |
| Reasons for censorship                   |                       |                          |                 |
| Alive                                    | 146 (40.8)            | 142 (39.3)               | 288 (40.1)      |
| Patient no longer willing to participate | 59 (16.5)             | 57 (15.8)                | 116 (16.1)      |
| Lost to follow-up                        | 9 (2.5)               | 13 (3.6)                 | 22 (3.1)        |

Abbreviations: EU=European Union, ITT=intent-to-treat, N=total number of patients.

<!-- image -->

Abbreviations: EU=European Union, ITT=intent-to-treat.

Figure 6: Kaplan-Meier plot of overall survival - ITT population

## Summary of main study(ies)

The following table summarises the efficacy results from the main studies supporting the present application.

These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk

<div style=\"page-break-after: always\"></div>

assessment (see later sections).

## Table 25: Summary of Efficacy for trial B7193003 (including secondary endpoints at week 55)

| Title: A Phase 3 Randomized, Double-Blind Study of PF-06439535 Plus Paclitaxel-Carboplatin and Bevacizumab Plus Paclitaxel-Carboplatin for the First-Line Treatment of Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer   | Title: A Phase 3 Randomized, Double-Blind Study of PF-06439535 Plus Paclitaxel-Carboplatin and Bevacizumab Plus Paclitaxel-Carboplatin for the First-Line Treatment of Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer   | Title: A Phase 3 Randomized, Double-Blind Study of PF-06439535 Plus Paclitaxel-Carboplatin and Bevacizumab Plus Paclitaxel-Carboplatin for the First-Line Treatment of Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer   | Title: A Phase 3 Randomized, Double-Blind Study of PF-06439535 Plus Paclitaxel-Carboplatin and Bevacizumab Plus Paclitaxel-Carboplatin for the First-Line Treatment of Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                        | B7391003                                                                                                                                                                                                                                | B7391003                                                                                                                                                                                                                                | B7391003                                                                                                                                                                                                                                                                                                                                                          |
| Design                                                                                                                                                                                                                                  | Multinational, double-blind, randomized, parallel-group Phase 3 clinical trial.                                                                                                                                                         | Multinational, double-blind, randomized, parallel-group Phase 3 clinical trial.                                                                                                                                                         | Multinational, double-blind, randomized, parallel-group Phase 3 clinical trial.                                                                                                                                                                                                                                                                                   |
| Design                                                                                                                                                                                                                                  | Duration of main phase:                                                                                                                                                                                                                 | Duration of main phase:                                                                                                                                                                                                                 | 55 weeks of treatment and follow-up for disease progression, and overall survival until unacceptable toxicity, discretion of the investigator, regulatory request, death, withdrawal of consent occurred, or end of treatment (EOT).                                                                                                                              |
| Hypothesis                                                                                                                                                                                                                              | Equivalence                                                                                                                                                                                                                             | Equivalence                                                                                                                                                                                                                             | Equivalence                                                                                                                                                                                                                                                                                                                                                       |
| Treatments groups                                                                                                                                                                                                                       | PF-06439535                                                                                                                                                                                                                             | PF-06439535                                                                                                                                                                                                                             | -Chemotherapy: Carboplatin (AUC 6) + Paclitaxel 200 mg/m2 Q3W for at least 4 and not more than 6 cycles. -PF-06439535: 15 mg/kg intravenous (IV) infusion Q3W for at least 4 and not more than 6 cycle with chemotherapy followed by the assigned blinded bevacizumab monotherapy. N=358 subjects randomized                                                      |
| Treatments groups                                                                                                                                                                                                                       | Bevacizumab-EU                                                                                                                                                                                                                          | Bevacizumab-EU                                                                                                                                                                                                                          | -Chemotherapy: Carboplatin (AUC 6) + Paclitaxel 200 mg/m2 Q3W for at least 4 and not more than 6 cycles -bevacizumab 15 mg/kg intravenous (IV) infusion Q3W Q3W for at least 4 and not more than 6 cycle with chemotherapy followed by the assigned blinded bevacizumab monotherapy for 6 cycles N=361 subjects randomized                                        |
| Endpoints definitions                                                                                                                                                                                                                   | Primary endpoint                                                                                                                                                                                                                        | Objective response rate (ORR)                                                                                                                                                                                                           | ORR defined as the percent of patients within each treatment group who achieved a BOR of CR or PR by Week 19, in accordance with RECIST version 1.1, and subsequently confirmed on a follow-up tumour assessment by Week 25. The primary endpoint of ORR was based on the Sponsor's derived BOR using tumour measurements reported by the investigator in the CRF |
| Endpoints definitions                                                                                                                                                                                                                   | Secondary endpoint                                                                                                                                                                                                                      | Duration of objective response (DOR)                                                                                                                                                                                                    | DOR was defined as the time from date of the first documentation of objective tumour response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD in patients who achieved PR or CR by Week 19 subsequently confirmed by Week 25.                                                                            |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary endpoint                                                                                                                   | One year progression free survival rate (PFS)                                                                                        | PFS was defined as the time from date of randomization to first progression of disease or death due to any cause, whichever occurred first. The tumour assessment was based on investigator assessment in accordance with RECIST version 1.1   | PFS was defined as the time from date of randomization to first progression of disease or death due to any cause, whichever occurred first. The tumour assessment was based on investigator assessment in accordance with RECIST version 1.1   |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Secondary endpoint                                                                                                                   | One year survival rate (OS)                                                                                                          | Survival (time to death) was defined as the time from date of randomization to death due to any causes.                                                                                                                                        | Survival (time to death) was defined as the time from date of randomization to death due to any causes.                                                                                                                                        |
| Database lock for primary endpoints             | 08 May 2017                                                                                                                          | 08 May 2017                                                                                                                          | 08 May 2017                                                                                                                                                                                                                                    | 08 May 2017                                                                                                                                                                                                                                    |
| Results and Analysis                            | Results and Analysis                                                                                                                 | Results and Analysis                                                                                                                 | Results and Analysis                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                           |
| Analysis description                            | Primary Analysis                                                                                                                     | Primary Analysis                                                                                                                     | Primary Analysis                                                                                                                                                                                                                               | Primary Analysis                                                                                                                                                                                                                               |
| Analysis population and time point description  | Intent-to-treat population consists of all randomized subjects. All data during study are included in the analyses (Final data set). | Intent-to-treat population consists of all randomized subjects. All data during study are included in the analyses (Final data set). | Intent-to-treat population consists of all randomized subjects. All data during study are included in the analyses (Final data set).                                                                                                           | Intent-to-treat population consists of all randomized subjects. All data during study are included in the analyses (Final data set).                                                                                                           |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                      | Treatment group                                                                                                                      | PF-06439535                                                                                                                                                                                                                                    | Bevacizumab-EU                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                    | Number of subject                                                                                                                    | 358                                                                                                                                                                                                                                            | 361                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | ORR (CR+PR), n (%)                                                                                                                   | ORR (CR+PR), n (%)                                                                                                                   | 162 (45.3%)                                                                                                                                                                                                                                    | 161 (44.6%)                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | 95% exact CI (%)                                                                                                                     | 95% exact CI (%)                                                                                                                     | [40.01, 50.57]                                                                                                                                                                                                                                 | [39.40, 49.89]                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | PFS (% event free at week 55)                                                                                                        | PFS (% event free at week 55)                                                                                                        | 32.3                                                                                                                                                                                                                                           | 30.5                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | 95%CI (%)                                                                                                                            | 95%CI (%)                                                                                                                            | [26.9, 37.8]                                                                                                                                                                                                                                   | [25.3, 35.8]                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | DOR (% event free at week 55 after confirmed objective response)                                                                     | DOR (% event free at week 55 after confirmed objective response)                                                                     | 32.0                                                                                                                                                                                                                                           | 30.8                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                               | 95% CI                                                                                                                               | [24.2, 40.1]                                                                                                                                                                                                                                   | [23.3, 38.6]                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | OS (% survival at week 55) 65.8                                                                                                      | OS (% survival at week 55) 65.8                                                                                                      |                                                                                                                                                                                                                                                | 64.1                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                               | 95% CI                                                                                                                               | [60.5, 70.6]                                                                                                                                                                                                                                   | [58.6, 69.0]                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  | Primary endpoint ORR                                                                                                                 | Primary endpoint ORR                                                                                                                 | Comparison groups                                                                                                                                                                                                                              | PF-06439535 versus Bevacizumab-EU                                                                                                                                                                                                              |
| Effect estimate per comparison                  |                                                                                                                                      |                                                                                                                                      | Un-stratified risk difference in ORR (%)                                                                                                                                                                                                       | 0.6531                                                                                                                                                                                                                                         |
| Effect estimate per comparison                  |                                                                                                                                      |                                                                                                                                      | 95% CI of difference*                                                                                                                                                                                                                          | [-6.6080, 7.9082]                                                                                                                                                                                                                              |
| Effect estimate per comparison                  |                                                                                                                                      |                                                                                                                                      | Un-stratified risk ratio                                                                                                                                                                                                                       | 1.0146                                                                                                                                                                                                                                         |
| Effect estimate per comparison                  |                                                                                                                                      |                                                                                                                                      | 95% CI of risk ratio 90% CI of risk ratio                                                                                                                                                                                                      | [0.8628, 1.1933] [0.8856, 1.1625]                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|       | Secondary endpoint PFS                                                                                                                                  | Comparison groups                                                                                                                                       | PF-06439535 versus Bevacizumab-EU                                                                                                                       |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
|       | Secondary endpoint PFS                                                                                                                                  | Hazard ratio                                                                                                                                            | 0.930                                                                                                                                                   |
|       | Secondary endpoint PFS                                                                                                                                  | 95% CI of hazard ratio                                                                                                                                  | 0.776-1.114                                                                                                                                             |
|       | Secondary endpoint PFS                                                                                                                                  | P-value                                                                                                                                                 | 0.4388                                                                                                                                                  |
|       | Secondary endpoint DOR                                                                                                                                  | Comparison groups                                                                                                                                       | PF-06439535 versus Bevacizumab-EU                                                                                                                       |
|       | Secondary endpoint DOR                                                                                                                                  | Hazard ratio                                                                                                                                            | 0.790                                                                                                                                                   |
|       | Secondary endpoint DOR                                                                                                                                  | 95% CI of hazard ratio                                                                                                                                  | 0.600-1.039                                                                                                                                             |
|       | Secondary endpoint DOR                                                                                                                                  | P-value                                                                                                                                                 | 0.0906                                                                                                                                                  |
|       | Secondary endpoint OS                                                                                                                                   | Comparison groups                                                                                                                                       | PF-06439535 versus Bevacizumab-EU                                                                                                                       |
|       | Secondary endpoint OS                                                                                                                                   | Hazard ratio                                                                                                                                            | 0.918                                                                                                                                                   |
|       | Secondary endpoint OS                                                                                                                                   | 95% CI of hazard ratio                                                                                                                                  | 0.729-1.157                                                                                                                                             |
|       | Secondary endpoint OS                                                                                                                                   | P-value                                                                                                                                                 | 0.4726                                                                                                                                                  |
| Notes | *Calculated based on 2-sided Miettinen and Nurminen method without strata for risk difference for confirmed response. EU equivalence margins (95% CI in | *Calculated based on 2-sided Miettinen and Nurminen method without strata for risk difference for confirmed response. EU equivalence margins (95% CI in | *Calculated based on 2-sided Miettinen and Nurminen method without strata for risk difference for confirmed response. EU equivalence margins (95% CI in |

## 2.4.3. Discussion on clinical efficacy

Study B7391003 is a multinational, double-blind, randomised (1:1), parallel-group, multiple dose study evaluating the efficacy, safety, PK, and immunogenicity of PF-06439535 plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin for the first-line treatment for patients with advanced non-squamous NSCLC.

## Design and conduct of clinical studies

Randomisation was stratified by region, gender (male/female) and smoking history (never/ever). A total of 719 subjects were enrolled to receive either treatment of PF-06439535 plus paclitaxel and carboplatin or bevacizumab-EU plus paclitaxel and carboplatin for at least 4 and no more than 6 cycles, followed by bevacizumab monotherapy.

All clinical studies were conducted in accordance with the ethical principles of the Declaration of Helsinki and were consistent with International Conference on Harmonisation (ICH) 'Guideline for Good Clinical Practice (GCP)' (ICH E6). GCP inspections were conducted at two centres by Ukraine Ministry of Health in the study and no major deviations were observed.

The chosen patient population of histologically or cytologically confirmed diagnosis of non-squamous NSCLC with the presence of newly diagnosed stage IIIB or IV NSCLC (according to Revised International System for Staging Lung Cancer Criteria of 2010) or recurrent NSCLC with at least one measurable lesion as defined by RECIST version 1.1, is considered acceptable for the purpose to establishing clinical similarity between PF-06439535 plus paclitaxel-carboplatin versus reference bevacizumab plus paclitaxel-carboplatin. NSCLC is regarded as a representative indication for the reference product. Exclusion of patients with known sensitising EGFR mutations (exon 19 deletion or exon 21 L858R) or EML4-ALK translocation positive mutations, is considered appropriate.

The drug was administered intravenously at hospitals and the regimen was according to the Avastin product labelling. The primary efficacy endpoint of Study B7391003 was ORR defined as the percent of patients within

<div style=\"page-break-after: always\"></div>

each treatment group who achieved a BOR of CR or PR by Week 19 in accordance with RECIST 1.1 and subsequently confirmed on a follow-up tumour assessment by Week 25.

The inclusion and exclusion criteria used in the Phase 3 study were also according to the Avastin labelling and therefore considered adequate. Sample size calculations, randomisation and blinding procedures are also considered adequately performed.

ORR is considered acceptable as primary endpoint since ORR in NSCLC patients have been observed to be the most sensitive endpoint observed through the bevacizumab reference product trials.

The selected primary and secondary outcomes, their measurement time points as well as the pre-selected criteria for biosimilarity are in general according to the CHMP scientific advice provided, as well as according to relevant CHMP guidelines for biosimilar clinical development. RD of ORR at week 19 in the PP population with 95% CIs has also been provided, confirming the conclusion on similarity of efficacy in the ITT population.

The equivalence study design with the type I error rate controlled at 2.5% has previously been accepted by CHMP (EMA/CHMP/SAWP/667247/2015), and the planning of a trial based on the operating characteristic of an equivalence margin of about ± 12-13% points on the RD scale is considered feasible. The same advice pointed out that the chosen RD margin may be justified statistically by being lower than the lower bound of a 95% confidence interval from a meta-analysis. It was also pointed out that there is a need to justify the margin from a clinical perspective. There should be a clinical discussion of the irrelevance of the margin, which may lead to a smaller margin if the clinical irrelevance of the statistically derived margin cannot be justified. However, it is reasonable to assume that the margin would have been in the range of 10-13% regardless, and the result of the trial is well within these limits.

## Efficacy data and additional analyses

Overall, 719 subjects with non-squamous NSCLC were randomised; 358 in the PF-06439535 arm vs. 361 in the bevacizumab-EU arm. Intent to treat was the main protocol specified population for analysis. There were no protocol deviations that were likely to significantly impact on study findings.

Results from the analysis of the primary endpoint, ORR, met the pre-specified equivalence criterion in both populations. In the ITT population, the ORR was similar for the treatment groups (45.3% in the PF-06439535 group and 44.6% in the -EU group). The analysis of ORR provided an un-stratified risk difference of 0.6531% (PF-06439535 versus bevacizumab-EU), with a 95% CI of (-6.6080%, 7.9082%), which fell entirely within the pre-determined equivalence margin (-13% to 13%). Further analysis of the PP population (both RD and RR) supports the conclusion. Sub-population analyses were conducted for ORR, and overall, no marked differences in the treatment comparisons were observed across subgroup categories.

In the ITT population, the percentages of patients who progressed/died or were censored, were comparable between the two treatment groups.

The probability of being progression free at Week 55 was 32.3% (95% CI: 26.9%, 37.8%) in the PF-06439535 group and 30.5% (95% CI: 25.3%, 35.8%) in the bevacizumab-EU group. The probability of not having subsequent progression or death at Week 55 after a confirmed objective response was 32.0% (95% CI: 24.2%, 40.1%) in the PF-06439535 group, and 30.8% (95% CI: 23.3%, 38.6%) in the bevacizumab-EU group.

Analysis of the primary efficacy endpoint of ORR was repeated at week 55 as a sensitivity analysis. The results were consistent with those from the analysis performed previously at Week 25.

<div style=\"page-break-after: always\"></div>

## 2.4.4. Conclusions on the clinical efficacy

Similarity between PF-06439535 and EU-licensed bevacizumab reference product was demonstrated in the ITT-population, with RD of ORR at week 19 within the pre-specified equivalence margin (-13% to 13%). Equivalence between PF-06439535 and reference bevacizumab was also shown by RD of ORR in the PP population.

From the statistical point of view, the choice of the margin using the 95-95 rule seems reasonable. Since the treatment effect attributable to bevacizumab is small, the applicant should have provided clinical justification for the equivalence margin obtained in the study, in addition to the statistical considerations in the report. However, based on similar studies it is likely that the confidence interval for the difference obtained in the study would have been within a clinically justifiable margin.

The secondary outcomes (PFS, duration of response, OS) as well as the different sensitivity analyses were in line with the primary outcome, supporting the biosimilarity claim between PF-06439535 and the bevacizumab reference product.

In conclusion, from an efficacy point of view, the MAA of PF-06439535 is approvable as a biosimilar to Avastin (bevacizumab-EU). Since the mechanism of action of bevacizumab is the same independent of indication, extrapolation to all other indications labelled for the reference product bevacizumab is considered acceptable.

## 2.5. Clinical safety

Comparative safety data of PF-06439535 was derived from two clinical studies:

-  Study B7391001 was a, double blind, randomized, parallel-group, single-dose, 3-arm, comparative PK study of PF-06439535 and bevacizumab sourced from the US and EU administered to healthy males.
-  Study B7391003 was a multinational, parallel arm, randomized, double-blind, multiple dose study to compare the safety and efficacy of PF-06439535 plus paclitaxel and carboplatin with bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment of advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous-non-small cell lung cancer (NSCLC).

The safety population consists of a total of 815 subjects who received at least 1 dose of study medication in studies B7391001 (101 subjects) and B7391003 (714 subjects) of which 388 subjects received PF-06439535. The safety data represent the final data when all patients have completed the week 55 visit.

## Patient exposure

## Study B7391001

The subjects were randomized to one of the three arms to receive a single IV dose of 5 mg/kg of PF-06439535 or bevacizumab-EU or bevacizumab-US. Exposure to investigational product was comparable across the treatment groups; 33 subjects in the PF-06439535 arm, 35 subjects in the bevacizumab-EU arm and 33 subjects in the bevacizumab US arm.

## Study B7391003

Patients were randomized in a 1:1 ratio to receive a IV dose of 15 mg/kg of PF-06439535 plus paclitaxel and carboplatin or bevacizumab-EU plus paclitaxel and carboplatin for at least four and no more than six cycles (1 Cycle=21 days [3 week] ± 4 days), followed by the assigned blinded bevacizumab monotherapy. A total of 356

<div style=\"page-break-after: always\"></div>

patients received study treatment in the PF-06439535 treatment arm and 358 in the bevacizumab-EU treatment arm.

Table 26: Summary of treatment exposure for Bevacizumab, Paclitaxel, and Carboplatin - Safety population study B7391003

|                                     | PF-06439535 (N=356)                 | PF-06439535 (N=356)                 | PF-06439535 (N=356)                 | Bevacizumab-EU (N=358)              | Bevacizumab-EU (N=358)              | Bevacizumab-EU (N=358)              | Total (N=714)                       | Total (N=714)                       | Total (N=714)                       |
|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                                     | Bevacizumab                         | Paclitaxel                          | Carboplatin                         | Bevacizumab                         | Paclitaxel                          | Carboplatin                         | Bevacizumab                         | Paclitaxel                          | Carboplatin                         |
| Summaryof duration(cycles):         | Summaryof duration(cycles):         | Summaryof duration(cycles):         | Summaryof duration(cycles):         | Summaryof duration(cycles):         | Summaryof duration(cycles):         | Summaryof duration(cycles):         | Summaryof duration(cycles):         | Summaryof duration(cycles):         | Summaryof duration(cycles):         |
| Number of patients                  | 355                                 | 356                                 | 356                                 | 358                                 | 358                                 | 358                                 | 713                                 | 714                                 | 714                                 |
| Mean                                | 10.7                                | 4.9                                 | 4.9                                 | 10.7                                | 5.0                                 | 5.0                                 | 10.7                                | 4.9                                 | 5.0                                 |
| SD                                  | 6.77                                | 1.52                                | 1.52                                | 6.67                                | 1.45                                | 1.41                                | 6.72                                | 1.49                                | 1.47                                |
| Median                              | 10.0                                | 6.0                                 | 6.0                                 | 10.0                                | 6.0                                 | 6.0                                 | 10.0                                | 6.0                                 | 6.0                                 |
| Range                               | 1-32                                | 1-6                                 | 1-6                                 | 1-30                                | 1-6                                 | 1-6                                 | 1-32                                | 1-6                                 | 1-6                                 |
| Number(%)ofpatients intreatedcycle: | Number(%)ofpatients intreatedcycle: | Number(%)ofpatients intreatedcycle: | Number(%)ofpatients intreatedcycle: | Number(%)ofpatients intreatedcycle: | Number(%)ofpatients intreatedcycle: | Number(%)ofpatients intreatedcycle: | Number(%)ofpatients intreatedcycle: | Number(%)ofpatients intreatedcycle: | Number(%)ofpatients intreatedcycle: |
| ≥1                                  | 355 (99.7)                          | 356 (100.0)                         | 356 (100.0)                         | 358 (100.0)                         | 358 (100.0)                         | 358 (100.0)                         | 713 (99.9)                          | 714 (100.0)                         | 714 (100.0)                         |
| M2                                  | 336 (94.4)                          | 335 (94.1)                          | 335 (94.1)                          | 344 (96.1)                          | 344 (96.1)                          | 345 (96.4)                          | 680 (95.2)                          | 679 (95.1)                          | 680 (95.2)                          |
| ≥3                                  | 318 (89.3)                          | 317 (89.0)                          | 317 (89.0)                          | 325 (90.8)                          | 323 (90.2)                          | 327 (91.3)                          | 643 (90.1)                          | 640 (89.6)                          | 644 (90.2)                          |
| ≥4                                  | 302 (84.8)                          | 303 (85.1)                          | 304 (85.4)                          | 312 (87.2)                          | 308 (86.0)                          | 313 (87.4)                          | 614 (86.0)                          | 611 (85.6)                          | 617 (86.4)                          |
| ≥5                                  | 280 (78.7)                          | 228 (64.0)                          | 230 (64.6)                          | 290 (81.0)                          | 234 (65.4)                          | 238 (66.5)                          | 570 (79.8)                          | 462 (64.7)                          | 468 (65.5)                          |
| ≥6                                  | 265 (74.4)                          | 201 (56.5)                          | 204 (57.3)                          | 278 (77.7)                          | 207 (57.8)                          | 211 (58.9)                          | 543 (76.1)                          | 408 (57.1)                          | 415 (58.1)                          |
| ≥7                                  | 241 (67.7)                          | 0                                   | 0                                   | 253 (70.7)                          | 0                                   | 0                                   | 494 (69.2)                          | 0                                   | 0                                   |

The number of patients in each treated cycles (up to ≥cycle 35) for the monotherapy setting is similar in the two treatment groups.

## Adverse events

## Study B7391001

Of the 101 subjects that received study drug, 55 subjects (54.5%) experienced 107 AEs. The majority of these were Grade 1 or Grade 2. The most common all-causality TEAEs (reported in &gt;3 subjects) were upper respiratory tract infection, headache, dyspepsia, myalgia and diarrhoea.

Table 27: Summary of Treatment-Emergent Adverse Events (All Causalities) - Safety Population, Study B7391001

|                                                               | PF-06439535   | Bevacizumab   | Bevacizumab   | Total     |
|---------------------------------------------------------------|---------------|---------------|---------------|-----------|
|                                                               |               | -EU           | -US           |           |
| Subjects Evaluable for AEs                                    | N=33 (%)      | N=35 (%)      | N=33 (%)      | N=101 (%) |
| Number of adverse events                                      | 30            | 45            | 32            | 107       |
| Subjects with adverse events                                  | 16 (48.5)     | 22 (62.9)     | 17 (51.5)     | 55 (54.5) |
| Subjects with serious adverse events                          | 0             | 1 (2.9)       | 0             | 1 (1.0)   |
| Subjects with grade 3 or 4 adverse e                          | 0             | 1 (2.9)       | 0             | 1 (1.0)   |
| Subjects with grade 5 adverse events                          | 0             | 0             | 0             | 0         |
| Subjects discontinued due to adverse events                   | 0             | 0             | 0             | 0         |
| Subjects with dose reduced due to adverse events              | 0             | 0             | 0             | 0         |
| Subjects with temporary discontinuation due to adverse events | 0             | 0             | 0             | 0         |

## Treatment related AEs

<div style=\"page-break-after: always\"></div>

Twenty (19.8%) subjects experienced 31 treatment-related AEs. The majority of the treatment related AEs were Grade 1 or Grade 2. The most common treatment-related AEs (reported in &gt;2 subjects) were Dyspepsia (1 in the PF-06439535 arm, 2 in the bevacizumab-EU arm and 1 in the bevacizumab-US arm) and Rash macular (1 in the PF-06439535 arm and 2 in the bevacizumab-EU arm).

## Study B7391003

Table 28: Treatment-emergent adverse events occurring in ≥ 10% of patients in any treatment group (All-Causalities) by combination therapy and monotherapy (Study B7391003)

|                                                 | PF-06439535                       | PF-06439535                           | Bevacizumab-EU                    | Bevacizumab-EU                        | Total                             | Total                               |
|-------------------------------------------------|-----------------------------------|---------------------------------------|-----------------------------------|---------------------------------------|-----------------------------------|-------------------------------------|
| SystemOrganClass andPreferredTerm               | Combination Therapy (N=356) n (%) | Bevacizumab Monotherapy (N=254) n (%) | Combination Therapy (N=358) n (%) | Bevacizumab Monotherapy (N=262) (%) u | Combination Therapy (N=714) n (%) | Bevacizuma Monotheral (N=516) n (%) |
| Total                                           | 310 (87.1)                        | 161 (63.4)                            | 311 (86.9)                        | 167 (63.7)                            | 621 (87.0)                        | 328 (63.6)                          |
| Blood and lymphatic system disorders            |                                   |                                       |                                   |                                       |                                   |                                     |
| Anaemia                                         | 85 (23.9)                         | 39 (15.4)                             | 97 (27.1)                         | 24 (9.2)                              | 182 (25.5)                        | 63 (12.2)                           |
| Neutropenia                                     | 54 (15.2)                         | 17 (6.7)                              | 58 (16.2)                         | 16 (6.1)                              | 112 (15.7)                        | 33 (6.4)                            |
| Thrombocytopenia                                | 53 (14.9)                         | 19 (7.5)                              | 59 (16.5)                         | 21 (8.0)                              | 112 (15.7)                        | 40 ( 7.8)                           |
| Gastrointestinal disorders                      |                                   |                                       |                                   |                                       |                                   |                                     |
| Constipation                                    | 35 (9.8)                          | 4 (1.6)                               | 26 (7.3)                          | 5 (1.9)                               | 61 (8.5)                          | 9 (1.7)                             |
| Diamhoea                                        | 38 (10.7)                         | 11 (4.3)                              | 45 (12.6)                         | 8 (3.1)                               | 83 (11.6)                         | 19 (3.7)                            |
| Nausea                                          | 64 (18.0)                         | 11 (4.3)                              | 66 (18.4)                         | 7 (2.7)                               | 130 (18.2)                        | 18 (3.5)                            |
| Vomiting                                        | 34 (9.6)                          | 9 (3.5)                               | 26 (7.3)                          | 10 (3.8)                              | 60 (8.4)                          | 19 (3.7)                            |
| Generaldisordersand administrationsite          |                                   |                                       |                                   |                                       |                                   |                                     |
| conditions Asthenia                             | 36 (10.1)                         | 14 (5.5)                              | 33 (9.2)                          | 13 (5.0)                              | 69 (9.7)                          | 27 ( 5.2)                           |
| Fatigue                                         | 56 (15.7)                         | 26 (10.2)                             | 49 (13.7)                         | 28 (10.7)                             | 105 (14.7)                        | 54 (10.5)                           |
| Investigations                                  |                                   |                                       |                                   |                                       |                                   |                                     |
| Alanine aminotransferase increased              | 30 (8.4)                          | 27 (10.6)                             | 20 (5.6)                          | 23 (8.8)                              | 50 ( 7.0)                         | 50 (9.7)                            |
| Aspartate aminotransferase increased            | 23 (6.5)                          | 30 (11.8)                             | 19 (5.3)                          | 24 (9.2)                              | 42 (5.9)                          | 54 (10.5)                           |
| Weight decreased                                | 19 (5.3)                          | 18 (7.1)                              | 20 (5.6)                          | 14 (5.3)                              | 39 (5.5)                          | 32 ( 6.2)                           |
| Metabolismandnutritiondisorders                 |                                   |                                       |                                   |                                       |                                   |                                     |
| Decreased appetite                              | 36 (10.1)                         | 15 (5.9)                              | 38 (10.6)                         | 10 (3.8)                              | 74 (10.4)                         | 25 ( 4.8)                           |
| Musculoskeletal andconnective tissue            |                                   |                                       |                                   |                                       |                                   |                                     |
| disorders Arthralgia                            | 36 (10.1)                         | 6 (2.4)                               | 41 (11.5)                         | 2 (0.8)                               | 77 (10.8)                         | 8 (1.6)                             |
| Myalgia                                         | 53 (14.9)                         | 4(1.6)                                | 47 (13.1)                         | 6 (2.3)                               | 100 (14.0)                        | 10 ( 1.9)                           |
| Nervous system disorders                        |                                   |                                       |                                   |                                       |                                   |                                     |
| Headache                                        | 18 (5.1)                          | 14 (5.5)                              | 24 (6.7)                          | 17 (6.5)                              | 42 (5.9)                          | 31 (6.0)                            |
| Neuropathy peripheral                           | 49 (13.8)                         | 7 (2.8)                               | 58 (16.2)                         | 13 (5.0)                              | 107 (15.0)                        | 20 (3.9)                            |
| Paraesthesia                                    | 38 (10.7)                         | 12 (4.7)                              | 31 (8.7)                          | 2 (0.8)                               | 69 (9.7)                          | 14 ( 2.7)                           |
| Peripheral sensory neuropathy                   | 33 (9.3)                          | 4(1.6)                                | 43 (12.0)                         | 8 (3.1)                               | 76 (10.6)                         | 12 (2.3)                            |
| Respiratory, thoracic and mediastinal disorders |                                   |                                       |                                   |                                       |                                   |                                     |
| Cough                                           | 28 (7.9)                          | 18 (7.1)                              | 31 (8.7)                          | 20 (7.6)                              | 59 (8.3)                          | 38 (7.4)                            |
| Dyspnoea                                        | 22 (6.2)                          | 14 (5.5)                              | 26 (7.3)                          | 13 (5.0)                              | 48 ( 6.7)                         | 27 (5.2)                            |
| Epistaxis                                       | 36 (10.1)                         | 9 (3.5)                               | 26 (7.3)                          | 9 (3.4)                               | 62 (8.7)                          | 18 (3.5)                            |
| Skin andsubcutaneoustissue disorders Alopecia   | 165 (46.3)                        | 10 (3.9)                              | 163 (45.5)                        | 16 (6.1)                              | 328 (45.9)                        | 26 ( 5.0)                           |
| Vascular disorders Hypertension                 | 40 (11.2)                         | 26 (10.2)                             | 45 (12.6)                         | 26 (9.9)                              | 85 (11.9)                         | 52 (10.1)                           |

Combination therapy includes chemotherapy-only cycles.

For one patient, the 7th cycle of chemotherapy which was recorded on Concomitant Medication was excluded from this summary

Abbreviations: EU=European Union; N=number of patients evaluable for AEs; n=number of patients that met the criteria.

## TEAEs of grade 3 or higher

A total of 343 (48%) patients that had a TEAE reported a Grade 3 or higher, 171 [48%] and 172 [48%] patients in the PF-06439535 and bevacizumab-EU group, respectively. The most frequently reported (≥5%) Grade 3 or higher TEAEs were hypertension, with 33 (9.3%) patients in the PF-06439535 group and 31 (8.7%) patients in the bevacizumab-EU group followed by neutropenia with 26 (7.3%) patients in the PF-06439535 group and 32 (8.9%) patients in the bevacizumab-EU group and anaemia with 19 (5.3%) patients in the PF-06439535 group

<div style=\"page-break-after: always\"></div>

and 18 (5.0%) patients in the bevacizumab-EU group. Grade 3 or higher febrile neutropenia was reported in a total of 18 patients (nine [2.5%] patients in each arm).

Table 29: Treatment-Emergent Adverse Events of Grade 3 or Higher by MedDRA Preferred Term in  5% of Patients in Either Treatment Group (All Causalities) - Safety Population, Study B7391003

| Number (%o) of Patients with AEs by MedDRAPreferred Term   | PF-06439535 (N=356)   | Bevacizumab-EU (N=358)   | Total (N=714)   |
|------------------------------------------------------------|-----------------------|--------------------------|-----------------|
| Any AEs                                                    | 171 (48.0)            | 172 (48.0)               | 343 (48.0)      |
| Hypertension                                               | 33 (9.3)              | 31 (8.7)                 | 64 (9.0)        |
| Neutropenia                                                | 26 (7.3)              | 32 (8.9)                 | 58 (8.1)        |
| Anaemia                                                    | 19 (5.3)              | 18 (5.0)                 | 37 (5.2)        |

Source:Table 14.3.1.2.4.2

Included data up to 28 days after the last dose of study drug or to start of subsequent anti-cancer therapy (whichever came first).

Abbreviations: AE=adverse event, EU=European Union, MedDRA=Medical Dictionary for Regulatory Activities, N=number of patients evaluable for AEs.

a.MedDRA version 20.1 coding dictionary applied

## Bevacizumab related TEAEs

Bevacizumab-related TEAEs were those AEs considered related to bevacizumab with or without causal relationship to chemotherapy in accordance to the investigator's assessment.

<div style=\"page-break-after: always\"></div>

Table 30: Treatment-Emergent Adverse Events (Bevacizumab-Related) a  - Safety Population, Study B7391003

| Nunber (%) of Patients                                                               | PF-06439535 (N=356)   | Bevacizumab-EU (N=358)   | Total (N=714)   |
|--------------------------------------------------------------------------------------|-----------------------|--------------------------|-----------------|
| Nunber of adver'se events                                                            | 625                   | 574                      | 1199            |
| Patients with adverse events                                                         | 190 (53.4)            | 199 (55.6)               | 389 (54.5)      |
| Patients with serious adverse events                                                 | 23 (6.5)              | 17 (4.7)                 | 40 (5.6)        |
| Patients with Grade 3 or 4 adverse events                                            | 60 (16.9)             | 49 (13.7)                | 109 (15.3)      |
| Patients with Grade 5 adverse events                                                 | 6 (1.7)               | 1 (0.3)                  | 7 (1.0)         |
| Patients discontinued any treatment due to adverse events                            | 33 (9.3)              | 25 (7.0)                 | 58 (8.1)        |
| Patients discontinued bevacizumab only due to adverse events                         | 16 (4.5)              | 12 (3.4)                 | 28 (3.9)        |
| Patients discontinued bevacizumab and chemotherapy due to adverse events             | 13 (3.7)              | 9 (2.5)                  | 22 (3.1)        |
| Patients discontinued paclitaxel due to adverse events                               | 17 (4.8)              | 13 (3.6)                 | 30 (4.2)        |
| Patients discontinued carboplatin due to adverse events                              | 16 (4.5)              | 13 (3.6)                 | 29 (4.1)        |
| Patients temporarily discontinued bevacizumab only due to adverse events             | 16 (4.5)              | 11 (3.1)                 | 27 (3.8)        |
| Patients temporarily discontinued bevacizumab and chemotherapy due to adverse events | 15 (4.2)              | 13 (3.6)                 | 28 (3.9)        |
| Patients temporarily discontinued paclitaxel due to adverse events                   | 16 (4.5)              | 14 (3.9)                 | 30 (4.2)        |
| Patients temporarily discontinued carboplatin due to adverse events                  | 14 (3.9)              | 13 (3.6)                 | 27 (3.8)        |
| Patients with dose reduction of bevacizumab only due to adverse events               | 0                     | 0                        | 0               |
| Patients with dose reduction of bevacizumab and chemotherapy due to                  | 0                     | 0                        | 0               |
| adverse events Patients with dose reduction of paclitaxel due to adverse events      | 4 (1.1)               | 7 (2.0)                  | 11 (1.5)        |
| Patients with dose reduction of carboplatin due to adverse events                    | 6 (1.7)               | 7 (2.0)                  | 13 (1.8)        |

Included data up to 28 days after the last dose of study drug or to start of subsequent anti-cancer therapy (whichever came first).

Except for the 'number of adverse events', patients were counted only once per treatment in each row.

Serious adverse events - according to the investigator's assessment.

Severity counts were based on the maximum severity or grade of events.

MedDRA version 20.1 coding dictionary applied.

Abbreviations: AE=adverse event; EU=European Union, IRR=infusion related reaction; MedDRA=Medical Dictionary for Regulatory Activities, N=number of patients evaluable for adverse events.

a. AEs related to bevacizumab with or without causal relationship to chemotherapy.

b. Bevacizumab discontinuations may have occurred concurrently with chemotherapy discontinuations.

c. Unifying diagnosis of 'infusion related reaction' included instead of the individual signs and symptoms of IRRs.

The most frequently reported Grade 3 and 4 bevacizumab-related TEAEs were hypertension, with 23 (6.5%) patients (Grade 3: 23) in the PF-06439535 group, and 14 (3.9%) patients (Grade 3: 14) in the bevacizumab-EU group followed by neutropenia with 6 (1.7%) patients (Grade 3: 4 [1.1%]; Grade 4: 2 [0.6%]) in the PF-06439535 group and 8 (2.2%) patients (Grade 3: 2 [0.6%]; Grade 4: 6 [1.7%]) in the bevacizumab-EU group) and anaemia, with 5 (1.4%) patients (Grade 3: 5) in the PF-06439535 group and 4 (1.1%) patients (Grade 3: 4) in the bevacizumab-EU group.

<div style=\"page-break-after: always\"></div>

Bevacizumab related TEAEs were similar both in the combination and/or monotherapy setting.

## Other significant adverse events

##  Infusion related reactions (IRR)

## Study B7391003

Table 31: Summary of infusion related reaction (all causalities) - safety population, study B7391003

| Nunber (%) of Patients                                    | PF-06439535 (N=356)   | Bevacizumab-EU (IN=358)   | Total (N=714)   |
|-----------------------------------------------------------|-----------------------|---------------------------|-----------------|
| Number of adverse events                                  | 22                    | 36                        | 58              |
| Patientswith adverse events                               | 19 (5.3)              | 22 (6.1)                  | 41 (5.7)        |
| Patients with serious adverse events                      | 0                     | 1 (0.3)                   | 1 (0.1)         |
| Patients with Grade 3 or 4 adverse events                 | 6 (1.7)a              | 5 (1.4)a                  | 11 (1.5)        |
| Patients with Grade 5 adverse events                      | 0                     | 0                         | 0               |
| Patients discontinued any treatment due to adverse events | 0                     | 4 (1.1)                   | 4 (0.6)         |

Included data up to 28 days after the last dose of study drug or to start of subsequent anti-cancer therapy (whichever came first).

Except for the 'number of adverse events', patients were counted only once per treatment in each row.

Serious adverse events - according to the investigator's assessment.

Severity counts were based on the maximum severity or grade of events.

MedDRA version 20.1 coding dictionary applied.

Abbreviations: EU=European Union, MedDRA=Medical Dictionary for Regulatory Activities, N=number of patients evaluable for adverse events.

a. No patients had Grade 4 adverse events.

Hypertension is the most frequently reported IRR (10 [2.8%] patients in the PF-06439535 group and 11 [3.1%] in the bevacizumab EU group) - each treatment group for all causality IRRs. Ten (2.8%) patients in the PF-06439535 group and 8 (2.2%) patients in the bevacizumab EU group experienced bevacizumab-related hypertension.

There were no IRR related SAEs reported and no temporary or permanent study treatment discontinuations due to bevacizumab-related IRRs.

-  Potential hypersensitivity/Anaphylaxis

## Study B7391003

Table 32: Summary of Treatment-Emergent Adverse Events (All Causalities - Anaphylactic Reaction and Hypersensitivity) - Safety Population, study B7391003

| Number (%) of Patients                                 | PF-06439535 N=356   | Bevacizumab-EU N=358   |
|--------------------------------------------------------|---------------------|------------------------|
| Number of TEAEs                                        | 178                 | 207                    |
| Number (%) of patients with                            |                     |                        |
| Any TEAEs                                              | 114 (32.0)          | 132 (36.9)             |
| Grade 3 or higher TEAEs                                | 16 (4.5)            | 21 (5.9)               |
| Treatment-related TEAEs                                | 72 (20.2)           | 71 (19.8)              |
| Bevacizumab-related TEAEs                              | 44 (12.4)           | 38 (10.6)              |
| Treatment-related TEAEs resulting in discontinuation   | 2 (0.6)             | 5 (1.4)                |
| Bevacizumab related TEAEs resulting in discontinuation | 2 (0.6)             | 1 (0.3)                |
| Serious TEAEs                                          | 6 (1.7)             | 9 (2.5)                |
| SeriousTEAEsresultinginbevacizumabdiscontinuation      | 4 (1.1)             | 3 (0.8)                |

Bevacizumab Related: Related to Bevacizumab with or without background chemotherapy.

Treatment Related: Related to Bevacizumab, Paclitaxel and/or Carboplatin.

<div style=\"page-break-after: always\"></div>

## Treatment-emergent adverse event of special interest

In Study B7391003, TEAEs of special interest were selected based on the established safety profile of Bevacizumab (as reported in the Avastin USPI and SmPC).

-  Arterial Thromboembolic Events (ATE)

## Study B7391003

Table 33: Risk Difference of Treatment-Emergent Arterial Thromboembolic Events (All Causalities) - Safety Population

| Number (%) of Patients With AEs by SOC and MedDRA? Preferred Term   | PF-06439535 (N=356)   | Bevacizumab- EU (N=358)   |                 | 95% Confidence Interval   | 95% Confidence Interval   |
|---------------------------------------------------------------------|-----------------------|---------------------------|-----------------|---------------------------|---------------------------|
|                                                                     | n (%)                 | n (%)                     | Risk Difference | Lower Limit               | Upper Limit               |
| Total                                                               | 8 (2.2)               | 7 (2.0)                   | 0.292           | -2.009                    | 2.640                     |
| Cardiac disorders                                                   |                       |                           |                 |                           |                           |
| Acute myocardial infarction                                         | 1 (0.3)               | 1 (0.3)                   | 0.002           | -1.301                    | 1.320                     |
| Myocardial infarction                                               | 1 (0.3)               | 1 (0.3)                   | 0.002           | -1.301                    | 1.320                     |
| Silent myocardial infarction                                        | 0                     | 1 (0.3)                   | -0.279          | -1.563                    | 0.763                     |
| Nervous systen disorders                                            |                       |                           |                 |                           |                           |
| Cerebral ischaemia                                                  | 2 (0.6)               | 0                         | 0.562           | -0.475                    | 2.015                     |
| Cerebrovascular insufficiency                                       | 1 (0.3)               | 0                         | 0.281           | -0.772                    | 1.558                     |
| Ischemic stroke                                                     | 0                     | 3 (0.8)                   | -0.838          | -2.429                    | 0.249                     |
| Vascular disorders                                                  |                       |                           |                 |                           |                           |
| Embolism arterial                                                   | 2 (0.6)               | 1 (0.3)                   | 0.282           | -1.048                    | 1.746                     |
| Peripheral artery thrombosis                                        | 1 (0.3)               | 0                         | 0.281           | -0.772                    | 1.558                     |
| Arterial occlusive disease                                          | 0                     | 1 (0.3)                   | -0.279          | -1.563                    | 0.763                     |

Included data up to 28 days after the last dose of study drug or start of subsequent anti-cancer therapy (whichever was earlier).

95% CIs were provided to help gauge the precision of the estimates for risk difference.

CIs were not adjusted for multiplicity and were to be used for screening purposes only.

Risk difference was computed as PF-06439535 versus bevacizumab-EU.

Risk difference and its lower and upper limits were represented as percent in the report.

95% CIs were obtained using the exact method by Chan and Zhang (1999).

A total of 4 patients in the PF-06439535 group and 1 patient in the bevacizumab-EU group had a bevacizumab-related ATE, including acute myocardial infarction (Grade 5), cerebral ischemia (Grade 1), embolism arterial (Grade 3), and peripheral artery thrombosis (Grade 3), reported in 1 patient each in the PF-06439535 group and embolism arterial (Grade 3) and arterial occlusive disease (Grade 3) reported by 1 patient in the bevacizumab-EU group.

<div style=\"page-break-after: always\"></div>

##  Bleeding/Haemorrhage

## Study B7391003

Table 34: Risk Difference of Treatment-Emergent Adverse Events of Special Interest (All Causalities) Bleeding/Haemorrhage (Including Pulmonary Haemorrhage) - Safety Population

| Number (%) of Patients With AEsby SOC and       | PF-06439535 (N=356)                             | Bevacizumab-EU (N=358)                          |                                                 | 95% Confidence Interval                         | 95% Confidence Interval                         |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| MedDRA\" Preferred Term                          |                                                 |                                                 | Risk Difference                                 | Lower Limit                                     | Upper Limit                                     |
|                                                 | n (%)                                           | n (%)                                           |                                                 |                                                 |                                                 |
| Total                                           | 83 (23.3)                                       | 69 (19.3)                                       | 4.041                                           | -1.985                                          | 10.082                                          |
| Gastrointestinal disorders                      |                                                 |                                                 |                                                 |                                                 |                                                 |
| Haematochezia                                   | 3 (0.8)                                         | 1 (0.3)                                         | 0.563                                           | -0.810                                          | 2.186                                           |
| Haemorrhoidal haemorrhage                       | 2 (0.6)                                         | 0                                               | 0.562                                           | -0.475                                          | 2.015                                           |
| Gingival bleeding                               | 17 (4.8)                                        | 16 (4.5)                                        | 0.306                                           | -2.896                                          | 3.534                                           |
| Anal haemorrhage                                | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| Lip haemorrhage                                 | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| Lower gastrointestinal                          | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| haemorrhage                                     |                                                 |                                                 |                                                 |                                                 |                                                 |
| Melaena                                         | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| Mouth haemorrhage                               | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| Rectal haemorrhage                              | 1 (0.3)                                         | 1 (0.3)                                         | 0.002                                           | -1.301                                          | 1.320                                           |
| Haematemesis                                    | 0                                               | 1 (0.3)                                         | -0.279                                          | -1.563                                          | 0.763                                           |
| Injury. poisoning and procedural complications  | Injury. poisoning and procedural complications  | Injury. poisoning and procedural complications  | Injury. poisoning and procedural complications  | Injury. poisoning and procedural complications  | Injury. poisoning and procedural complications  |
| Procedural haemorrhage                          | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| Subarachnoid haemorrhage                        | 0                                               | 1 (0.3)                                         | -0.279                                          | -1.563                                          | 0.763                                           |
| Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        |
| Cerebral haemorrhage                            | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| Haemorrhagic stroke                             | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| Renal and urinary disorders Haematuria          | 8 (2.2)                                         | 9 (2.5)                                         | -0.267                                          | -2.734                                          | 2.159                                           |
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders |
| Epistaxis                                       | 41 (11.5)                                       | 33 (9.2)                                        | 2.299                                           | -2.219                                          | 6.868                                           |
| Haemoptysis                                     | 15 (4.2)                                        | 13 (3.6)                                        | 0.582                                           | -2.387                                          | 3.612                                           |
| Laryngeal haemorrhage                           | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| Pulmonary haemorrhage                           | 3 (0.8)                                         | 3 (0.8)                                         | 0.005                                           | -1.669                                          | 1.694                                           |
| Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          |
| Petechiae                                       | 0                                               | 1 (0.3)                                         | -0.279                                          | -1.563                                          | 0.763                                           |
| Vascular disorder's                             | Vascular disorder's                             | Vascular disorder's                             | Vascular disorder's                             | Vascular disorder's                             | Vascular disorder's                             |
| Haemorrhage                                     | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| Subgaleal haematoma                             | 1 (0.3)                                         | 1 (0.3)                                         | 0.002                                           | -1.301                                          | 1.320                                           |
| Shock haemorrhagic                              | 0                                               | 1 (0.3)                                         | -0.279                                          | -1.563                                          | 0.763                                           |

Source: Module 5.3.5.1 B7391003 (Week 55) Table 14.3.1.2.5.3.1

Included data up to 28 days after the last dose of study drug or start of subsequent anti-cancer therapy (whichever was earlier).

95% CIs were provided to help gauge the precision of the estimates for risk difference.

CIs were not adjusted for multiplicity and were to be used for screening purposes only.

Risk difference was computed as PF-06439535 versus bevacizumab-EU.

Risk difference and its lower and upper limits were represented as percent in the table.

95% CIs were obtained using the exact method by Chan and Zhang (1999).

Abbreviations: AE=adverse event; CI=confidence interval; EU=European Union; MedDRA=Medical

Dictionary for Regulatory Activities; N=number of patients evaluable for AEs; n=number of patients with the event; SOC=system organ class.

a. MedDRA version 20.1 coding dictionary applied.

<div style=\"page-break-after: always\"></div>

The majority of the events of epistaxis and gingival bleeding were of Grade 1 or Grade 2 in both the treatment groups. There was one Grade 3 event of epistaxis in the PF-06439535 group which was reported as resolved at the time of this report. The majority of the bevacizumab-related haemoptysis events in both the treatment groups were of Grade 1 and Grade 2, and all of them resolved at the time of this report. One event of Grade 5 haemoptysis related to PF-06439535 was reported in the PF-06439535 group.

##  Cardiac disorder

Study B7391003

Table 35: Risk Difference of Treatment-Emergent Cardiac Disorders (All Causalities) - Safety Population

| Number(%)ofPatients WithAEsbySOCand MedDRA?Preferred Term   | PF-06439535 (N=356)   | Bevacizumab-EU (N=358)   | Risk       | 95%Confidence Interval   | 95%Confidence Interval   |
|-------------------------------------------------------------|-----------------------|--------------------------|------------|--------------------------|--------------------------|
|                                                             |                       |                          |            | Lower                    | Upper Limit              |
|                                                             | n (%)                 | n (%)                    | Difference | Limit                    |                          |
| Total                                                       | 29 (8.1)              | 29 (8.1)                 | 0.046      | -4.053                   | 4.152                    |
| Cardiac disorder's                                          |                       |                          |            |                          |                          |
| Bundle branch block right                                   | 2 (0.6)               | 0                        | 0.562      | -0.475                   | 2.015                    |
| Extrasystoles                                               | 2 (0.6)               | 0                        | 0.562      | -0.475                   | 2.015                    |
| Mitral valve incompetence                                   | 2 (0.6)               | 0                        | 0.562      | -0.475                   | 2.015                    |
| Tricuspidvalveincompetence                                  | 2 (0.6)               | 0                        | 0.562      | -0.475                   | 2.015                    |
| Tachycardia                                                 | 4 (1.1)               | 3 (0.8)                  | 0.286      | -1.422                   | 2.107                    |
| Left ventricular dysfunction                                | 3 (0.8)               | 2 (0.6)                  | 0.284      | -1.253                   | 1.943                    |
| Cardiac arrest                                              | 2 (0.6)               | 1 (0.3)                  | 0.282      | -1.048                   | 1.746                    |
| Ventricular extrasystoles                                   | 2 (0.6)               | 1 (0.3)                  | 0.282      | -1.048                   | 1.746                    |
| Angina unstable                                             | 1 (0.3)               | 0                        | 0.281      | -0.772                   | 1.558                    |
| Degenerative aortic valve                                   | 1 (0.3)               | 0                        | 0.281      | -0.772                   | 1.558                    |
| disease                                                     |                       |                          |            |                          |                          |
| Diastolic dysfunction                                       | 1 (0.3)               | 0                        | 0.281      | -0.772                   | 1.558                    |
| Left atrial dilatation                                      | 1 (0.3)               | 0                        | 0.281      | -0.772                   | 1.558                    |
| Mitral valve sclerosis                                      | 1 (0.3)               | 0                        | 0.281      | -0.772                   | 1.558                    |
| Sinus tachycardia                                           | 1 (0.3)               | 0                        | 0.281      | -0.772                   | 1.558                    |
| Ventricularflutter                                          | 1 (0.3)               | 0                        | 0.281      | -0.772                   | 1.558                    |
| Cardiac failure                                             | 2 (0.6)               | 2 (0.6)                  | 0.003      | -1.498                   | 1.507                    |
| Acute coronary syndrome                                     | 1 (0.3)               | 1 (0.3)                  | 0.002      | -1.301                   | 1.320                    |
| Acutemyocardialinfarction                                   | 1 (0.3)               | 1 (0.3)                  | 0.002      | -1.301                   | 1.320                    |
| Cardiacseptal hypertrophy                                   | 1 (0.3)               | 1 (0.3)                  | 0.002      | -1.301                   | 1.320                    |
| Cardiovascular insufficiency                                | 1 (0.3)               | 1 (0.3)                  | 0.002      | -1.301                   | 1.320                    |
| Left ventricular hypertrophy                                | 1 (0.3)               | 1 (0.3)                  | 0.002      | -1.301                   | 1.320                    |
| Myocardial infarction                                       | 1 (0.3)               | 1 (0.3)                  | 0.002      | -1.301                   | 1.320                    |
| Pericardial effusion                                        | 1 (0.3)               | 1 (0.3)                  | 0.002      | -1.301                   | 1.320                    |
| Supraventricular                                            | 1 (0.3)               | 1 (0.3)                  | 0.002      | -1.301                   | 1.320                    |
| extrasystoles Arrhythmia                                    | 1 (0.3)               | 2 (0.6)                  | -0.278     | -1.752                   | 1.059                    |
| Arteriosclerosis coronary artery                            | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Bradycardia                                                 | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Cardiomyopathy                                              | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Metabolic cardiomyopathy                                    | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Mitral valve disease                                        | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Myocardialischaemia                                         | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Palpitations                                                | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Pericarditis                                                | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Right ventricular failure                                   | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Silentmyocardialinfarction                                  | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Sinus bradycardia                                           | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Supraventriculartachycardia                                 | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Cardio-respiratory arrest                                   | 0                     | 2 (0.6)                  | -0.559     | -2.003                   | 0.495                    |
| Atrial fibrillation                                         | 0                     | 3 (0.8)                  | -0.838     | -2.429                   | 0.249                    |

Included data up to 28 days after the last dose of study drug or start of subsequent anti-cancer therapy (whichever was earlier).

<div style=\"page-break-after: always\"></div>

95% CIs were provided to help gauge the precision of the estimates for risk difference. CIs were not adjusted for multiplicity and were to be used for screening purposes only. Risk difference was computed as PF-06439535 versus bevacizumab-EU. Risk difference and its lower and upper limits were represented as percent in the table. 95% CIs were obtained using the exact method by Chan and Zhang (1999). Abbreviations: AE=adverse event; CI=confidence interval; EU=European Union; MedDRA=Medical Dictionary for Regulatory Activities; N=number of patients evaluable for AEs; n=number of patients with the event; SOC=system organ class. a. MedDRA version 20.1 coding dictionary applied.

In total, the number of patients with cardiac disorders (all causality) were identical with 29 patients in each group. Bevacizumab-related cardiac disorder events were reported in eight (2.2%) patients in the PF 06439535 group and 7 (2.0%) in the bevacizumab-EU group.

The events of bevacizumab-related congestive heart failure were reported in one (0.3%) patient in the PF-06439535 group and two (0.6%) patients in the bevacizumab-EU group.

One (0.3%) patient each in PF-06439535 group and bevacizumab-EU group had Grade 3 or higher ejection fraction decreased. In the bevacizumab-EU group one (0.3%) patient each had Grade 3 or higher right ventricular failure and pulmonary oedema (all-causality).

##  Hypertension (Grade 3 or higher)

## Study B7391003

Table 36: Risk Difference of Treatment-Emergent Hypertension (Grade 3 or Higher)-Safety Population

| Number (%) of Patients With AEs by SOC and   | PF-06439535 (N=356)   | Bevacizumab-EU (N=358)   |            | 95%Confidence Interval   | 95%Confidence Interval   |
|----------------------------------------------|-----------------------|--------------------------|------------|--------------------------|--------------------------|
| MedDRA\"Preferred Term                        |                       |                          | Risk       | Lower Limit              | Upper Limit              |
|                                              | n (%)                 | n (%)                    | Difference |                          |                          |
| Total                                        | 34 (9.6)              | 32 (8.9)                 | 0.612      | -3.711                   | 4.949                    |
| Investigations                               |                       |                          |            |                          |                          |
| Blood pressure increased                     | 1 (0.3)               | 0                        | 0.281      | -0.772                   | 1.558                    |
| Blood pressure systolic increased            | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |
| Vasculardisorders                            |                       |                          |            |                          |                          |
| Hypertension                                 | 33 (9.3)              | 31 (8.7)                 | 0.610      | -3.645                   | 4.883                    |
| Hypertensive crisis                          | 0                     | 1 (0.3)                  | -0.279     | -1.563                   | 0.763                    |

Included data up to 28 days after the last dose of study drug or start of subsequent anti-cancer therapy (whichever was earlier).

95% CIs were provided to help gauge the precision of the estimates for risk difference.

CIs were not adjusted for multiplicity and were to be used for screening purposes only.

Risk difference was computed as PF-06439535 versus bevacizumab-EU.

Risk difference and its lower and upper limits were represented as percent in the table.

95% CIs were obtained using the exact method by Chan and Zhang (1999).

Abbreviations: AE=adverse event; CI=confidence interval; EU=European Union; MedDRA=Medical Dictionary for Regulatory Activities; N=number of patients evaluable for AEs; n=number of patients with the event; SOC=system organ class.

a) MedDRA version 20.1 coding dictionary applied.

A total of 23 (6.5%) patients in the PF 06439535 group and 14 (3.9%) patients in the bevacizumab EU group had bevacizumab-related Grade 3 or higher hypertension.

##  Proteinuria/Nephrotic Syndrome

## Study B7391003

A total of 28 (7.9%) patients in the PF-06439535 group and 34 (9.5%) patients in the bevacizumab-EU group had an all-causality TEAE of proteinuria/nephrotic syndrome. Four (1.1%) patients in PF-06439535 group and

<div style=\"page-break-after: always\"></div>

five (1.4%) patients in the bevacizumab-EU group had Grade 3 or higher TEAE of proteinuria. A total of 21 (5.9%) patients in the PF-06439535 group and 27 (7.5%) patients in the bevacizumab-EU group had bevacizumab related proteinuria nephrotic syndrome.

##  Venous Thromboembolic Events (VTEs)

## Study B7391003

Table 37: Risk Difference of Treatment-Emergent Venous Thromboembolic Events (All Causalities)-Safety Population

| Number (%) of Patients WithAEsbySOC and         | PF-06439535 (N=356)                             | Bevacizumab-EU (N=358)                          |                                                 | 95% Confidence Interval                         | 95% Confidence Interval                         |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| MedDRA? Preferred Term                          |                                                 |                                                 | Risk                                            | Lower                                           | Upper Limit                                     |
|                                                 | n (%)                                           | n (%)                                           | Difference                                      | Limit                                           |                                                 |
| Total                                           | 13 (3.7)                                        | 11 (3.1)                                        | 0.579                                           | -2.195                                          | 3.424                                           |
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders |
| Pulmonary embolism                              | 10 (2.8)                                        | 6 (1.7)                                         | 1.133                                           | -1.168                                          | 3.609                                           |
| Pulmonary infarction                            | 0                                               | 1 (0.3)                                         | -0.279                                          | -1.563                                          | 0.763                                           |
| Vascular disorders                              | Vascular disorders                              | Vascular disorders                              | Vascular disorders                              | Vascular disorders                              | Vascular disorders                              |
| Brachiocephalic vein occlusion                  | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| Brachiocephalic vein thrombosis                 | 1 (0.3)                                         | 0                                               | 0.281                                           | -0.772                                          | 1.558                                           |
| Deep vein thrombosis                            | 1 (0.3)                                         | 1 (0.3)                                         | 0.002                                           | -1.301                                          | 1.320                                           |
| Paget-Schroetter syndrome                       | 0                                               | 1 (0.3)                                         | -0.279                                          | -1.563                                          | 0.763                                           |
| Subclavian vein thrombosis                      | 0                                               | 1 (0.3)                                         | -0.279                                          | -1.563                                          | 0.763                                           |
| Thrombophlebitis superficial                    | 0                                               | 1 (0.3)                                         | -0.279                                          | -1.563                                          | 0.763                                           |
| Venous thrombosis                               | 0                                               | 1 (0.3)                                         | -0.279                                          | -1.563                                          | 0.763                                           |

Included data up to 28 days after the last dose of study drug or start of subsequent anti-cancer therapy (whichever was earlier).

95% CIs were provided to help gauge the precision of the estimates for risk difference.

CIs were not adjusted for multiplicity and were to be used for screening purposes only.

Risk difference was computed as PF-06439535 versus bevacizumab-EU.

Risk difference and its lower and upper limits were represented as percent in the table.

95% CIs were obtained using the exact method by Chan and Zhang (1999).

Abbreviations: AE=adverse event; CI=confidence interval; EU=European Union; MedDRA=Medical Dictionary for Regulatory Activities; N=number of patients evaluable for AEs; n=number of patients with the event; SOC=system organ class.

a. MedDRA version 20.1 coding dictionary applied.

Grade 3 and 4 events of pulmonary embolism were reported in 8 (2.2%) patients in the PF-06439535 group and in four (1.1%) patients in the bevacizumab-EU group. From the eight patients with pulmonary embolism of Grade 3 or 4 in the PF-06439535 group, the causality was assessed as disease under study for three (0.8%) patients, PF-06439535 for four (1.1%) patients, of which one event was also attributed to paclitaxel and carboplatin in one (0.3%) patient, and disease under study in one (0.3%) patient also possibly attributable to PF-06439535. In the bevacizumab-EU group, Grade 3 and 4 events of pulmonary embolism were due to bevacizumab alone for three (0.8%) patients and disease under study for one (0.3%) patients.

##  Gastrointestinal (GI) Perforations

## Study B7391003

In the PF-06439535 group there were no GI perforation related events reported. In the bevacizumab-EU group there was one (0.3%) patient each with small intestinal perforation, appendicitis perforated and peritonitis. The event of peritonitis was Grade 1, and the event of small intestinal perforation and appendicitis perforated were

<div style=\"page-break-after: always\"></div>

Grade 4 in one patient each. The grade 4 small intestinal perforation and appendicitis perforated were reported as resolved at the time of this report.

##  Wound Healing Complications

## Study B7391003

In the PF-06439535 group, one (0.3%) patient reported a TEAE wound abscess event. There were no events reported in the bevacizumab EU group.

-  Non-Gastrointestinal Fistula

One grade 1 event of non-gastrointestinal fistula was reported for one (0.3%) patient in each treatment group.

-  Posterior Reversible Encephalopathy Syndrome (PRES)

No TEAE of Posterior Reversible Encephalopathy Syndrome (PRES) was reported in either treatment group.

## Serious adverse event/deaths/other significant events

## Study B7391001

Two serious adverse events (SAE) were reported in this study:

- One SAE of Grade 4 concussion was reported for a subject who was involved in a motor vehicle accident as a passenger.
- One SAE of appendicitis occurred prior to study medication administration in one subject.

Both SAEs were assessed as not related to treatment by the investigator.

## Study B7391003

## Table 38: Treatment-Emergent Serious Adverse Events Occurring in ≥1% of Patients in Either Treatment Group (All Causalities, All Cycles) - Safety Population

| Number (%) of Patients with AEs by MedDRA\"Preferred Term   | PF-06439535 (N=356)   | Bevacizumab-EU (N=358)   | Total (N=714)   |
|------------------------------------------------------------|-----------------------|--------------------------|-----------------|
| Any AEs                                                    | 81 (22.8)             | 80 (22.3)                | 161 (22.5)      |
| Pneumonia                                                  | 8 (2.2)               | 6 (1.7)                  | 14 (2.0)        |
| Febrile neutropenia                                        | 5 (1.4)               | 7 (2.0)                  | 12 (1.7)        |
| Neutropenia                                                | 4 (1.1)               | 6 (1.7)                  | 10 (1.4)        |
| Disease progression                                        | 4 (1.1)               | 5 (1.4)                  | 9 (1.3)         |
| Pulmonary embolism                                         | 7 (2.0)               | 2 (0.6)                  | 9 (1.3)         |
| Anaemia                                                    | 2 (0.6)               | 5 (1.4)                  | 7 (1.0)         |
| Asthenia                                                   | 4 (1.1)               | 1 (0.3)                  | 5 (0.7)         |
| Gastroenteritis                                            | 4 (1.1)               | 0                        | 4 (0.6)         |
| Hyponatraemia                                              | 4 (1.1)               | 0                        | 4 (0.6)         |

Included data up to 28 days after the last dose of study drug or start of subsequent anti-cancer therapy (whichever was earlier).

Abbreviations: AE=adverse event; EU=European Union, MedDRA=Medical Dictionary for Regulatory Activities, N=number of patients evaluable for adverse events.

a. MedDRA version 20.1 coding dictionary applied.

In the PF-06439535 group, there were 34 (9.6%) patients, 15 (4.2%) patients, and 21 (5.9%) patients with maximum CTCAE Grade 3, Grade 4, and Grade 5 SAEs, respectively, and in the bevacizumab-EU group, the corresponding number of patients were 30 (8.4%), 20 (5.6%), and 24 (6.7%), respectively.

<div style=\"page-break-after: always\"></div>

## Bevacizumab related SAEs

A total of 23 (6.5%) patients in the PF-06439535 group, and 17 (4.7%) patients in the bevacizumab-EU group had at least 1 bevacizumab-related SAE. The most frequently reported bevacizumab-related SAEs were neutropenia, which was reported by 1 (0.3%) patient in the PF-06439535 group and 3 (0.8%) patients in the bevacizumab-EU group, and pulmonary embolism, which was reported by 2 (0.6%) patients in the PF-06439535 group and 2 (0.6%) patients in the bevacizumab-EU group. In the PF-06439535 group, there were 11 (3.1%) patients, 3 (0.8%) patients, and 6 (1.7%) patients with maximum CTCAE Grade 3, Grade 4, and Grade 5 bevacizumab-related SAEs, respectively, and in the bevacizumab-EU group, the corresponding number of patients were 5 (1.4%), 9 (2.5%), and 1 (0.3%), respectively.

## Deaths

## Study B7391003

## Grade 5 TEAEs

In the PF 06439535 group, out of 356 patients that received study treatment, 21 (5.9%) patients had Grade 5, and in the bevacizumab-EU group, out of 358 patients, 24 (6.7%) patients had Grade 5 TEAEs within the safety reporting period TEAEs (all-causality). There was 1 bevacizumab-related Grade 5 event (pulmonary haemorrhage) in the bevacizumab-EU group and six bevacizumab-related Grade 5 events (acute myocardial infarction, pneumonia, haemoptysis, pulmonary haemorrhage, haemorrhage and death) in the PF-06439535 group.

## Deaths for Overall Survival

Table 39: Summary of Deaths Reported During the Study - ITT Population

| Numbar of Subjectn       | PP-06439535 358   | Bovaciwumab-Ru 361   | Total 719   |
|--------------------------|-------------------|----------------------|-------------|
| Doath                    | 144(40.2)         | 149 (41.3)           | 293 (40.8)  |
| Dineann under Study      | 129 (36.0)        | 127 (35.2)           | 256 (35.6)  |
| Study Treatmant Toxicity | 3 (0.8)           | 1 (0.3)              | 4 (0.6)     |
| Unknown                  | 3(0.8)            | 10 (2.8)             | 13 (1.8)    |
| Othar                    | 10 (2.8)          | 11 (3.0)             | 21 (2.9)    |

Patients may have more than one reported reason for the cause of death.

## Laboratory findings

## Study B7391003 (NSCLC Patients)

## Hematology

The majority of patients in both treatment groups had hematology baseline values of Grade 0 or Grade 1. A few patients shifted from lower grades to Grade 4 as follows:

Platelet count : Ten (10, 3.2%) patients in the PF-06439535 group and 7 (2.1%) patients in the bevacizumab-EU group had post-baseline shifts to Grade 3 platelet count from baseline. Two (2, 0.6%) patients

<div style=\"page-break-after: always\"></div>

in the PF-06439535 group and 7 (2.1%) patients in the bevacizumab-EU group had post-baseline shifts to Grade 4 platelet counts from baseline.

White blood cell counts : Six (6, 1.9%) patients in the PF-06439535 group and 15 (4.5%) patients in the bevacizumab-EU group had post-baseline shifts to Grade 3 white blood cell count from baseline. One (1, 0.3%) patient in the PF-06439535 group and 3 (0.9%) patients in the bevacizumab-EU group had post-baseline shifts to Grade 4 white blood cell count from baseline.

Hemoglobin : Sixteen (16, 4.7%) patients in the PF-06439535 group and 19 (5.5%) patients in the bevacizumab-EU group had post-baseline shifts to Grade 3 hemoglobin decreased/ anaemia from baseline. No patients had post-baseline shifts to Grade 4 hemoglobin decreased/anaemia in either treatment group.

## Chemistry

The majority of patients in both treatment groups had chemistry baseline values of Grade 0 or Grade 1. Shifts from lower grades to higher Grades are as follows:

ALT : Nine (9, 2.6%) patients in the PF-06439535 group and 3 (0.9%) patients in the bevacizumab-EU group had post-baseline shifts to Grade 3 ALT from baseline. No patients had post-baseline shifts to Grade 4 ALT in either treatment group.

AST : Six (6, 1.8%) patients in the PF-06439535 group and 5 (1.4%) patients in the bevacizumab-EU group had post-baseline shifts to Grade 3 AST from baseline. No patients had post-baseline shifts to Grade 4 AST in either treatment group.

Alkaline phosphatase : One (1, 0.3%) patient in the PF-06439535 group and 2 (0.6%) patients in the bevacizumab-EU group had post-baseline Grade 3 alkaline phosphatase. No patients had post-baseline Grade 4 alkaline phosphatase in either treatment group.

Total bilirubin : Five (5, 1.5%) patients in the PF-06439535 group and 2 (0.6%) patients in the bevacizumab-EU group had post-baseline shifts to Grade 3 total bilirubin from baseline. No patients had post-baseline shifts to Grade 4 total bilirubin in either treatment group.

Serum or Plasma Creatinine : One (1, 0.3%) patient in the PF-06439535 group and 1 (0.3%) patient in the bevacizumab-EU group had post-baseline shifts to Grade 3 creatinine increase from baseline. No patients had post-baseline shifts to Grade 4 creatinine increase in either treatment group.

Albumin : Two (2, 0.6%) patients in the PF-06439535 group and no patients in the bevacizumab-EU group had post-baseline shifts to Grade 3 hypoalbuminemia from baseline. No patients had post-baseline shifts to Grade 4 hypoalbuminemia in either treatment group.

Sodium : Ninety-three (93) patients in the PF-06439535 group and 96 patients in the bevacizumab-EU group had low sodium results post-baseline. Of these patients, 26 (28%) patients in the PF-06439535 group and 22 (22.9%) patients in the bevacizumab-EU group had post-baseline Grade 3 hyponatremia. No patients in the PF-06439535 group and 2 (2.1%) patients in the bevacizumab-EU group had post-baseline Grade 4 hyponatremia.

## Urine Protein

Based on the initial dipstick urinalysis results, no patients shifted to Grade 3 or Grade 4  proteinuria from lesser baseline Grades in either treatment group.

## Individual Clinically Significant Laboratory Abnormalities

<div style=\"page-break-after: always\"></div>

Of the safety population, 3 patients had elevated ALT or AST defined as ≥3 × ULN and elevated total bilirubin of ≥2 × ULN.

One patient in the PF-06439535 group experienced elevated ALT of 683 IU/L (16 × ULN, reference range: 8 - 42 IU/L), elevated total bilirubin 46.1 μmol/L (2.45 × ULN, reference range: 2 - 18.8 μmol/L) with AST and alkaline phosphatase within normal range on Study Day 106 after 6 cycles of combinational therapy and met the laboratory abnormalities component of the Hy's law criteria. The patient continued on maintenance blinded bevacizumab monotherapy for an additional 16 cycles without recurrence of LFTs and/or total bilirubin elevations. Considering the ALT, AST and bilirubin values normalized despite continuing the bevacizumab-blinded therapy and background paclitaxel and carboplatin; the study Sponsor did not attribute the increased ALT and increased total bilirubin to bevacizumab-blinded therapy, to background chemotherapy or to any study procedure.

The remaining 2 patients did not meet the Hy's law criteria. Two (2) patients had elevated alkaline phosphatase (cholestasis) concurrently with elevated AST or ALT and total bilirubin. The investigators reported the alternative cause of the elevations as disease under study for both cases.

## Electrocardiograms

A review of the data concluded that no clinically meaningful differences were observed for ECGs between the 2 treatment groups.

## Left Ventricular Ejection Fraction

The mean LVEF values were generally comparable across the 2 treatment groups. A total of 30 patients had a maximum decrease of 10% to 19% from Baseline in LVEF at the End of Treatment visit, among whom 13 patients were in the PF-06439535 group and 17 patients were in the bevacizumab-EU group. A total of 2 patients had a maximum decrease of ≥20% from Baseline in LVEF at the End of Treatment visit (1 patient each in the PF-06439535 group and the bevacizumab-EU group).

## Immunological events

## Results from analyses based on Week 55 data

Results of monitoring of immunogenicity, including long-term data until week 55, also showed comparable results between PF-06439535 and bevacizumab-EU, which supports biosimilarity.

Table 40 : Summary of ADA incidence by treatment group - safety population

| Visit               | Criteria   | PF-06439535 (N=356)   | Bevacizumab-EU (N=358)   | Total (N=714)   |
|---------------------|------------|-----------------------|--------------------------|-----------------|
| Cycle 1             | n          | 352                   | 353                      | 705             |
| (prior totreatment) | Positive   | 1 (0.3)               | 3 (0.8)                  | 4 (0.6)         |
| (prior totreatment) | Negative   | 350 (99.4)            | 350 (99.2)               | 700 (99.3)      |
| (prior totreatment) | Not tested | 1 (0.3)               | 0                        | 1 (0.1)         |
| Overall             | n          | 339                   | 350                      | 689             |
| (post-treatment)    | Positive   | 5 (1.5)               | 5 (1.4)                  | 10 (1.5)        |
| (post-treatment)    | Negative   | 334 (98.5)            | 345 (98.6)               | 679 (98.5)      |

Abbreviations: ADA=anti-drug antibody, EU=European Union, N=the number of patients who received study drug, n=the number of patients evaluated at each visit.

<div style=\"page-break-after: always\"></div>

According to the applicant, percentages were based on the number of patients at each visit. All samples were taken prior to dosing. For calculation of the overall incidence of post-treatment ADA, n=number of patients with at least 1 post Cycle 1 ADA sample were tested. Patients with a positive ADA sample at any time post Cycle 1 were defined as having an overall positive ADA status. ADA positive samples was defined as ADA titer ≥2.29, ADA negative samples was defined as ADA titer &lt;2.29.

Table 41: Summary of neutralising Ab incidence by treatment group - safety population

| Visit              | Criteria   | PF-06439535 (N=356)   | Bevacizumab-EU (N=358)   | Total (N=714)   |
|--------------------|------------|-----------------------|--------------------------|-----------------|
| Cycle 1            | 11         | 352                   | 353                      | 705             |
| (priortotreatment) | Positive   | 1 (0.3)               | 0                        | 1 (0.1)         |
| (priortotreatment) | Negative   | 0                     | 3 (0.8)                  | 3 (0.4)         |
| (priortotreatment) | Not tested | 351 (99.7)            | 350 (99.2)               | 701 (99.4)      |
| Overall            | 11         | 339                   | 350                      | 689             |
| post-treatment)    | Positive   | 0                     | 3 (0.9)                  | 3 (0.4)         |
| post-treatment)    | Negative   | 339 (100.0)           | 347 (99.1)               | 686 (99.6)      |

Mean serum concentrations of PF-06439535 and bevacizumab-EU seemed to be comparable between the two treatment groups at selected time points from Baseline (Cycle 1 Day 1) through Cycle 18 Day 1 in both chemotherapy and monotherapy periods. The observed rate of both ADAs and NAbs was low, with comparable percentages of patients with ADAs and NAbs observed for both treatment groups.

Due to the low number of patients with ADAs, the association between immunogenicity and safety was difficult to evaluate. The presence of ADAs was apparently not associated with serious infusion related reactions or anaphylactic reactions.

No apparent impact of the observed ADAs on PK was seen, since the PK concentrations in the ones with ADA positive samples were in general close to the group average of the observed concentrations in the corresponding treatment group.

All five patients with treatment-emergent ADA in the PF-06439535 group had low titers and the observed treatment-emergent ADAs appeared to be transient. The same conclusion could be drawn for the bevacizumab-EU group, where the four patients with detected treatment-emergent ADAs had low titers and the treatment-emergent ADAs also appeared to be transient.

## Discontinuation due to adverse events

## Permanent Discontinuation From Study Due to Adverse Events

Study B7391003

<div style=\"page-break-after: always\"></div>

Table 42: Reasons for Discontinuations from Treatment - Safety Population

| Number (%) of patients                                                  | PF-06439535 (N=356)   | Bevacizumab-EU (N=358)   | Total (N=714)   |
|-------------------------------------------------------------------------|-----------------------|--------------------------|-----------------|
| Primaryreasonfor discontinuationfrom bevacizumab treatmenta             |                       |                          |                 |
| Adverse event                                                           | 52 (14.6)             | 39 (10.9)                | 91 (12.7)       |
| Completed                                                               | 2 (0.6)               | 0                        | 2 (0.3)         |
| Global deterioration of health status                                   | 14 (3.9)              | 10 (2.8)                 | 24 (3.4)        |
| Lost to follow-up                                                       | 2 (0.6)               | 4 (1.1)                  | 6 (0.8)         |
| Objective progression or relapse                                        | 153 (43.0)            | 170 (47.5)               | 323 (45.2)      |
| Other                                                                   | 5 (1.4)               | 5 (1.4)                  | 10 (1.4)        |
| Protocol violation                                                      | 1 (0.3)               | 3 (0.8)                  | 4 (0.6)         |
| Patient diedb                                                           | 17 (4.8)              | 19 (5.3)                 | 36 (5.0)        |
| Patient refused continued treatment for reason other than adverse event | 15 (4.2)              | 12 (3.4)                 | 27 (3.8)        |
| Total                                                                   | 261 (73.3)            | 262 (73.2)               | 523 (73.2)      |
| Primary reason for discontinuation from paclitaxel treatment            |                       |                          |                 |
| Adverse event                                                           | 41 (11.5)             | 48 (13.4)                | 89 (12.5)       |
| Completed                                                               | 246 (69.1)            | 240 (67.0)               | 486 (68.1)      |
| Global deterioration of health status                                   | 10 (2.8)              | 8 (2.2)                  | 18 (2.5)        |
| Lost to follow-up                                                       | 1 (0.3)               | 3 (0.8)                  | 4 (0.6)         |
| Objective progression or relapse                                        | 27 (7.6)              | 26 (7.3)                 | 53 (7.4)        |
| Other                                                                   | 5 (1.4)               | 3 (0.8)                  | 8 (1.1)         |
| Protocol violation                                                      | 0                     | 3 (0.8)                  | 3 (0.4)         |
| Patient diedb                                                           | 13 (3.7)              | 14 (3.9)                 | 27 (3.8)        |
| Patient refused continued treatment for reason other than adverse event | 6 (1.7)               | 6 (1.7)                  | 12 (1.7)        |
| Total                                                                   | 349 (98.0)            | 351 (98.0)               | 700 (98.0)      |
| Primary reason for discontinuation from carboplatin treatment           |                       |                          |                 |
| Adverse event                                                           | 38 (10.7)             | 42 (11.7)                | 80 (11.2)       |
| Completed                                                               | 249 (69.9)            | 245 (68.4)               | 494 (69.2)      |
| Global deterioration of health status                                   | 11 (3.1)              | 8 (2.2)                  | 19 (2.7)        |
| Lost to follow-up                                                       | 1 (0.3)               | 3 (0.8)                  | 4 (0.6)         |
| Objective progression or relapse                                        | 26 (7.3)              | 26 (7.3)                 | 52 (7.3)        |
| Other                                                                   | 5 (1.4)               | 3 (0.8)                  | 8 (1.1)         |
| Protocol violation                                                      | 0                     | 3 (0.8)                  | 3 (0.4)         |
| Patient diedb                                                           | 13 (3.7)              | 15 (4.2)                 | 28 (3.9)        |
| Patient refused continued treatment for reason other than adverse event | 6 (1.7)               | 6 (1.7)                  | 12 (1.7)        |
| Total                                                                   | 349 (98.0)            | 351 (98.0)               | 700 (98.0)      |

Completed: Patients had completed 4-6 cycles of carboplatin and paclitaxel.

Abbreviation: EU=European Union, N=number of patients who received study treatments.

a Bevacizumab discontinuations may have occurred concurrently with chemotherapy discontinuations.

b Death is the primary reason for treatment discontinuation. Other reasons for treatment discontinuation (e.g., adverse event, global deterioration of health status or disease progression) are reported for the remaining deaths which occurred during the safety reporting period.

The number of patients that temporarily discontinued from bevacizumab only due to AEs was similar in the two groups (11.8 % in PF-06439535 vs. 10.9% in the bevacizumab-EU group).

Blinded bevacizumab therapy continued until objective progression, intolerable toxicity or withdrawn consent.

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

The safety population consisted of all subjects who received at least one dose of either PF06439535 from the single-dose, comparative PK study (study B7391001, N= 101) in healthy males and the phase 3, multi-dose study (study B7391003, N = 714) designed to compare the safety and efficacy in patients with advanced NSCLCs. The number of subjects exposed to PF-06439535 was 33 healthy males and 355 patients with advanced NSCLCs.

The safety population is considered sufficient to study relevant safety signals of this comparability exercise.

In study B7391001 the subjects were randomised to one of three arms (PF-06439535, bevacizumab-EU, bevacizumab-US) to receive a single IV dose of 5 mg/kg whereas in study B7391003 patients were randomized in a 1:1 ratio to receive a IV dose of 15 mg/kg of PF-06439535 plus paclitaxel and carboplatin or bevacizumab-EU plus paclitaxel and carboplatin for at least four and no more than six cycles, followed by the assigned blinded bevacizumab monotherapy. Overall, in the B7391003 study, the extent of exposure was the same across both treatment groups with a mean duration of bevacizumab treatment being 12 cycles (week 55 data cutoff). Paclitaxel and carboplatin treatment also had a similar median duration of treatment across both arms. In addition, the number of patients in each treatment cycle in the monotherapy setting was also similar between the two groups. Similar numbers of subjects that experienced TEAEs were reported in the three arms of the single-dose study 7391001 in healthy volunteers with no clinically meaningful differences. Also, the number of subjects with AEs as per SOC and PT are small and similar, and do not indicate a clinically relevant difference in safety signals between PF-06439535, bevacizumab-EU and bevacizumab-US given as single dose of 5 mg/kg in the study B7391001 of healthy subjects. No infusion related reactions (IRRs) were reported in this study.

For study B7391003 the majority of patients (97 % in both arms) had at least one all causality TEAE, with similar number of patients that experienced SAE, grade 3 or 4 AE and grade 5 AE. Moreover, reported discontinuations were similar between the two groups and the primary reason for discontinuation of bevacizumab in both treatment groups was disease progression or relapse. The most frequently reported all causality TEAEs (&gt;15%) were alopecia, anaemia, fatigue, nausea, neutropenia, thrombocytopenia, hypertension and peripheral neuropathy. The majority of the events reported were Grade 1 or Grade 2 in both treatment groups with the exception of hypertension, where 9% had Grade 3 events in both groups. All causality SAEs were reported for 22.8% in the PF-06439535 group and 22.3% in the bevacizumab-EU group, with the most frequent events including pneumonia, febrile neutropenia and pulmonary embolism with comparable numbers in both arms. Moreover, reported discontinuations were similar between the two groups and the primary reason for discontinuation of bevacizumab in both treatment groups was disease progression or relapse. The number of patients that temporarily discontinued from bevacizumab only due to AEs was similar in the two groups (11.8 % in PF-06439535 vs. 10.9% in the bevacizumab-EU group.

Approximately half of all patients experienced at least one bevacizumab-related TEAE, with an even distribution between the two groups for the totality of events. However, a numerical imbalance between the two groups is generally reported with a higher incidence of patients that experienced bevacizumab-related SAEs (6.5 % vs 4.7% in the PF-06439535 and bevacizumab-EU, respectively), grade 3 or 4 TEAEs (16.9 % vs 13.7%, respectively) and grade 5 TEAEs (1.7 % vs 0.3%, respectively) in the PF-06439535 arm. No clustering to a single SOC or PT was observed and the numerical imbalance is generally spread over the different PTs with few patients in each term (except for hypertension, neutropenia and anaemia that were reported most frequently). Based on the distribution of events over the different preferred terms, this difference is noteworthy, but is considered not to constitute a safety issue.

<div style=\"page-break-after: always\"></div>

There were no bevacizumab-related IRR SAEs reported and no temporary or permanent study treatment discontinuations due to bevacizumab-related IRRs. For AESIs, similar frequencies were reported in both arms overall and considered to have no clinically meaningful differences.

Importantly, the reported TEAEs are generally in line with the safety profile of the reference product Avastin, with no new safety findings reported in this study. No deaths were reported in study B7391001.

In the PF-06439535 group 5.9% patients had Grade 5 events compared to 6.7% of patients in the bevacizumab-EU group, within the safety reporting period of TEAEs (all-causality). A notable difference in bevacizumab-related grade 5 events between the two arms was reported, with one bevacizumab-related Grade 5 event (pulmonary haemorrhage) in the bevacizumab-EU group and six bevacizumab-related Grade 5 events (acute myocardial infarction, pneumonia, haemoptysis, pulmonary haemorrhage, haemorrhage and death) in the PF-06439535 group.  This may relate to the general tendency of numerically more TEAEs in the PF-06439535 group as compared to the bevacizumab group. Immunogenicity was demonstrated to be comparable between PF-06439535 and bevacizumab-EU also after updating with long-term results from week 55.

Laboratory values for both haematology and chemistry were generally comparable between the two treatment groups. Few and comparable shifts in haematology to Grade 4 were reported in the two arms. Two patients in the bevacizumab-EU group and 1 patient in the PF-06439535 group had a post-baseline shift to Grade 4 hyponatremia.

One patient in the PF-06439535 group experienced elevated ALT of 683 U/L (16 × ULN, reference range: 8 - 42 U/L), elevated total bilirubin 46.1 μmol/L (2.45 × ULN, reference range: 2 - 18.8 μmol/L) with AST and alkaline phosphatase within normal range on Study Day 106 after 6 cycles of combinational therapy and met the laboratory abnormalities component of the Hy's law criteria. The patient continued on maintenance blinded bevacizumab monotherapy for an additional 16 cycles without recurrence of LFTs and/or total bilirubin elevations. Considering the ALT, AST and bilirubin values normalized despite continuing the bevacizumab-blinded therapy and background paclitaxel and carboplatin, it is not considered that the increased ALT and increased total bilirubin is attributed to bevacizumab-blinded therapy, to background chemotherapy, or to any study procedure.

## 2.5.2. Conclusions on the clinical safety

Based on the safety documentation of comparative study B7391003 where PF-06439535 was compared to bevacizumab-EU (Avastin), no new safety signals different from the Avastin SmPC were detected. The submitted safety data are considered satisfactory to support a biosimilar claim for PF-06439535.

## 2.6. Risk Management Plan

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                             |
|------------------------------|--------------------------------------------------------|
| Important identified risks   | Bleeding/haemorrhage Pulmonary haemorrhage Proteinuria |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                              | Arterial thromboembolic events (ATE) Hypertension Congestive heart failure Wound-healing complications Gastrointestinal perforations Posterior reversible encephalopathy syndrome (PRES) Neutropenia Venous thromboembolic events (VTE) Fistula (other than gastrointestinal) Thrombotic microangiopathy Pulmonary hypertension Ovarian failure Hypersensitivity reactions/infusion reactions Gallbladder perforation Peripheral sensory neuropathy Cardiac disorders (excluding CHF and ATE) Osteonecrosis of the jaw Necrotizing fasciitis Adverse events following off-label intravitreal use |
| Important potential risks    | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Missing information          | Safety profile of the different treatment combinations in patients with non-squamous NSCLC Long-term effects of bevacizumab when used in the paediatric population Safety and efficacy in patients with renal impairment                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns                                                     |
|------------------------------|--------------------------------------------------------------------------------|
|                              | Safety and efficacy in patients with hepatic impairment Use in lactating women |

## Pharmacovigilance plan

The PRAC, having considered the data submitted, is of the opinion that routine pharmacovigilance is sufficient to identify and characterise the risks of the product.  Specific adverse reaction follow-up questionnaires are in place in accordance with the reference product: Arterial Thromboembolic Events (ATE), Interstitial Lung Disease, Osteonecrosis of the Jaw and Congestive Heart Failure.

## Risk minimisation measures

| Safety concern                                      | Routine risk minimisation measures                                          | Additional risk minimisation measures   |
|-----------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------|
| Important Identified Risks                          | Important Identified Risks                                                  | Important Identified Risks              |
| Bleeding/haemorrhage                                | SmPC Sections 4.4 and 4.8; PL Sections 2, 3, and 4.                         | None                                    |
| Pulmonary haemorrhage                               | SmPC Sections 4.4 and 4.8; PL Sections 2 and 4.                             | None                                    |
| Proteinuria                                         | SmPC Sections 4.4 and 4.8; PL Sections 2, 3, and 4.                         | None                                    |
| Arterial thromboembolic events                      | SmPC Sections 4.4 and 4.8; PL Sections 2, 3, and 4. Data Capture Aids (DCA) | None                                    |
| Hypertension                                        | SmPC Sections 4.4 and 4.8; PL Sections 2, 3, and 4.                         | None                                    |
| Congestive heart failure                            | SmPC Sections 4.4 and 4.8; PL Sections 2 and 4. Data Capture Aids (DCA)     | None                                    |
| Wound healing complications                         | SmPC Sections 4.4 and 4.8; PL Sections 2, 3, and 4.                         | None                                    |
| Gastrointestinal perforation                        | SmPC Sections 4.4 and 4.8; PL Sections 2, 3, and 4.                         | None                                    |
| Posterior Reversible Encephalopathy Syndrome (PRES) | SmPC Sections 4.4 and 4.8; PL Sections 2 and 4.                             | None                                    |
| Neutropenia                                         | SmPC Sections 4.4 and 4.8; PL Sections 2 and 4.                             | None                                    |
| Venous thromboembolic events                        | SmPC Sections 4.4 and 4.8; PL Sections 2, 3, and 4.                         | None                                    |
| Fistula (other than gastrointestinal)               | SmPC Sections 4.4 and 4.8; PL                                               | None                                    |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                            | Routine risk minimisation measures                                      | Additional risk minimisation measures   |
|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------|
|                                                                                           | Sections 2, 3, and 4.                                                   |                                         |
| Thrombotic microangiopathy                                                                | SmPC Section 4.8; PL Section 4.                                         | None                                    |
| Pulmonary hypertension                                                                    | SmPC Section 4.8; PL Section 4.                                         | None                                    |
| Ovarian failure                                                                           | SmPC Sections 4.4, 4.6, and 4.8; PL Section 4.                          | None                                    |
| Hypersensitivity reactions and infusion reactions                                         | SmPC Sections 4.3, 4.4 and 4.8; PL Sections 2 and 4.                    | None                                    |
| Gallbladder perforation                                                                   | SmPC Sections 4.4 and 4.8; PL Section 4.                                | None                                    |
| Peripheral sensory neuropathy                                                             | SmPC Section 4.8; PL Section 4.                                         | None                                    |
| Cardiac Disorders (excl. CHF and ATE)                                                     | SmPC Section 4.8; PL Section 4.                                         | None                                    |
| Osteonecrosis of the jaw                                                                  | SmPC Sections 4.4 and 4.8; PL Sections 2 and 4. Data Capture Aids (DCA) | None                                    |
| Necrotizing fasciitis                                                                     | SmPC Sections 4.4 and 4.8; PL Sections 2, 3, and 4.                     | None                                    |
| AEs following Off-Label lntravitreal Use                                                  | SmPC Section 4.4; PL Section 4.                                         | None                                    |
| Embryo-foetal development disturbance                                                     | SmPC Sections 4.3, 4.6, 4.8, and 5.3; PL Section 2.                     | None                                    |
| Osteonecrosis in Children                                                                 | SmPC Section 4.8; PL Section 2.                                         | None                                    |
| Missing information                                                                       |                                                                         |                                         |
| Safety profile of the different treatment combinations in patients with nonsquamous NSCLC | None.                                                                   | None                                    |
| Long-term use in paediatric patients                                                      | SmPC Section 4.2, 4.8, and 5.1; PL Section 2.                           | None                                    |
| Patients with renal impairment                                                            | SmPC Section 4.2 and 5.2                                                | None                                    |
| Patients with Hepatic Impairment                                                          | SmPC Section 4.2 and 5.2                                                | None                                    |
| Use in Lactating Women                                                                    | SmPC Section 4.3 and 4.6; PL Section 2.                                 | None                                    |

## Conclusion

The CHMP and PRAC considered that the risk management plan version 0.3 is acceptable.

## 2.7. Pharmacovigilance

## Pharmacovigilance system

The  CHMP  considered  that  the  pharmacovigilance  system  summary  submitted  by  the  applicant  fulfils  the

<div style=\"page-break-after: always\"></div>

requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.8. Product information

## 2.8.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the applicant and has been found acceptable as the package leaflet will have the same content and layout as the reference medicinal product Avastin.

## 2.8.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Zirabev (bevacizumab) is included in the additional monitoring list as it is a biological product authorised after 1 January 2011.

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Biosimilarity assessment

## 3.1. Comparability exercise and indications claimed

The applicant seeks a marketing authorisation in the same therapeutic indication as approved for bevacizumab-EU (Avastin) which are not currently under patent protection: Adult patients with metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer, advanced and/or metastatic renal cell cancer and persistent, recurrent, or metastatic carcinoma of the cervix.

## Quality

To establish biosimilarity of PF-06439535 to Avastin bevacizumab-EU and bevacizumab-US on the quality level, an analytical similarity study was performed comparing PF-06439535 to reference bevacizumab-EU and bevacizumab-US. A total of 10 drug substance batches and 16 drug product batches of PF-06439535, 50 batches of the reference product bevacizumab-EU and 46 batches of bevacizumab-US drug product (400 mg/16 mL and 100 mg/4 mL presentations), were included in the analytical similarity study.

## Non-clinical

Formal scientific advice from CHMP in 2015 included an opinion related to non-clinical development. In general the CHMP agreed that the proposed preclinical and pharmacological approach was sufficient for biosimilarity purposes. A GLP-compliant, 1-month, repeat-dose intravenous (IV) bolus comparative toxicity study in Cynomolgus monkeys of PF-06439535 with bevacizumab-EU has been conducted (Study 13GR179).  In

<div style=\"page-break-after: always\"></div>

addition, a non-comparative 2 week repeat-dose toxicity with only PF-06439535 was performed in rats, on the request of a regulatory authority outside Europe (Study 8305590).

## Clinical

## Pharmacokinetics

With the present application (EMEA/H/C/4697) the applicant provided study results from three clinical trials regarding pharmacokinetics.

In the phase I clinical study B7391002 in healthy subjects, the primary objective was to assess inter-subject variability in single dose pharmacokinetics (PK) of bevacizumab in healthy subjects and for the planning of the pivotal PK study.

The pivotal phase I clinical study B7391001 was conducted to compare the pharmacokinetics and pharmacodynamics following injection of 5 mg/kg body weight of PF-06439535 or bevacizumab (Avastin). Comparability could be concluded for both primary endpoints Cmax and AUCinf, and none of the other PK parameters revealed any statistically significant difference between PF-06439535 and Avastin.

In the phase III clinical study B7391003, no difference in Ctrough was observed between the PF-06439535 and the bevacizumab groups at any time-point.

## Efficacy and safety

Study B7391003: A completed, multinational, double-blind, randomised (1:1), parallel-group, multiple dose study evaluating the efficacy, safety, PK, and immunogenicity of PF-06439535 plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC in the first-line treatment setting. The primary objective of the study was to compare the efficacy, immunogenicity and safety of PF-06439535 versus bevacizumab-EU. The primary endpoint was overall response rate (ORR)- the percent of patients within each treatment group that achieved complete response (CR) or partial response (PR) by Week 19 of the study and subsequently confirmed on a follow-up tumour assessment by Week 25, based on the pre-specified equivalence margins required by EMA. Data from week 55 support the secondary endpoints.

## 3.2. Results supporting biosimilarity

## Quality

A comprehensive analytical similarity assessment which included comparative evaluations of biological activities, primary structure, higher order structure, N-linked glycan profile, charge heterogeneity, product purity (monomer, HMMS, HC+LC, fragments), disulfide bonds and forced degradation profiles. The biological activities were evaluated by a comprehensive set of functional assays and binding studies addressing both Fab and Fc-functions of the molecule. The inhibition of growth assay using HUVEC cells, used to measure potency, showed comparable responses for PF-06439535 and reference products. Comparable binding to VEGF target antigen by ELISA, was observed for isoforms VEGF165, VEGF121, VEGF189 and VEGF206. No differences are observed in FcRn, Fcγ and C1q binding. Additionally, no ADCC or CDC activity was observed.

## Non-clinical

Overall, the results from the comparative toxicity study in Cynomolgus monkeys (Study 13GR179) add to the totality of evidence to support the demonstration of PF-06439535 as a biosimilar product to bevacizumab (EU). Repeated dose toxicity studies in non-human primates are usually not recommended for similar biological

<div style=\"page-break-after: always\"></div>

products (EMA/CHMP/BMWP/403543/2010). From a 3R perspective and with reference to the European guidance document EMA/CHMP/BMWP/403543/2010, neither the study in monkey, nor the study in rat were warranted.

## Clinical

## Pharmacokinetics

Comparability between PF-06439535 and bevacizumab-EU at the PK level has been shown in an adequately performed phase I PK study and a phase III efficacy/safety study.

## Efficacy

Trial B7391003 met its primary objective.

The results of the analysis of the primary endpoint, ORR, met the pre-specified equivalence criterion (-13% to 13%) for the ITT population, the ORR was similar between both treatment groups (45.3% in the PF-06439535 group and 44.6% in the bevacizumab-EU group). The analysis of ORR provided an un-stratified risk difference of 0.6531% (PF-06439535 versus bevacizumab-EU), with a 95% CI of (-6.6080%, 7.9082%), which fell within the pre-defined equivalence margins. Results obtained with the ITT population were supported by sensitivity analyses of the PP population and analysis of un-stratified risk ratio. Sensitivity analysis of data from Week 55 further supports the conclusion made above.

## Safety

Based on the safety documentation of the phase III study B7391003 where PF-06439535 was compared to bevacizumab-EU (Avastin), no new safety signals different from the Avastin SmPC were detected. The safety data are comparable in the two treatment groups and considered satisfactory to support a biosimilar claim for PF-06439535.

Results of monitoring of immunogenicity, including long-term data until week 55, showed comparable results between PF-06439535 and bevacizumab-EU, also supporting biosimilarity.

## 3.3. Uncertainties and limitations about biosimilarity

## Quality

For PF-06439535 batches, the relative potency (measured by inhibition of cell growth assay) was observed to be in the lower region compared to that of bevacizumab-EU. However, the statistical quality range for relative potency of bevacizumab-EU covers the range for PF-06439535. In addition, binding studies to isoforms of VEGF by ELISA demonstrated comparable results between PF-06439535 and bevacizumab-EU.

## Clinical

N/A

## 3.4. Discussion on biosimilarity

## Quality

Analytical similarity of PF-06439535 drug product to reference product Avastin (bevacizumab-EU and bevacizumab-US) has been acceptably demonstrated, excepted for the potency measured by inhibition of cell growth assay (HUVEC assay).

<div style=\"page-break-after: always\"></div>

## Clinical

## Pharmacokinetics

Comparability between PF-06439535 and Avastin at the PK level has been shown in a phase I PK similarity study and a phase III efficacy/safety study.

## Efficacy

Similarity between PF-06439535 and EU-licensed bevacizumab reference product was demonstrated in the ITT population. Equivalence between PF-06439535 and reference bevacizumab was also supported by sensitivity analysis of the PP population.

## Safety

No signals of new adverse reaction were detected in the comparative study and within the limitation of a single study with a limited number of patients, the safety profile of PF-06439535 versus bevacizumab-EU is considered similar.

## 3.5. Extrapolation of safety and efficacy

The mechanism of action of bevacizumab is the same, independent of indication. Therefore, extrapolation to all other indications labelled for the reference product bevacizumab is considered acceptable, provided that similarity of PF-06439535 to the bevacizumab reference product is convincingly demonstrated both at the quality, non-clinical and clinical level. Currently patented indications are excluded.

## 3.6. Conclusions on biosimilarity and benefit risk balance

Based on the review of the submitted data, Zirabev is considered biosimilar to the reference product Avastin. Therefore, a benefit/risk balance comparable to the reference product can be concluded.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Zirabev is favourable in the following indication:

Zirabev in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.

Zirabev in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.

Zirabev, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.

Zirabev in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.

<div style=\"page-break-after: always\"></div>

Zirabev, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

-  At the request of the European Medicines Agency;
-  Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.